<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006329" GROUP_ID="SCHIZ" ID="581206032013173771" MERGED_FROM="" MODIFIED="2013-12-04 13:54:51 +0000" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;&lt;p&gt;&lt;br&gt;Old title: Cessation of medication for people with schizophrenia already stable on chlorpromazine&lt;/p&gt;" NOTES_MODIFIED="2013-12-04 13:52:34 +0000" NOTES_MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2013-12-04 13:54:51 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Cessation of medication for people with schizophrenia already stable on chlorpromazine</TITLE>
<CONTACT MODIFIED="2013-12-04 13:54:51 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="EBA2E5B082E26AA20078D4E6AAEB7CC4" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Muhammad Qutayba</FIRST_NAME><LAST_NAME>Almerie</LAST_NAME><POSITION>Academic Clinical Fellow</POSITION><EMAIL_1>qalmerie@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Surgery</DEPARTMENT><ORGANISATION>Leeds Teaching Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Beckett Street</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS9 7TF</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-12-04 13:54:51 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="EBA2E5B082E26AA20078D4E6AAEB7CC4" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Muhammad Qutayba</FIRST_NAME><LAST_NAME>Almerie</LAST_NAME><POSITION>Academic Clinical Fellow</POSITION><EMAIL_1>qalmerie@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Surgery</DEPARTMENT><ORGANISATION>Leeds Teaching Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Beckett Street</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS9 7TF</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="BB5128CD82E26AA20047FC71FEE4EAA4" ROLE="AUTHOR"><FIRST_NAME>Hassan</FIRST_NAME><LAST_NAME>Alkhateeb</LAST_NAME><POSITION>Medical student</POSITION><EMAIL_1>Mdhassan1@lycos.com</EMAIL_1><ADDRESS><ORGANISATION>Damascus University</ORGANISATION><ADDRESS_1>Iskendarieh Street</ADDRESS_1><ADDRESS_2>Al Wozara Building NO 28 , 9th floor</ADDRESS_2><CITY>Damascus</CITY><COUNTRY CODE="SY">Syrian Arab Republic</COUNTRY></ADDRESS></PERSON><PERSON ID="7425" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Adib</FIRST_NAME><LAST_NAME>Essali</LAST_NAME><POSITION>Head of Centre</POSITION><EMAIL_1>adib-essali@hotmail.com</EMAIL_1><EMAIL_2>adib-essali@hotmail.com</EMAIL_2><MOBILE_PHONE>00963933212321</MOBILE_PHONE><ADDRESS><DEPARTMENT>Psychiatry Centre</DEPARTMENT><ORGANISATION>Modern Psychiatry Hospital</ORGANISATION><ADDRESS_1>27 Al Zahrawi Street</ADDRESS_1><ADDRESS_2>Rawda</ADDRESS_2><CITY>Damascus</CITY><COUNTRY CODE="SY">Syrian Arab Republic</COUNTRY><PHONE_1>+ 963 11 444 1510</PHONE_1><FAX_1>+ 963 11 512 5737</FAX_1></ADDRESS></PERSON><PERSON ID="EBA2E88E82E26AA20078D4E6D607135E" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Hosam</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Matar</LAST_NAME><POSITION>Surgical Trainee</POSITION><EMAIL_1>hematar@doctors.org.uk</EMAIL_1><EMAIL_2>hematar@hotmail.co.uk</EMAIL_2><MOBILE_PHONE>07826692764</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Trauma and Orthopaedics</DEPARTMENT><ORGANISATION>Northern General Hospital</ORGANISATION><ADDRESS_1>Herries Road</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S5 7AU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 7826692764</PHONE_1></ADDRESS></PERSON><PERSON ID="EBA2E70882E26AA20078D4E6E8760D38" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Emtithal</FIRST_NAME><LAST_NAME>Rezk</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>emmi_r88@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Infectious Diseases Department</DEPARTMENT><ORGANISATION>Al-Mowasat Hospital</ORGANISATION><ADDRESS_1>27 Al Zahrawi Street</ADDRESS_1><ADDRESS_2>Damascus University</ADDRESS_2><CITY>Damascus</CITY><COUNTRY CODE="SY">Syrian Arab Republic</COUNTRY><PHONE_1>00963 933 554 004</PHONE_1><FAX_1>00963 11 444 52 50</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-12-04 13:48:43 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="26" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="7" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="6" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2013-12-04 13:31:09 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-07-31 14:30:28 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), no new studies found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-12-04 13:31:09 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-12-04 13:31:09 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="1" YEAR="2009"/>
<DESCRIPTION>
<P>Author order amended</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-01-16 10:53:36 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Dr. Naser Al Merie</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Mr. Yahya Matar</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Mr.Bassam Alkhateeb</NAME>
<COUNTRY CODE="BH">Bahrain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Faculty of Medicine, Damascus University</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-12-04 13:52:34 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-04-25 17:58:36 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-25 17:58:36 +0100" MODIFIED_BY="[Empty name]">Cessation of medication for people with schizophrenia already stable on chlorpromazine</TITLE>
<SUMMARY_BODY>
<P>The course of schizophrenia can be varied with some people experiencing a single episode of psychosis while others suffer repeated episodes. Often people with schizophrenia want to stop treatment with chlorpromazine once symptoms have subsided. This review highlights the risks of stopping chlorpromazine for those with established illness. Halting medication with chlorpromazine increases the risk of relapse over all time periods. Relapses are damaging and can be dangerous.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-12-04 13:52:34 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-12-04 13:52:34 +0000" MODIFIED_BY="[Empty name]">
<P>Chlorpromazine, one of the first generation of antipsychotic drugs, is effective in the treatment of schizophrenia. For most people schizophrenia is a life-long disorder but about a quarter of those who have a first psychotic breakdown do not go on to experience further breakdowns. Most people with schizophrenia are prescribed antipsychotic drugs, although use is often intermittent. The effects of stopping medication are not well researched in the context of systematic reviews.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To quantify the effects of stopping chlorpromazine for people with schizophrenia stable on this drug.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-07-31 14:31:13 +0100" MODIFIED_BY="[Empty name]">
<P>We supplemented an electronic search of the Cochrane Schizophrenia Group Trials Register (March 2006 and July 2012) with reference searching of all identified studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included all relevant randomised clinical trials.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We independently inspected citations and abstracts, ordered papers and re-inspected and quality assessed these. We independently extracted data and resolved disputes during regular meetings. We analysed dichotomous data using fixed effects relative risk (RR) and the 95% confidence interval (CI). For continuous data, where possible, we calculated the weighted mean difference (WMD). We excluded the data where more than 40% of people were lost to follow up.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We included ten trials involving 1042 people with schizophrenia stable on chlorpromazine. Even in the short term, those who remained on chlorpromazine were less likely to experience a relapse compared to people who stopped taking chlorpromazine (n=376, 3 RCTs, RR 6.76 CI 3.37 to 13.54, NNH NNH 4 CI 2 to 8). Medium term (n=850, 6 RCTs, RR 4.04 CI 2.81 to 5.8, NNH 4 CI 3 to 7) and long term data were similar (n=510, 3 RCTs, RR 1.70 CI 1.44 to 2.01, NNH 4 CI 3 to 6). People allocated to chlorpromazine withdrawal were not significantly more likely to stay in the study compared with those continuing chlorpromazine treatment (n=374, 1 RCT, RR 1.14 CI 0.55 to 2.35). In sensitivity analyses, there was a significant difference in the 'relapse' outcome between trials for those diagnosed according to checklist criteria compared to those with a clinical diagnosis.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>This review confirms clinical experience and quantifies the risks of stopping chlorpromazine medication for a group of people with schizophrenia who are stable on this drug. With its moderate adverse effects, chlorpromazine is likely to remain one of the most widely prescribed treatments for schizophrenia.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-07-31 13:20:28 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>The efficacy of chlorpromazine and other phenothiazine derivatives in treating acute episodes of schizophrenia has long been demonstrated in randomised controlled trials (RCTs) (e.g. <LINK REF="REF-NIMH-1964" TYPE="REFERENCE">NIMH 1964</LINK>). The importance of maintenance drug therapy in the treatment of schizophrenia has been evident since the early 1960s. Initial studies indicated that about a half to two thirds of patients with schizophrenia who were stable on medication relapsed following cessation of maintenance pharmacological therapy, compared with between five and 30% of the patients maintained on medication (<LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>, <LINK REF="REF-Davis-1975" TYPE="REFERENCE">Davis 1975</LINK>). A review of 66 studies performed between 1985 and 1993 demonstrated that medication cessation was associated with a 53.2% relapse rate within 6.3 to 9.7 months compared with 15.6% within 7.9 months in the maintenance groups (<LINK REF="REF-Gilbetr-1995" TYPE="REFERENCE">Gilbetr 1995</LINK>). Thus, findings from medication discontinuation studies have conclusively shown that, as a group, patients with schizophrenia fare better if they receive antipsychotic medication than no medication whatsoever.</P>
<P>Although schizophrenia is generally thought to be a life-long disorder requiring indefinite pharmacological treatment, prolonged use of antipsychotic medication carries the risk of adverse effects, and few people want to take medication for months and often years, least of all the population most commonly hit by new episodes of schizophrenia, those in their late teens or early 20s. </P>
<P>The course of schizophrenia varies, and may follow one of four patterns (<LINK REF="REF-Shepherd-1989" TYPE="REFERENCE">Shepherd 1989</LINK>); 13% may have a single episode with no subsequent impairment, 30% may have several episodes with no or minimal impairment, 10% may suffer impairment following the first episode with occasional exacerbation of symptoms and no return to normality, and 47% show impairment increasing after each exacerbation. Presently, it is not possible to predict the course of an illness. Medication cessation studies may help identify the characteristics of those patients who will have a single episode and not require maintenance drug treatment. Such studies may also help identify those who will follow a relapsing course and may benefit from intermittent treatment, and those who require indefinite maintenance drug treatment.</P>
<P>The clinician is left with a dilemma. Most people probably should take medication for longer than they want to, yet the epidemiology tells clinicians that some patients will be able to avoid taking these powerful medications in the long term. Evidence for the efficacy of medication is plentiful and often supported by industry funding. Cessation trials are not in the interest of industry to undertake, and appear less common. Nevertheless, this latter type of study does ask an important question. Certainly, follow up (<LINK REF="REF-Curson-1985" TYPE="REFERENCE">Curson 1985</LINK>) and audit (<LINK REF="REF-Essali-1993" TYPE="REFERENCE">Essali 1993</LINK>) studies of people on long acting injectable antipsychotics who stop medication do strongly suggest that, for this group at least, cessation is inadvisable. In this review we aimed to investigate the quantitative effects of stopping chlorpromazine for people stable on this drug by reviewing available trial-based evidence.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To investigate the effects of stopping chlorpromazine therapy in people with schizophrenia stable on chlorpromazine.</P>
<P>It is expected that several sensitivity analyses could be undertaken within this review. The following hypotheses will be tested:</P>
<P>When compared with placebo, for the primary outcomes of interest (see: 'Criteria' for considering studies for this review) chlorpromazine cessation is differentially effective for:<BR/>1. Men and women.<BR/>2. People who are under 18 years of age, between 18 and 64, or over 65 years of age.<BR/>3. People who became ill recently (i.e. acute episode approximately less than one month's duration) as opposed to people who have been ill for longer period.<BR/>4. People who are given low doses (1- 500 mg/day), and those given high doses (over 501 mg/day).<BR/>5. People who have schizophrenia diagnosed according to any operational criterion i.e. a pre-stated checklist of symptoms/problems/time periods/exclusions) as opposed to those who have entered the trial with loosely defined illness. <BR/>6. People treated earlier (pre-1990) and people treated in recent years (1990 to 2006).</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-07-31 13:20:28 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We included all relevant randomised controlled trials. We included trials described as 'double-blind' if it was implied that the study was randomised and we included these in a sensitivity analysis. If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion did result in statistically significant differences, we did not add the data from these lower quality studies to the results of the better trials, but presented these within a subcategory. We excluded quasi-randomised studies, such as those allocating by alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people with schizophrenia and schizophrenia-like psychoses (schizophreniform and schizoaffective disorders). There is no clear evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Placebo: (active or inactive) or no treatment.<BR/>2. Chlorpromazine: any dose or mode of administration (oral or by injection).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. General<BR/>1.1 Global state improvement*<BR/>1.2 Relapse - as defined by each study*<BR/>1.3 Leaving the study early<BR/>1.4 Death (suicide and non-suicide</P>
<P>2. Mental state<BR/>2.1 General symptoms<BR/>2.2 Specific symptoms<BR/>2.2.1 Positive symptoms (delusions, hallucinations, disordered thinking)<BR/>2.2.2 Negative symptoms (avolition, poor self-care, blunted affect)<BR/>2.2.3 Mood - depression</P>
<P>3. Behaviour<BR/>3.1 General behaviour<BR/>3.2 Specific behaviours (e.g. aggressive or violent behaviour)<BR/>3.2.1 Social functioning<BR/>3.2.2 Employment status during trial (employed/unemployed)<BR/>3.2.3 Occurrence of violent incidents (to self, others or property)</P>
<P>4. Adverse effects</P>
<P>5. Economic<BR/>5.1 Cost of care.</P>
<P>* We chose relapse and global state improvement (as defined in the individual studies) as the primary outcome measures.</P>
<P>We grouped outcomes into the short term (0-8 weeks), medium term (eight weeks to six months) and long term (six months to two years)</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-07-31 13:20:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Electronic searches<BR/>We searched The Cochrane Schizophrenia Group Trials Register (March 2006) using the phrase:<BR/>[(((anadep* or chloractil* or chlorazin* or chlorpromados* or chlorpromazine* or chlorprom-ez-ets* or (chlor p-z)* or chromedazine* or cpz* or elmarine* or esmind* or fenactil* or hibanil* or hibernal* or klorazin* or klorproman* or klorpromez* or largactil* or megaphen* or neurazine* or plegomazine* or procalm* or promachel* or promacid* or promapar* or promexin* or promosol* or prozil* or psychozine* or psylactil* or serazone* or sonazine* or thoradex* or thorazine* or tranzine*) AND (cessation* or withdr?w* or discontinu* or halt* or stop* or drop?out* or dropout*)) in title, abstract, index terms of REFERENCE) or ((chlorpromazine* and withdrawal*) in interventions of STUDY)]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module).</P>
<P>1. 1 Cochrane Schizophrenia Group Trials Register<B> </B>
</P>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register (July 2012)</P>
<P>[(((*anadep* or *chlora* or *chlorprom* or *chlor p-z* or *chromedazine* or *cpz* or *elmarine* or *esmind* or *fenactil* or *hibanil* or *hibernal* or *klorazin* or *klorproman* or *klorpromez* or *largactil* or *megaphen* or *neurazine* or *plegomazine* or *procalm* or *promachel* or *promacid* or * proma* or *promexin* or *promosol* or *prozil* or *psychozine* or *psylactil* or *serazone* or *sonazine* or *thoradex* or *thorazine* or *tranzine*) AND (*cessation* or *withdr?w* or *discontinu* or * halt* or * stop* or *drop?out* or *dropout*)) in title, abstract, index terms of REFERENCE) or ((*chlorpromazine* and *withdrawal*) in interventions of STUDY)]</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are assigned to existing or new review titles.</P>
<P>2. Reference searching<BR/>We inspected the references of all identified studies for further trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Selection of trials<BR/>We (MQM, ER, HA and HEM) independently inspected references located through electronic or reference searches in order to identify randomised trials meeting the inclusion criteria. Where disagreement occurred we resolved this by discussion, or, when there was still doubt, we acquired the full article for further inspection. Once the full articles were obtained, we (MQM, HEM) independently decided whether they met review criteria. Once again, disagreement was resolved by discussion. If doubt remained, we added the study to the list of those awaiting assessment, pending acquisition of more information.</P>
<P>2. Assessment of methodological quality <BR/>The methodological quality of trials was assessed using the criteria described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). These criteria are based on the evidence of a strong relationship between allocation concealment and direction of effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), and define the following categories: </P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results) <BR/>C. High risk of bias (inadequate allocation concealment).<BR/>Only trials falling in category A or category B were included in this review. </P>
<P>3. Data collection <BR/>We (MQM, ER, HA and HEM) independently extracted data from selected trials and held regular meetings during the data extraction period and resolved disputes by discussion.</P>
<P>4. Data synthesis </P>
<P>4.1 Data types<BR/>We assessed outcomes using continuous (for example changes on a behaviour scale) or dichotomous (for example, either 'no important changes' or 'important changes' in a person's behaviour) measures. Included studies reported no categorical measures (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change').</P>
<P>4.2 Incomplete data <BR/>We did not include trial outcomes if more than 40% of participants were not reported in the final analysis. </P>
<P>4.3 Dichotomous - yes/no - data <BR/>On the condition that more than 60% of people completed the study, everyone allocated to the intervention was counted whether they completed the follow up or not. We conducted an intention to treat analysis assuming that those who dropped out had the negative outcome, with the exception of death. Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. We used those predefined cut off points used by the authors of every study determining clinical effectiveness. Otherwise we considered a rating of 'at least much improved' according to the Clinical Global Impression Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>), or a 50% reduction in a scale-derived score, a clinically significant response.</P>
<P>We calculated the relative risk (RR) and its 95% confidence interval (CI) because RR has been shown to be more intuitive than odds ratios (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) and odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation may lead to an overestimate of the impression of the effect. We calculated RR and its 95% CI based on a fixed effects model.</P>
<P>4.4 Continuous data <BR/>4.4.1 Normally distributed data: continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we multiplied the standard deviation for scales starting from zero by two, and if the result was more than the mean, we considered the mean unlikely to be an appropriate measure of the centre of the distribution, (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). If a scale started from a positive value (such as PANSS which can have values from 30 to 210) we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score. </P>
<P>4.4.2 Rating scales: <BR/>A wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. We only included continuous data from rating scales if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>), the instrument was either a self report or completed by a rater, and the instrument could be considered a global assessment of an area of functioning. However, as it was expected that therapists would frequently also be the rater, we commented on such data as 'prone to bias'. </P>
<P>4.4.3 Summary statistic<BR/>For continuous outcomes we estimated a weighted mean difference (WMD) between groups, again based on a fixed effects model. </P>
<P>4.5 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for these using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for these using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>5. Investigation for heterogeneity<BR/> We judged clinical heterogeneity within all comparisons between included studies, and visually inspected graphs in order to investigate the possibility of statistical heterogeneity. This was supplemented by the I-squared statistic which provides an estimate of the percentage of variability due to heterogeneity rather than to chance alone. An I-squared estimate equal to or greater than or equal to 75% indicates the presence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). </P>
<P>6. Sensitivity analyses <BR/>We attempted to test the effects of gender, age, diagnostic criteria and date of publication on the primary outcome of relapse.</P>
<P>7. General <BR/>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for chlorpromazine.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>For substantive descriptions of the studies please see Included and Excluded Studies tables.</P>
<P>1. Excluded studies<BR/>We excluded 29 studies; three were not randomised and 19 trials did not involve withdrawal of chlorpromazine. However, three studies did include withdrawal of chlorpromazine but reported no usable outcomes. Four other studies, employed different phenothiazines, one of which was chlorpromazine, but outcome data were not broken down between the different compounds. </P>
<P>2. Awaiting assessment<BR/>There are no studies awaiting assessment.</P>
<P>3. Ongoing studies<BR/>We know of no ongoing studies.</P>
<P>4. Included studies<BR/>We included ten studies.</P>
<P>4.1 Methods<BR/>In all included studies, randomisation was either reported or implied. The mean duration of intervention was 294 days (~ten months), but this was highly skewed (SD 299 days). The most common study length was six months but the range was wide; with the shortest trial lasting for one month (<LINK REF="STD-Zeller-1956" TYPE="STUDY">Zeller 1956</LINK>) and the longest for three years (<LINK REF="STD-Hogarty-1973-a" TYPE="STUDY">Hogarty 1973 a</LINK>).</P>
<P>4.2 Setting<BR/>Most studies were hospital-based. Only <LINK REF="STD-Hogarty-1973-a" TYPE="STUDY">Hogarty 1973 a</LINK> was undertaken in the community.</P>
<P>4.3 Participants<BR/>Participants in most trials were reportedly suffering from schizophrenia, with two exceptions; people in <LINK REF="STD-Zeller-1956" TYPE="STUDY">Zeller 1956</LINK> were "psychotic patients", and <LINK REF="STD-Freeman-1962" TYPE="STUDY">Freeman 1962</LINK> included a few people with chronic brain syndrome and personality disorders as well as those with schizophrenia. Schizophrenia was diagnosed using some diagnostic criteria or pre-stated set of symptoms in only a few trials. The mean age of participants was about 44 yrs (~SD 7), and their illness were mostly chronic with mean hospitalisation period of about 20 years. Six studies involved only male participants (three studies did not mention the sex of participants, <LINK REF="STD-Mathur-1981" TYPE="STUDY">Mathur 1981</LINK>, <LINK REF="STD-Shawver-1959" TYPE="STUDY">Shawver 1959</LINK>, <LINK REF="STD-Zeller-1956" TYPE="STUDY">Zeller 1956</LINK>). Overall the male to female ratio was about 3:1 (M 630, F 217). </P>
<P>4.4 Study size<BR/>The total number of participants was 1024 (mean 104, SD~121). This ranged from 20 (<LINK REF="STD-Pigache-1973" TYPE="STUDY">Pigache 1973</LINK>) to 374 (<LINK REF="STD-Hogarty-1973-a" TYPE="STUDY">Hogarty 1973 a</LINK>).</P>
<P>4.5 Interventions<BR/>All participants were people with schizophrenia stable on chlorpromazine medication and randomised into two groups. Chlorpromazine was discontinued for the first group and replaced with placebo. The second group continued to receive chlorpromazine at different doses ranging from 100 mg/day (<LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>) to 510 mg/day (<LINK REF="STD-Greenberg-1966" TYPE="STUDY">Greenberg 1966</LINK>). The mean dose was 270mg/day with (SD~135).</P>
<P>4.6 Outcomes<BR/>All outcomes were dichotomous and but several scales described below were used to generate these data.</P>
<P>4.7.1 Global state<BR/>4.7.1.1 Clinical Global Impression (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater recovery.</P>
<P>4.7.1.2 Multidimensional Rating Scale (<LINK REF="REF-Lorr-1953" TYPE="REFERENCE">Lorr 1953</LINK>)<BR/>The Multidimensional Rating Scale or Hamilton's schizophrenia scale is a modification of the Inpatient Multidimensional Psychiatric Scale. The MDRSP is to be completed after a psychiatric interview. It consists of 18 items, in the form of simple questions, to be rated along a four point scale. The severity scores are defined by short behavioural descriptions on the form, thus avoiding interpretation problems. The scale is mainly designed for the evaluation of chronically hospitalised schizophrenic patients.</P>
<P>4.7.2 Mental state<BR/>4.7.2.1 Brief Psychiatric Rating Scale (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>A brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The original scale has sixteen items, but a revised eighteen-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0-126, with high scores indicating more severe symptoms.</P>
<P>4.7.2.2 Wing Scale (<LINK REF="REF-Wing-1961" TYPE="REFERENCE">Wing 1961</LINK>)<BR/>The Wing scale has been successful in detecting the efficacy of antipsychotic drugs. The SRSS is a simple four item rating scale: 1) incongruity of affect, 2) poverty of speech, 3) incoherence of speech and 4) coherent delusions. In spite of the availability of definitions and examples, the items remain a bit vague. The SRSS's original purpose was to classify subjects, and, although it cannot be used for diagnosis, as the items are taken from the key symptoms of the disease in the rather strict sense in which it is defined in placeEurope, a high score would support a diagnosis of schizophrenia. Training is probably necessary, as it is for the use of any scale based on the typical experiences of schizophrenics which are not as easily open to empathy as are the emotions of depressed or anxious patients. The interview format is free and, for an experienced rater, the time to complete the SRSS after the interview is less than a minute.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation<BR/>None of the included studies described the methods used to generate random allocation. A form of allocation concealment (sealed envelopes) was described in only one study (<LINK REF="STD-Pigache-1973" TYPE="STUDY">Pigache 1973</LINK>). For the other studies, readers are given little assurance that bias was minimised during the allocation procedure. Five (5/10) studies reported that the participants allocated to each treatment group were very similar. Five (5/10) studies had exactly the same number of participants in the chlorpromazine and placebo groups, yet only <LINK REF="STD-Shawver-1959" TYPE="STUDY">Shawver 1959</LINK> reported that participants were randomly assigned in blocks. It seems improbable that such equal numbers could have been obtained in the remaining four studies unless block randomisation was used. </P>
<P>2. Blindness<BR/>Six of the ten included trials described a double-blinding procedure; four indicated that attempts at blinding had been made but gave no description of such attempts, and a single study, <LINK REF="STD-Mathur-1981" TYPE="STUDY">Mathur 1981</LINK>, gave no indication that blinding had been attempted.</P>
<P>3. Early withdrawals<BR/>Interestingly, the description of those who left the studies early was very poor. Only three studies reported early withdrawals yet they gave little or no details of why people left the studies early. </P>
<P>4. Outcome reporting<BR/>Studies frequently presented both dichotomous and continuous data in graphs. Sometimes, just statistical measures of probability (p-values) were reported making it impossible to acquire raw data for synthesis. It was also common to use p-values as a measure of association between intervention and outcomes instead of showing the strength of the association. Although p-values are influenced by the strength of the association, they also depend on the sample size of the groups. Although raw data may be extracted from p-values if the exact p-values were known, this extraction was not possible in the studies included in this review because p-values were reported as 'p&lt;0.05' or 'p&gt;0.05'. Frequently continuous data were poorly described: often no standard deviations/errors were presented or no data were presented at all. In this way a lot of potentially informative data were lost. Some studies attempted at using the original trials as vehicles for answering a host of questions about schizophrenia. As a consequence, data from the randomised parts of the studies became buried beneath copious subgroup analyses. </P>
<P>5. Overall quality<BR/>The quality of trials, as measured using the criteria described in the Cochrane Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>), varied. Inclusions in this review necessitated at least a Category B on the Cochrane Handbook rating of allocation. As we considered nine studies to be in category 'B' whilst only one study achieved Category A status, some data must be considered to be prone to a moderate degree of bias.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. The search, trial selection and data extraction <BR/>The searches yielded 60 electronic records, of which 20 were easily rejected after first inspection. The other 40 papers were considered to match the inclusion criteria closely enough to be mentioned in either the 'Included studies' or 'Excluded studies' section. During the data extraction process, we inspected the references of these papers and identified nine more papers as being relevant. </P>
<P>The review currently cites 31 papers as 'excluded studies' and 18 papers as included. There was over 80% agreement for trial selection and once we had investigated disagreement, acquired and re-inspected papers, concordance became 100%. Initially there was also over 80% agreement in all but 'numbers completing the study' (70%) and listing of outcome instruments. For the latter, in about one fifth of reports, we often failed to identify the same number of scales, often when several had been used.</P>
<P>2. COMPARISON: CHLROPROMAZINE WITHDRAWAL vs CONTINUING ON CHLORPROMAZINE </P>
<P>2.1 Global state<BR/>2.1.1 Not improved or worsened<BR/>Only <LINK REF="STD-Zeller-1956" TYPE="STUDY">Zeller 1956</LINK> reported usable data regarding global state improvement at short-term follow-up (n=95, 1 RCT, RR 2.46 CI 1.51 to 3.99, NNH 3 CI 2) favouring chlorpromazine continuation. </P>
<P>2.1.2 Relapse<BR/>The data for this primary outcome were extracted and sorted into short, medium and long-term relapse. The results are homogeneous (p=0.36, 0.13, 0.46 respectively) and overall data significantly favoured chlorpromazine continuation. In the short term three trials presented usable data regarding relapse and favoured chlorpromazine continuation (n=376, 3 RCTs, RR 6.76 CI 3.37 to 13.54, NNH 4 CI 2 to 8). In the medium term six trials presented usable data regarding relapse and again the results favoured chlorpromazine continuation (n=850, 6 RCTs, RR 4.04 CI 2.81 to 5.81, NNH 4 CI 3 to 7). In the long term follow up category we obtained data from three trials which again favoured chlorpromazine continuation (n=510, 3 RCTs, RR 1.70 CI 1.44 to 2.01, NNH 4 CI 3 to 6). </P>
<P>2.2 Leaving the study early<BR/>Only one large study, <LINK REF="STD-Hogarty-1973-a" TYPE="STUDY">Hogarty 1973 a</LINK> with a duration of more than three years showed that people allocated to the chlorpromazine cessation group were not significantly more likely to stay in the study than those who were allocated to the chlorpromazine continuation group (n=374, 1 RCT, RR 1.14 CI 0.55 to 2.35). Surprisingly, we were unable to obtain any further data regarding patients who left the study early from other included studies. </P>
<P>2.3 Mental state<BR/>For this important outcome data were very limited. One included trial, <LINK REF="STD-Morton-1968" TYPE="STUDY">Morton 1968</LINK>, presented usable data relating to this outcome. This study reported no difference in mental state in patients who continued taking chlorpromazine in comparison with those in the cessation group using a cut off point of at least a 50% decline in score to indicate 'improvement' (n=12, 1 RCT, RR not improved 1.0 CI 0.60 to 1.66).</P>
<P>2.4 Missing outcomes<BR/>No usable data were presented in any of the included trials about either the adverse effects or the economic (cost-effectiveness) consequences of continuing on chlorpromazine or withdrawing from this medication.</P>
<P>2.4 SENSITIVITY ANALYSES<BR/>A number of sensitivity analyses could not be performed as data were only available for people from different age groups, gender (male, female), chronicity and for those treated before or after 1990. However, sensitivity analyses on groups with different chlorpromazine dosages, or different diagnostic criteria were possible. </P>
<P>2.4.1 Low dose (&lt;500mg/day) versus high dose (&gt;500mg/day): Relapse <BR/>Limited data were available for participants who took low dosages of chlorpromazine compared with those whose took higher dosages. The only primary outcome for which data were available for comparison was 'relapse'. <LINK REF="STD-Greenberg-1966" TYPE="STUDY">Greenberg 1966</LINK> was the only one with dose &gt;500 mg/day (n=42) while the other five studies used doses &lt;500 mg/day (n=934). There were no significant differences in the outcomes of 'relapse' between these two groups as the wide confidence intervals for these groups of studies overlap.</P>
<P>2.4.2 People diagnosed according to any operational criteria versus those who have not been diagnosed using operational criteria<BR/>The available relevant studies allowed synthesis of data for the outcomes of 'relapse'. <LINK REF="STD-Hogarty-1973-a" TYPE="STUDY">Hogarty 1973 a</LINK> was the only trial with patients diagnosed according to an operational criterion (n=374) while nine other trials included patients with schizophrenia diagnosed clinically (n=638). 'Relapse' in trials with patients clinically diagnosed showed a significant difference in comparison with those who diagnosed patients according to operational criteria, yet both groups favours chlorpromazine continuation.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. Strengths and weakness of the review<BR/>1.1 Adding the old to the new<BR/>This review includes trials that span nearly five decades of evaluative studies within psychiatry. It is possible that the rigour of these experiments has changed over time, as have participants and even the formulation of the drug (it was thought that introduction of impurities in early formulations of chlorpromazine led to jaundice). There is some empirical evidence that the quality of schizophrenia trial reporting has not changed much over time (<LINK REF="REF-Thornley-1998" TYPE="REFERENCE">Thornley 1998</LINK>) or, if it has changed, it may even have declined (<LINK REF="REF-Ahmed-1998" TYPE="REFERENCE">Ahmed 1998</LINK>). We have found no time-related differences in reporting of studies within this review and no suggestion of a change of the effect size over time. Synthesis of results seems justified. </P>
<P>1.2 Failing to identify old trials<BR/>We identified trials by meticulous searching. Nevertheless, for a compound formulated so long ago, publication biases may be difficult to avoid. The strength of this review is that it presents up-to-date quantitative data for the withdrawal of a benchmark treatment for schizophrenia which is used throughout the world.</P>
<P>2. Applicability<BR/>The 11 included studies in this review included many people who would be recognisable in everyday practice. There are those with strictly diagnosed illnesses, very likely to suffer from schizophrenia, and people whose illness was diagnosed using less rigorous criteria. Although the outcomes that have been used in this review are accessible to both clinicians and recipients of care, generalising to treatment in community settings, could be problematic. Most studies were undertaken in hospital, whereas the great majority of people with schizophrenia reside in the community.</P>
<P>3. Homogeneity<BR/>We did not find heterogeneity. The test for homogeneity is based on the I-square statistic, and is often fairly weak because the number of studies is small. However, the results of such tests, when statistically significant, suggest caution when adding trial data together.</P>
<P>4. COMPARISON: CHLROPROMAZINE WITHDRAWAL VERSUS CONTINUING ON CHLORPROMAZINE </P>
<P>4.1.Global state<BR/>4.1.1 Global improvement<BR/>There were few data, but they show that global state deteriorated significantly after cessation of chlorpromazine (NNH 3 CI 2 to 7). These findings are limited and derived from only one study (n=95) but are consistent with clinical impressions. </P>
<P>4.1.2 Relapse<BR/>This is a primary outcome in this review and there were data regarding the relapse from studies with different periods of follow ups, but the strongest results come from studies of six months duration. For this period, which was classified as medium term follow up, data were obtained from six trials and homogeneous data clearly favoured chlorpromazine continuation over its cessation. The people included in the trials that provide data for this review were, largely, very chronically unwell. Stopping the drug on which they had been stable often resulted in relapse with a relatively small NNH with tight confidence intervals (NNH 4 CI 3 to 7). </P>
<P>4.1.4 Death <BR/>It may be surprising that there were no deaths reported among over 1000 people with schizophrenia who were randomised to chlorpromazine cessation or chlorpromazine continuation. The lifetime incidence of suicide for people suffering from schizophrenia is 10-13% (<LINK REF="REF-Caldwell-1992" TYPE="REFERENCE">Caldwell 1992</LINK>). Furthermore, the use of large doses of antipsychotic drugs has been associated with sudden death (<LINK REF="REF-Jusic-1994" TYPE="REFERENCE">Jusic 1994</LINK>) but there are no records of such events within this review. The fact that there were no deaths may reflect the fact that either trial-care is more vigilant than routine care or that death is an under-reported outcome.</P>
<P>4.2 Leaving the study early<BR/>Withdrawing chlorpromazine seems to result in no more people leaving the study compared with continuation of the same drug (n=374, 1 RCT, RR 1.14 CI 0.55 to 2.35). We are unclear what this finding represents. It could be a function of good trial design, or reflect the nature of the patient group.</P>
<P>4.3 Mental state <BR/>In fact, very little can be said about mental state from chlorpromazine withdrawing trials included in this review, and we were only able to obtain usable data from one small study (<LINK REF="STD-Morton-1968" TYPE="STUDY">Morton 1968</LINK>, n=12). However, trials comparing instigation of chlorpromazine with placebo presented good data about mental state and this has been fully assessed in another Cochrane review (<LINK REF="REF-Thornley-2006" TYPE="REFERENCE">Thornley 2006</LINK>).</P>
<P>4.4 Sensitivity analysis<BR/>As was likely from the start, the power to detect a real difference between studies in any one of the sensitivity analyses was very low. Only subsets of already limited lists of trials were available. The wide confidence intervals could be hiding true differences in effect between the sexes, age groups of people, acutely and chronically ill people, those allocated high or low doses of chlorpromazine, people diagnosed with operational criteria as opposed to more clinical diagnoses, and early trials versus current studies. The only suggestion of a statistically significant difference was for high dose versus low dose studies (relapse between nine weeks and six months). It is important to remember that this is now a non-randomised comparison between studies, rather than within a study, and that this is one of many statistical tests that were undertaken on this dataset. Further complicating matters is the fact that the other outcomes within this particular sensitivity analysis did not clearly support or refute this difference between high and low doses. The significant difference in the 'relapse' outcome between groups with clinically diagnosed schizophrenics and those diagnosed according to checklist criteria is interesting.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>1. For people with schizophrenia<BR/>For people with their first episode of schizophrenia medication is useful. Studies suggest that over 10% of this group will not go on to have further relapses. The trials in this review do not include people in this important group and the data do not easily relate to people with first episodes of this difficult and damaging illness. People whose illness is established, who have been stabilised on chlorpromazine, should not stop their medication in favour of placebo.</P>
<P>2. For clinicians<BR/>Much evidence points to intermittent cessation of medication as being the normal pattern of compliance. In this review we confirm much that clinicians already know, but this review does provide some quantification to support clinical impression. For people with established illnesses, chlorpromazine withdrawal shows significant increase in relapse across all time periods. For people in their first episode of schizophrenia about 13% will not go on to need antipsychotic medications in the long term (<LINK REF="REF-Shepherd-1989" TYPE="REFERENCE">Shepherd 1989</LINK>). This review does not help either identify or quantify risk in this important subgroup.</P>
<P>3. For managers or policy makers<BR/>Chlorpromazine is inexpensive and therefore it is understandable that it remains one of the most widely prescribed drugs used for treating people with schizophrenia. Clearly cessation is related to increased rates of relapse for those with established illness. Relapse incurs costs, as does the management of adverse effects of chlorpromazine. This review, however, does not contain cost-effectiveness data.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>So much more could have been learnt about the effects of the cessation of chlorpromazine if the studies in this review had clearly described the method of allocation, the integrity of blinding, especially for the more subjective outcomes, and the reasons for early withdrawal (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>).</P>
<P>2. More trials comparing chlorpromazine with placebo?<BR/>Even though chlorpromazine has been used as an antipsychotic drug for decades, there are still only a few well-conducted randomised, placebo-controlled trials measuring the effects of its cessation and potential to cause deterioration. Stopping medication, failing to comply with ongoing treatment is so common (<LINK REF="REF-CATIE-2005" TYPE="REFERENCE">CATIE 2005</LINK>) and therefore it is essential that clinicians and patients should know in quantitative terms, of the consequences of such an action. New studies evaluating the consequences of the cessation in comparison with the continuation of the treatment would be most welcome, but probably are only ethical for people who have decided to stop the medication anyway. Within the trial, people should be encouraged to either continue for some period or continue with their decision to stop, within the context of the trial. In this way the consequences of their decision could be closely monitored and any adverse consequences picked up very quickly. </P>
<P>We have outlined methods for a study in Table 04. Concrete and simple outcomes are of interest. For example, clearly reporting improvement, 'number of violent incidents', 'relapse' (giving some description of criteria), 'hospital discharge or admission', and 'presence of delusions or hallucinations' would have been helpful, and simple reporting of levels of satisfaction and quality of life would have been most informative. Chlorpromazine has been in use for decades, yet clinicians still have no trial-based data indicating how people with schizophrenia would fair in the short, medium and long term if the drug was stopped. If rating scales are to be employed, a concerted effort should be made to agree on which measures are the most useful. Studies within this review reported on so many scales that, even if results had not been poorly reported, they would have been difficult to synthesise in a clinically meaningful way.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank the members of the Cochrane Schizophrenia Group editorial base for their help, their support and the fun we had whilst working there.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Muhammad Qutayba Almerie - protocol development, data extraction, analysis, data interpretation and writing the final report. </P>
<P>Hosam El-Din Matar - protocol development, data extraction, analysis, data interpretation and writing the final report.</P>
<P>Hassan Alkhateeb - protocol development data extraction. </P>
<P>Emtithal Rezk - protocol development and data extraction.</P>
<P>Adib Essali - writing up the final report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-07-31 12:55:07 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Andrews-1976" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Andrews 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrews P, Hall JN, Snaith RP</AU>
<TI>A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1976</YR>
<VL>128</VL>
<PG>451-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="776312"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caffey-1964" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Caffey 1964" YEAR="1963">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Caffey EM, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, Rothstein C</AU>
<TI>Discontinuation or reduction of chemotherapy in chronic schizophrenics</TI>
<SO>Journal of Chronic Diseases</SO>
<YR>1964</YR>
<VL>17</VL>
<NO>4</NO>
<PG>347-58</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1965-09583-001"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caffey EM, Forrest IS, Frank TV, Klett CJ</AU>
<TI>Phenothiazine excretion in chronic schizophrenics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1963</YR>
<VL>120</VL>
<PG>578-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2361668"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freeman-1962" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Freeman 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freeman Leslie S, Alson Eli</AU>
<TI>Prolonged withdrawal of chlorpromazine in chronic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1962</YR>
<VL>23</VL>
<PG>522-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 74-32161"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-1966" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Greenberg 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg LM, Roth S</AU>
<TI>Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1966</YR>
<VL>123</VL>
<PG>221-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5947494"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogarty-1973-a" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Hogarty 1973 a" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg SC, Schooler NR, Hogarty GE, Roper M</AU>
<TI>Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1977</YR>
<VL>34</VL>
<NO>2</NO>
<PG>171-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="843177"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF</AU>
<TI>Drug and sociotherapy in the aftercare of schizophrenic patients. II two-year relapse rates</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1974</YR>
<VL>31</VL>
<NO>5</NO>
<PG>603-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4374155"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, Goldberg SC, Schooler NR</AU>
<TI>Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of non relapsed patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1974</YR>
<VL>31</VL>
<NO>5</NO>
<PG>609-18</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4374156"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, Goldberg SC</AU>
<TI>Drug and sociotherapy in the aftercare of schizophrenic patients. one-year relapse rates</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1973</YR>
<VL>28</VL>
<NO>1</NO>
<PG>54-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4345664"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, Ulrich RF</AU>
<TI>Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1977</YR>
<VL>34</VL>
<NO>3</NO>
<PG>297-301</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="190970"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathur-1981" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Mathur 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathur S, Hall JN</AU>
<TI>Phenothiazine withdrawal in schizophrenics in a hostel</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<PG>271-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7023591"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morton-1968" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Morton 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morton MR</AU>
<TI>A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1968</YR>
<VL>124</VL>
<NO>11</NO>
<PG>1585-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="68203217"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pigache-1973" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Pigache 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pigache RM, Norris HN</AU>
<TI>Measurement of drug action in schizophrenia</TI>
<SO>Clinical Science</SO>
<YR>1973</YR>
<VL>44</VL>
<NO>6</NO>
<PG>28</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73204883"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pigache RM</AU>
<TI>The Clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia with placebo substitution for chlorpromazine</TI>
<SO>Schizophrenia research</SO>
<YR>1993</YR>
<VL>10</VL>
<NO>1</NO>
<PG>39-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8369231"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shawver-1959" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Shawver 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shawver JR, Gorham DR, Leskin LW, Good WW, Kabnick DE</AU>
<TI>Comparison of chlorpromazine and reserpine in maintenance drug therapy</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1959</YR>
<VL>20</VL>
<PG>452-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="215095"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeller-1956" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Zeller 1956" YEAR="1956">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeller WW, Graffagnino PN, Cullen CF, Rietman HJ</AU>
<TI>Use of chlorpromazine and reserpine in the treatment of emotional disorders</TI>
<SO>JAMA</SO>
<YR>1956</YR>
<VL>160</VL>
<PG>179-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 81-02889"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Blackburn-1981" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Blackburn 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blackburn HL, Allen JL</AU>
<TI>Behavioral effects of interrupting and resuming tranquillizing medication among schizophrenics</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1981</YR>
<VL>133</VL>
<PG>302-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5327466"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bouchard-1998" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Bouchard 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bouchard RH, Pourcher E, Mérette C, Demers MF, Villeneuve J, Roy MA, Gauthier Y, Cliche D, Labelle A, Maziade M</AU>
<TI>One year follow up of schizophrenic patients treated with risperidone or classical neuroleptics: a prospective, randomized, multicentered open study</TI>
<SO>11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11th Congress of the European College of Neuropsychopharmacology [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1998 P2124"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1990" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Chouinard 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G</AU>
<TI>A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1990</YR>
<VL>358</VL>
<PG>111-19</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91050675"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crow-1986" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Crow 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crow TJ, MacMillan JF, Johnson AL, Johnstone EC</AU>
<TI>A randomised controlled trial of prophylactic neuroleptic treatment</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>148</VL>
<PG>120-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2870753"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diamond-1960" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Diamond 1960" YEAR="1960">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diamond LS, Marks JB</AU>
<TI>Discontinuance of tranquillizers among chronic schizophrenic patients receiving maintenance dosage</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1960</YR>
<VL>131</VL>
<PG>247-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1961-02332-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garfield-1966" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Garfield 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garfield SL, Gershon S, Sletten I, Neubauer H, Ferrel E</AU>
<TI>Withdrawal of ataractic medication in schizophrenic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1966</YR>
<VL>27</VL>
<NO>5</NO>
<PG>321-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5327466"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-1967" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Goldberg 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg SC, Schooler NR, Mattsson N</AU>
<TI>Paranoid and withdrawal symptoms in schizophrenia: differential symptom reduction over time</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1967</YR>
<VL>145</VL>
<NO>2</NO>
<PG>158-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4861752"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Good-1958" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Good 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Good WW, Sterling M, Holtzman WH</AU>
<TI>Termination of chlorpromazine with schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1958</YR>
<VL>115</VL>
<PG>443-48</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81014416"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mefferd RB Jr, Labrosse EH, Gawienowski AM, Williams RJ</AU>
<TI>Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1958</YR>
<VL>127</VL>
<PG>167-79</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81014416"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gross-1960" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Gross 1960" YEAR="1960">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gross M, Hitchman IL, Reeves WP, Lawrence J, Newell PC</AU>
<TI>Discontinuation of treatment with ataractic drugs. A preliminary report</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1960</YR>
<VL>116</VL>
<PG>931-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hine-1958" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Hine 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hine FR</AU>
<TI>Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1958</YR>
<VL>127</VL>
<PG>220-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5947494"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogarty-1973-b" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Hogarty 1973 b" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, Munetz MR</AU>
<TI>Pharmacogenic depression among outpatient schizophrenic patients: a failure to substantiate</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1984</YR>
<VL>4</VL>
<NO>1</NO>
<PG>17-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6141187"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howanitz-1996" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Howanitz 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Howanitz EM, Pardo M, Litwin P, Stern RG, Wainwright KM, FLosonczy M</AU>
<TI>Efficacy of clozapine versus chlorpromazine in geriatric schizophrenia</TI>
<SO>149th Annual Meeting of the American Psychiatric Association; 1996 Oct 2 - May 9; New York, New York, USA</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5947494"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knight-1979" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Knight 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knight RG, Harrison A</AU>
<TI>A double blind comparison of thiothixene and a trifluoperazine-chlorpromazine composite in the treatment of chronic schizophrenia</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1979</YR>
<VL>89</VL>
<NO>634</NO>
<PG>302-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79200326"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapolla-1967" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Lapolla 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apella A</AU>
<TI>A double blind evaluation of chlorpromazine versus a combination of perphenazine and amitriptyline</TI>
<SO>International Journal of Neuropsychiatry</SO>
<YR>1967</YR>
<VL>3</VL>
<NO>5</NO>
<PG>403-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1968-07423-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-1997" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Levine 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine J, Caspi N, Laufer N</AU>
<TI>Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>1</NO>
<PG>55-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98017426"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1997-06099-006"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mefferd-1958" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Mefferd 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mefferd RBJr, Labrosse EH, Gawienowski AM, Williams RJ</AU>
<TI>Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1958</YR>
<VL>127</VL>
<PG>167-79</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81014416"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melnyk-1966" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Melnyk 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melnyk WT, Worthington AG, Laverty SG</AU>
<TI>Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic in-patients</TI>
<SO>Canadian Psychiatric Association Journal</SO>
<YR>1966</YR>
<VL>11</VL>
<NO>5</NO>
<PG>410-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1966-13288-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montero-1971" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Montero 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Montero E</AU>
<TI>Thioridazine compared with a combination of chlorpromazine and trifluoperazine hydrochloride in schizophrenic patients</TI>
<SO>5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Mexico City, Mexico</SO>
<YR>1971</YR>
<PG>433</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4596671"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moss-1958" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Moss 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moss CS, Jensen RE, Morrow W, Freund HG</AU>
<TI>Specific behavioural changes produced by chlorpromazine in chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1958</YR>
<VL>115</VL>
<PG>449-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pai-2001" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Pai 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pai YM, Yu SC, Lin CC</AU>
<TI>Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study</TI>
<SO>154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98017426"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1997-06099-006"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pigache-1993" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Pigache 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pigache RM</AU>
<TI>Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study</TI>
<SO>Schizophrenia Research</SO>
<YR>1993</YR>
<VL>10</VL>
<NO>1</NO>
<PG>51-59</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8369232"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pokorny-1974" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Pokorny 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pokorny AD, Prien RF</AU>
<TI>Lithium in treatment and prevention of effective disorder: a VA NIMH collaborative study</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1974</YR>
<VL>35</VL>
<NO>7</NO>
<PG>327-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 53-03687"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pollack-1956" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Pollack 1956" YEAR="1956">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pollack B</AU>
<TI>The effect of chlorpromazine on the return rate of 250 patients released from the Rochester State Hospital</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1956</YR>
<VL>112</VL>
<PG>937</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prien-1968" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Prien 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prien RF, Cole JO, Bel kin NF</AU>
<TI>Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1968</YR>
<VL>115</VL>
<NO>523</NO>
<PG>679-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69279244"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prien RF, Levine J, Cole JO</AU>
<TI>Indications for high dose chlorpromazine therapy in chronic schizophrenia</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1970</YR>
<VL>31</VL>
<NO>11</NO>
<PG>739-45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4923151"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiele-1961" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Schiele 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiele BC, Vestre ND, Stein KE</AU>
<TI>A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic hospitalized, schizophrenic patients</TI>
<SO>Journal of Clinical and Experimental Psychopathology</SO>
<YR>1961</YR>
<VL>22</VL>
<NO>3</NO>
<PG>151-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14498342"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slotnick-1971" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Slotnick 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Slotnick VB</AU>
<TI>Management of the acutely agitated psychiatric patient with parental neuroleptics: the comparative symptom effectiveness profiles of haloperidol and chlorpromazine</TI>
<SO>5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Mexico City, Mexico</SO>
<YR>1971</YR>
<PG>531</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="215095"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Troshinsky-1962" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Troshinsky 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Troshinsky C, Aaronson H, Stone RK</AU>
<TI>Maintenance phenothiazines in aftercare of schizophrenic patients</TI>
<SO>Pennsylvania Psychiatric Bulletin</SO>
<YR>1962</YR>
<VL>2</VL>
<PG>11-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1982" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Wilson 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson LG, Roberts RW, Gerber CJ, Johnson MH</AU>
<TI>Pimozide versus chlorpromazine in chronic schizophrenia - a 52 week double blind study of maintenance therapy</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1982</YR>
<VL>43</VL>
<NO>2</NO>
<PG>62-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 68-06384"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wode_x002d_Helgodt-1981" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Wode-Helgodt 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wode-Helgodt B, Alfredsson G</AU>
<TI>Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses</TI>
<SO>Psychopharmacology</SO>
<YR>1981</YR>
<VL>73</VL>
<NO>1</NO>
<PG>55-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 68-06384"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-07-31 12:55:07 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-07-31 12:55:07 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ahmed-1998" NAME="Ahmed 1998" NOTES="&lt;p&gt;References to studies included in this review Abrams 1958 {published data only} Abrams J. Chlorpromazine in the treatment of chronic schizophrenia. Diseases of the Nervous System 1958;19:20-8. Links Baker 1959 {published data only} Baker JP. A controlled trial of ethylcrotonylurea. British Journal of Psychiatry 1959;105:852-62. Links Ban 1975 {published data only} Ban TA, Lehmann HE, Sterlin C, Climan M. Comprehensive clinical studies with thiothixene. Diseases of the Nervous System 1975;36:473-7. Links Bishop 1963 {published data only} Bishop M, Gallant DM. Behavioral toxicity associated with benzquinamide (Quantril) therapy in schizophrenic patients. American Journal of Psychiatry 1963;120:180-1. Links Borison 1991 {published data only} Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin 1991;27:103-6. Links Borison RL, Dren AT, Diamond BI. Sigma receptor antagonism and antipsychotic actions in schizophrenic patients. European Journal of Pharmacology 1990;183:2323. Links Chouinard 1990 {published data only} Chouinard G. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatria Scandinavica Supplementum 1990;358:111-9. Links Clark 1961 {published data only} Clark ML, Ray T, Paredes A, Costiloe J, Chappell J, Hagans J, Wolf S. Chlorpromazine in chronic schizophrenic women. I. Experimental design and effects at maximum point of treatment. Psychopharmacologia 1961;2:107-36. Links Clark ML, Ray TS, Ragland RE. Chlorpromazine in chronic schizophrenic women: rate of onset and rate of dissipation of drug effects. Psychosomatic Medicine 1963;25:212-17. Links Ray TS, Ragland RE, Clark ML. Chlorpromazine in chronic schizophrenic women: comparison of differential effects on various psychological modalities during and after treatment. Journal of Nervous and Mental Diseases 1964;138:348-53. Links Clark 1967 {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, Wolf S. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosomatic Medicine 1967;29:634-42. Links Clark 1968a {published data only} Clark ML, Huber WK, Kyriakopoulos AA, Ray TS, Colmore JP, Ramsey HR. Evaluation of trifluperidol in chronic schizophrenia. Psychopharmacologia 1968;12:193-203. Links Clark 1968b {published data only} Clark ML, Ray TS, Huber WK, Willis D, Ramsey HR. Evaluation of butaperazine in chronic schizophrenia. Clinical Pharmacology and Therapeutics 1968;97:57-64. Links Clark 1970a {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. Clinical Pharmacology and Therapeutics 1970;11:680-8. Links Serafetinides EA, Willis D, Clark ML. The EEG effects of chemically and clinically dissimilar antipsychotics: molindone vs. chlorpromazine. International Pharmacopsychiatry 1971;6:77-82. Links Clark 1970b {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark M, Ramsey H, Rahhal D, Serafetinides E, Wood F, Costiloe J. Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships. Archives of General Psychiatry 1972;27:479-83. Links Clark ML, Ramsey HR, Ragland RE, Rahhal DK, Serafetinides EA, Costiloe JP. Chlorpromazine in chronic schizophrenia - behavioral dose-response relationships. Psychopharmacologia 1970;18:260-70. Links Serafetinides EA, Willis D, Clark ML. EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking. Biological Psychiatry 1972;4:251-6. Links Clark 1971 {published data only} Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP. Drug treatment in newly admitted schizophrenic patients. Archives of General Psychiatry 1971;25:404-9. Links Clark 1972 {published data only} Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972;33:783-91. Links Serafetinides EA, Willis D, Clark ML. The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects. International Pharmacopsychiatry 1971;6:38-44. Links Clark 1977 {published data only} Clark ML, Paredes A, Costiloe JP, Wood F. Evaluation of butaclamol in chronic schizophrenic patients. Journal of Clinical Pharmacology 1977;17:529-36. Links Cohen 1968 {published data only} Cohen M, Freedman N, Englehardt DM. Family interaction patterns, drug treatment, and change in social aggression. Archives of General Psychiatry 1968;19(1):50-6. Links Graupner OK, Kalman EV. Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments [Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)]. Psychopharmacologia 1972;27(4):343-7. [MedLine: 73085373]. Links Cole 1964 {published data only} * Cole JO, Goldberg SC, Klerman GL National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 1964;10:246-61. Links Goldberg S, Klerman G, Cole J. Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. British Journal of Psychiatry 1965;111:120-33. Links Goldberg SC, Mattsson NB. Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System 1968;29:153-8. Links Cooper 2000 {published and unpublished data} Cooper SJ, Butler A, Tweed J, Welch CP. Zotepine in the treatment of chronic schizophrenia. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria: September 13-17, 1997. Cooper SJ, Raniwalla J, Welch C. Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo. XXth Collegium Internationale Neuro-psychopharmacologicum. Melbourne, Australia. Melbourne, Australia: 1996. * Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C. A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica 2000;101(3):218-25. [MedLine: 20184895]. Links Cooper SJ, Tweed J, Raniwalla J, Welch C. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Unpublished manuscript 1996. Cooper SJ, Welch CP. A comparison of zotepine and chlorpromazine on BPRS subscores. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria: September 13-17, 1997. Dean 1958 {published data only} Dean EF, Buker S. Schizophrenia treated with and without chlorpromazine. Rocky Mountain Medical Journal 1958;55:47-50. Links Engelhardt 1960 {published data only} Engelhardt D, Freedman N, Rosen B, Mann D, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. Archives of General Psychiatry 1964;11:162-9. Links Engelhardt DM, Freedman N, Glick BS, Hankoff LD, Mann D, Margolis R. Prevention of psychiatric hospitalization with use of psychopharmacological agents. Journal of the American Medical Association 1960;173:147-9. Links Engelhardt DM, Margolis RA, Rudorfer L, Paley HM. Physician bias and the double-blind. Archives of General Psychiatry 1969;20(3):315-20. Links Engelhardt DM, Rosen B, Freedman N, Mann D, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure. Journal of the American Medical Association 1963;186:981-3. Links Engelhardt DM, Rosen B, Freedman N, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization - a reevaluation. Archives of General Psychiatry 1967;16:98-101. Links Freedman N, Cutler R, Engelhardt DM, Margolis R. On the modification of paranoid symptomatology. Journal of Nervous and Mental Disease 1967;144:29-36. Links Freedman N, Cutler R, Engelhardt DM, Margolis R. On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines. Journal of Nervous and Mental Disease 1970;150:68-76. Links Rosen B, Engelhardt DM, Freedman N. The hospitalization proneness scale as a predictor of response to phenothiazine treatment. Journal of Nervous and Mental Disease 1968;6:476-80. Links Fink 1963 {published data only} Belmont I, Pollack M, Willner A, Klein D, Fink M. The effects of imipramine and chlorpromazine on perceptual analytic ability, perceptual analytic responsivity and memory as revealed in rorschach responses. Journal of Nervous and Mental Disease 1963;137(1):42-50. Links * Fink M, Pollack M, Klein DF, Blumberg AG, Belmont I, Karp E, Kramer JC, Willner A. Comparative studies of chlorpromazine and imipramine. I. Drug discriminating patterns. Neuropsychopharmacology 1963;3:370-2. Links Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Archives of General Psychiatry 1967;16:118-26. Links Klein DF. Psychiatric diagnosis and a typology of clinical drug effects. Psychopharmacologia 1968;13:359-86. Links Klein DF, Honigfeld G, Feldman S. Prediction of drug effect by diagnostic decision tree. Diseases of the Nervous System 1968;29:159-87. Links Levenstein S, Klein DF, Pollack M. Follow up study of formerly hospitalized voluntary psychiatric patients: the first two years. American Journal of Psychiatry 1966;122:1102-8. Links Fleming 1959 {published data only} Fleming B, Spencer A, Whitelaw E. A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis. British Journal of Psychiatry 1959;105:349-58. Links Grygier 1958 {published data only} Grygier P, Waters MA. Chlorpromazine used with an intensive occupational therapy program. A.M.A. Archives of Neurology and Psychiatry 1958;79:697-705. Links Hall 1955 {published data only} Hall RA, Dunlap DJ. A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics. Journal of Nervous and Mental Disease 1955;122:301-14. Links Hollister LE, Hall RA. Phenothiazine derivatives and morphologic changes in the liver. American Journal of Psychiatry 1966;123:211-2. Links Hamill 1975 {published data only} Hamill WT, Fontana AF. The immediate effects of chlorpromazine in newly admitted schizophrenic patients. American Journal of Psychiatry 1975;132:1023-6. Links Hamilton 1960 {published data only} Hamilton M, Smith A, Lapidus HR, Cadogan EP. A controlled trial of Thiopropazate Dihydrochloride (Dartalan), Chlorpromazine and occupational therapy in chronic schizophrenics. British Journal of Psychiatry 1960;106:40-55. Links Hine 1958 {published data only} Hine FR. Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic. Journal of Nervous and Mental Diseases 1958;127:220-7. Links Hogarty 1973 {published data only} Goldberg S, Schooler N, Hogarty G, Roper M. Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry 1977;34:171-84. Links Hogarty G, Goldberg S. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Archives of General Psychiatry 1973;28:54-64. Links Hogarty G, Goldberg S, Schooler N. Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients. Archives of General Psychiatry 1974;31:609-18. Links Hogarty G, Goldberg S, Schooler N, Ulrich R. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Archives of General Psychiatry 1974;31:603-8. Links Hogarty G, Ulrich R. Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry 1977;34:297-301. Links Hogarty GE, Munetz MR. Pharmacogenic depression among outpatient schizophrenic patients - a failure to substantiate. Journal of Clinical Psychopharmacology 1984;4:17-24. Links Klein 1973 {published data only} Klein D, Rosen B. Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients. Archives of General Psychiatry 1973;29:480-5. Links Kurland 1961 {published data only} Kurland AA, Hanlon TE, Tatom MH, Ota KY, Simopoulos AL. The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness. Journal of Nervous and Mental Disease 1961;133:1-18. Links Kurland AA, Hanlon TE, Tatom MH, Simopoulos AL. Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations. Journal of Nervous and Mental Disease 1961;132:61-74. Links Kurland AA, Nilsson GL, Hanlon TE. Pre-admission drug treatment of state psychiatric hospital patients. American Journal of Psychiatry 1959;115:1028-9. Links Kurland AA, Sutherland GF. The phenothiazine tranquilizers - their neurological complications and significance. Psychosomatics 1960;1:192-4. Links Letemendia 1967 {published data only} Letemendia F, Harris AD. Chlorpromazine and the untreated chronic schizophrenic: a long-term trial. British Journal of Psychiatry 1967;113:950-8. Links Nishikawa 1982 {published data only} Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology 1982;77:301-4. Links Payne 1960 {published data only} Payne P. A Comparison of Trifluopromazine, Chlorpromazine and a Placebo in Twenty-one Chronic Schizophrenic Patients. Manitoba Medical Review 1960:196-8. Links Peet 1981 {published data only} Peet M, Bethell M, Coates A, Khamnee A, Hall P, Cooper S, King D, Yates R. Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo. British Journal of Psychiatry 1981;139:105-11. Links Prien 1968 {published data only} Crane GE. Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie 1968;2:209-18. Links De Long SL. Incidence and significance of chlorpromazine-induced eye changes. Diseases of the Nervous System 1968;29:19-22. Links Gardos G, Cole JO, LaBrie RA. A 12-year follow-up study of chronic schizophrenics. Hospital and Community Psychiatry 1982;33:983-4. Links Mandel A, Gross M. Agranulocyctosis and phenothiazines. Diseases of the Nervous System 1968:32-6. Links Prien R, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group. Archives of General Psychiatry 1968;18:482-95. Links Prien R, DeLong S, Cole J, Levine J. Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry 1970;23:464-8. Links Prien RF, Cole JO, Belkin NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry 1968;115:679-86. Links Prien RF, Levine J, Cole JO. Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System 1970;31:739-45. Links Rappaport 1978 {published data only} Rappaport M, Hopkins HK, Hall K, Belleza T, Silverman J. Are there schizophrenics for whom drugs may be unnecessary or contraindicated?. International Pharmacopsychiatry 1978;13:100-11. Links Reardon 1966 {published data only} Reardon JD, Abrams S. Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System 1966;27:265-70. Links Reschke 1974 {published data only} Reschke RW. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Diseases of the Nervous System 1974;35:112-5. Links Saretsky 1966 {published data only} Saretsky T. Effects of chlorpromazine on primary-process thought manifestations. Journal of Abnormal Psychology 1966;71:247-52. Links Schiele 1961 {published data only} Schiele BC, Vestre ND, Stein KE. A comparison of thioridazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients. Journal of Clinical and Experiemental Psychopathology 1961;22:151-62. Links Serafetinides 1972 {published data only} Serafetinides EA, Clark ML. Psychological effects of single dose antipsychotic medication. Biological Psychiatry 1973;7:263-7. Links Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Diseases 1972;154:31-42. Links Serafetinides EA, Willis D. A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry 1973;8:245-7. Links Serafetinides EA, Willis D, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Diseases 1972;155:366-9. Links Shepherd 1956 {published data only} Shepherd M, Watt DC. A controlled clinical study of chlorpromazine and reserpine. Journal of Neurology, Neurosurgery and Psychiatry 1956;19:232-5. Links Simon 1958 {published data only} Simon W, Wirt AL, Wirt RD, Halloran AV. Long-term follow-up study of schizophrenic patients. Archives of General Psychiatry 1965;12:510-5. Links Simon W, Wirt R, Wirt A, Halloran A, Hinckley R, Lund J, Hopkins GW. A controlled study of the short-term differential treatment of schizophrenia. American Journal of Psychiatry 1958;114:1077-86. Links Smith 1961 {published data only} Smith ME. A clinical study of chlorpromazine and chlordiazepoxide. Connecticut State Medical Journal 1961;25:153-7. Links Somerville 1960 {published data only} Somerville DM, Cohen PH, Graves GD. Phenothiazine side-effects. Comparison of two major tranquillizers. British Journal of Psychiatry 1960;106:1417-24. Links Spohn 1977 {published data only} Spohn H, Lacoursiere R, Thompson K, Coyne L. Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Archives of General Psychiatry 1977;34(6):633-44. Links Tetreault 1969a {published data only} Tetreault L. Comparative study of two drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques 1969;22:221-8. Links Tetreault L, Bordeleau JM, Gauthier R, Vulpe M, Lapointe L. Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients. Diseases of the Nervous System 1969;30(2):74-84. Links Vaughan 1955 {published data only} Vaughan GF, Leiberman DM, Cook LC. Chlorpromazine in psychiatry. Lancet 1955;1:1083-7. Links Walsh 1959 {published data only} Walsh GP, Walton D, Black DA. The relative efficacy of &amp;quot;Vespral&amp;quot; and chlorpromazine in the treatment of a group of chronic schizophrenic patients. British Journal of Psychiatry 1959;105:199-209. Links Zuoze 1986 {published data only} Zuoze L, Youjun W, Shuzhong Z, Anguo H, Yuande C. Therapeutic effect of He-Ne laser irradiation of Point Erman in schizophrenic auditory hallucination - a clinical assessment. Journal of Traditional Chinese Medicine 1986;6:253-6. Links References to studies excluded from this review Abse 1960 Abse WD, Dahlstrom WG, Tolley AG. Evaluation of tranquilizing drugs in the management of acute mental disturbance. American Journal of Psychiatry 1960;117:973-80. Links Acker 1965 Acker CW. An exploration of the autonomic effects of phenothiazines. Psychopharmacologia 1965;7:150-8. Links Affleck 1966 Affleck DC, Eaton MT, Mansfield E. The action of a medication and the physician's expectations. Nebraska State Medical Journal 1966;51:331-4. Links Agarwal 1985 Agarwal AK, Winny GC. Role of ECT phenothiazine combination in schizophrenia. Indian Journal of Psychiatry 1985;27:233-6. Links Akimoto 1966 Akimoto H, Shimazaki T, Shibata N, Sato Y, Takahashi R. Current status of pharmacotherapy in schizophrenia. Folia Psychiatrica et Neurologica Japonica 1966;20(1):1-8. [MedLine: 67213329]. Links Alpert 1966 Alpert M, Hekimian LJ, Frosch WA. Evaluation of treatment with recorded interviews. American Journal of Psychiatry 1966;122:1258-64. Links Alpert 1978 Alpert M, Friedhoff A, Marcos L, Diamond F. Paradoxical reaction to L-dopa in schizophrenic patients. American Journal of Psychiatry 1978;135:1329-32. Links Alson 1964 Alson E, Hastings K. The use of adjective check lists with psychotic patients: the problem of pseudo-responses. Journal of Clinical Psychology 1964;20(4):462-3. Links Aman 1985 Aman MG, Singh NN. Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment. Journal of Mental Deficiency Research 1985;29(2):187-95. [MedLine: 85293054]. Links Amin 1977 Amin MM, Ban TA, Lehmann HE. A standard-controlled clinical study with benzquinamide in the treatment of chronic schizophrenic patients. Psychopharmacology Bulletin 1977;13:20-1. Links Ananth 1972 Ananth JV, Vacaflor L, Kekhwa G, Sterlin C, Ban TA. Nicotinic acid in the treatment of newly admitted schizophrenic patients: a placebo-controlled study. Internationale Zeitschrift Fur Klinische Pharmakologie Therapie und Toxikologie 1972;5(4):406-10. [MedLine: 72239308]. Links Andrews 1976 Andrews P, Hall JN, Snaith RP. A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. British Journal of Psychiatry 1976;128:451-5. Links Ashcroft 1961 Ashcroft GW, MacDougall EJ, Barker PA. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1961;107:287-93. [MedLine: 72239308]. Links Ayers 1984 Ayers T, Liberman RP, Wallace CJ. Subjective response to antipsychotic drugs: failure to replicate predictions of outcome. Journal of Clinical Psychopharmacology 1984;4:89-93. Links Azima 1954 Azima H, Ogle W. Effects of Largactil in mental syndomes. Canadian Medical Association Journal 1954;71:116-21. Links Bagadia 1981 Bagadia VN, Shah LP, Pradhan PV, Doshi J, Abhyankar R. Evaluation of cognitive effects of ECT: preliminary observations. Indian Journal of Psychiatry 1981;23:324-9. Links Ban 1977 Ban TA, Lehmann HE, Deutsch M. Negative findings with megavitamins in schizophrenic patients - preliminary report. Communications in Psychopharmacology 1977;1:119-22. Links Hoffer, J. Megavitamin treatment of schizophrenia. Canadian Psychiatric Association Journal 1975;20:492-5. Links Beech 1990 Beech A, Powell TJ, McWilliam J, Claridge GS. The effect of a small dose of chlorpromazine on a measure of 'cognitive inhibition'. Personality and Individual Differences 1990;11:1141-5. Links Benaim 1960 Benaim S. The effect of chlorpromazine on the incidence of epileptic phenomena during insulin coma therapy: A statistical investigation. Journal of Mental Science 1960;106:317-21. Links Bennett 1956 Bennett A, Ford F, Turk RE. Clinical investigation of chlorpromazine and reserpine in private psychiatric practice. American Journal of Psychiatry 1956;112:782-7. Links Blumberg 1964 Blumberg AG, Klein DF, Pollack M. Effects of chlorpromazine and imipramine on systolic blood pressure in psychiatric patients: Relationships to age, diagnosis and initial blood pressure. Journal of Psychiatric Research 1964;2(1):51-60. Links Blumberg 1969 Blumberg AG, Klein DF. Chlorpromazine-procyclidine and imipramine: effects on thyroid function in psychiatric patients. Clinical Pharmacology and Therapeutics 1969;10:350-4. Links Boullin 1975 Boullin DJ, Woods HF, Grimes RP, Grahame-Smith DG, Wiles D, Gelder MG, Kolakowska T. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. British Journal of Clinical Pharmacology 1975;2:29-35. Links Bowes 1956 Bowes, HA. The ataractic drugs: the present position of chlorpromazine, frenquel, pacatal, and reserpine in the psychiatric hospital. American Journal of Psychiatry 1956;113:530-9. Links Bressler 1971 Bressler B, Friedel RO. A comparison between chlorpromazine and thiothixene in a Veterans Administration Hospital population. Psychosomatics 1971;12:275-7. Links Brizer 1985 Brizer DA, Hartman N, Sweeney J, Millman RB. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. American Journal of Psychiatry 1985;142(9):1106-7. Links Burnett 1975 Burnett GB, Little SR, Graham N, Forrest AD. The assessment of thiothixene in chronic schizophrenia. A double-blind controlled trial. Diseases of the Nervous System 1975;36:625-9. Links Cabrera Gomez 1994 Cabrera Gomez JA, Cordero Gutierrez JR, Fernandez Lopez O, Reyes Gutierrez B, Romero Garcia K, Simon Consuegra J, Feas Cruz. Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon. Biotherapy 1994;7(1):27-37. Links Caffey 1963 * Caffey E, Forrest I, Frank T, Klett CJ. Phenothiazine excretion in chronic schizophrenics. American Journal of Psychiatry 1963;120:578-82. Links Caffey EM, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, Rothstein C. Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases 1964;17(4):347-58. Links Caffey 1975 Caffey EMJ, Prien RF. Practical considerations on treatment with antipsychotic preparations [Prakticheskie soobrazheniia o lechenii antipsikhoticheskimi preparatami]. Zhurnal Nevropatologii i Psikhiatrii 1975;75:1399-401. Links Campbell 1972 Campbell M, Fish B, Shapiro T, Floyd A. Acute responses of schizophrenic children to a sedative and a 'stimulating' neuroleptic: a pharmacologic yardstick. Current Therapeutic Research 1972;14:759-66. Links Campbell M, Fish B, Shapiro T, Floyd A. Thiothixene in young disturbed children. A pilot study. Archives of General Psychiatry 1970;23:70-2. Links Cardone 1969 Cardone S, Olson R. Chlorpromazine and body image. Effects on chronic schizophrenics. Archives of General Psychiatry 1969;20:576-82. Links Carrillo 1971 Carrillo C. Pharmacologlal treatment of the emotionally unstable character disorder. Vth World Congress of Psychiatry. Ciudad de Mexico. 1971. Casey 1960 Casey JF, Bennet IF, Lindley CJ, Hollister LE, Gordon MH, Springer NN. Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Archives of General Psychiatry 1960;2:210-20. Links Casey 1961 Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM. Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry 1961;117:997-1003. Links Chacon 1972 Chacon C, Harper P. Clinical and work performance variables in phenothiazine therapy of schizophrenia. Acta Psychiatrica Scandinavica 1973;49:65-76. Links Chacon Carlos, Harper P, Harvey GF. Work study in the assessment of the effects of phenothiazines in schizophrenia. Comprehensive Psychiatry 1972;13(6):549-54. [MedLine: 73051431]. Links Childers 1961 Childers RT, Therrien R. A comparison of the effectiveness of triluoperazine and chlorpromazine in schizophrenia. American Journal of Psychiatry 1961;118:552-4. Links Chouinard 1977 Chouinard G, Annable L, Kolivakis TN. Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology 1977;17(2-3):162-7. [MedLine: 77094284]. Links Chouinard-G 1983 Chouinard-G, Annable-L. Fluspirilene in the treatment of newly admitted schizophrenic patients. Psychopharmacology Bulletin 1983;19(1):136-8. Links Claghorn 1983 Claghorn J, Abuzzahab F, Wang R, Larson C, Gelenberg A, Klerman G, Tuason V, Steinbook R. The current status of Clozapine. Psychopharmacology Bulletin 1983;19:138-40. Links Clark 1970c Clark ML, Serafetinides EA, Wise JB, Colmore JP. Ocular pigment deposits: drug-induced false-positives. Journal of the American Medical Association 1970;214:2339. Links Clark 1970d Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark 1975 Clark ML, Kaul PN. A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. In: Gottschalk LA, Merlis S editor(s). Pharmacokinetics of psychoactive drugs. New York: Spectrum Publications, 1976:191-7. Clark ML, Kaul PN. A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. Psychopharmacology Bulletin 1975;11:28-30. Links Clark ML, Kaul PN, Whitfield LR. Chlorpromazine kinetics and clinical response. Psychopharmacology Bulletin 1978;14:43-5. Links Cole 1967 Cole JO, Schooler NR. Differences in clinical effects of three phenothiazines in &amp;quot;acute&amp;quot; schizophrenia. Diseases of the Nervous System 1967;28:369-83. Links Coons 1962 Coons WH, Boyd BA, White JG. Chlorpromazine, trifluoperazine and placebo with long term mental hospital patients. Canadian Psychiatric Association Journal 1962;7:159-63. [MedLine: 62022417]. Links Cowden 1956 Cowden RC, Zax M, Hague JR, Finney RC. Chlorpromazine: alone and as an adjunct to group psychotherapy in the treatment of psychiatric patients. American Journal of Psychiatry 1956;4:898-902. Links Crane 1970 Crane GE. High doses of trifluperazine and tardive dyskinesia. Archives of Neurology 1970;22(2):176-80. [MedLine: 70065772]. Links Crane 1971 Crane GE. Persistence of neurological symptoms due to neuroleptic drugs. American Journal of Psychiatry 1971;127:1407-10. Links Crow 1986 Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. II. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986;148:120-7. Links Johnstone EC, Crow TJ, Johnson AL, MacMillan JF. The Northwick Park study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. British Journal of Psychiatry 1986;148:115-20. Links MacMillan JF, Crow TJ, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. III. Short-term outcome in trial entrants and trial eligible patients. British Journal of Psychiatry 1986;148:128-33. Links Curry 1972 Curry SH, Adamson L. Double-blind trial of fluphenazine decanoate. Lancet 1972;2:543-4. Links Cutler 1957 Cutler RP, Monroe JJ, Anderson TE. Effects of &amp;quot;tranquilizers&amp;quot; upon pathological activity in psychotic patients: II. Reserpine. Archives of Neurology and Psychiatry 1957;78:61-8. Links Dally 1966 Dally P, Sargant W. Treatment and outcome of anorexia nervosa. British Medical Journal 1966;2:793-5. Links Danion 1992 Danion JM, Peretti S, Grange D, Bilik M, Imbs JL, Singer L. Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers. Psychopharmacology 1992;108(3):345-51. [MedLine: 92396807]. Links Daston 1958 Daston PG. Stylus maze performance of chronic schizophrenics taking chlorpromazine. Journal of Consulting Psychology 1958;22(5):384. Links Daston 1959 Daston PG. Effects of two phenothiazine drugs on concentrative attention span of chronic schizophrenics. Journal of Clinical Psychology 1959;15:106-9. Links Davies 1973 Davies AL, O'Leary J. The use of chlorpromazine in schizophrenia. Nursing Times 1973;69:1694-5. Links Dean 1967 Dean G. Mefenamic acid and chlorpromazine in porphyria variegata. South African Medical Journal 1967;41:925-7. Links Den 2000 Den Boer JA, Vahlne J O, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Human Psychopharmacology 2000;15(3):179-89. Links Denber 1955 Denber HCB, Merlis S. Studies on Mescaline. VI. Therapeutic Aspects of the Mescaline-Chlorpromazine Combination. Journal of Nervous and Mental Diseases 1955;122:463. Links Denber 1956 Denber H, Bird EG. Chlorpromazine in the treatment of mental illness. III. The problem of depression. American Journal of Psychiatry 1956;112:1021. Links Denber 1957 Denber HCB. Chlorpromazine-diethazine in the treatment of depression. Diseases of the Nervous System 1957;18:76-9. Links Desager 1988 Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF. Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology Berlin 1988;96:63-6. Links Douglas 1969 Douglas KW, Hindley JP. A comparison of mesoridazine and chlorpromazine in chronic psychiatric patients. Journal of Clinical Pharmacology and The Journal of New Drugs 1969;9:176-82. Links Downing 1963 Downing RW, Ebert JN, Shubrooks SJ. Effect of phenothiazines on the thinking of acute schizophrenics. Perceptual and Motor Skills 1963;17(2):511-20. Links Dube 1981 Dube S, Sethi B. Efficacy of lithium in schizophrenia. Indian Journal of Psychiatry 1981;23(2):193-9. Links Eitan 1991 Eitan N, Levin Y, Ben-Artzi E, Levy A, Neumann M. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica 1992;85:74-6. Links Ekdawi 1966 Ekdawi MY, Fowke R. A controlled trial of anti-parkinson drugs in drug-induced parkinsonism. British Journal of Psychiatry 1966;112(487):633-6. Links Elkes 1954 Elkes J, Elkes C. Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients. British Medical Journal 1954;2:560-5. Links Feldman 1956 Feldman PE, Lacy BS, Walker AE, Garrez NJ. A controlled, blind study of effects of thorazine on psychotic behavior. Bulletin of the Menninger Clinic 1956;20:25-47. Links Fink 1958 Fink M, Shaw R, Gross GE, Coleman FS. Comparative study of chlorpromazine and insulin coma in therapy of psychosis. Journal of the American Medical Association 1958;166(15):1846-50. Links Fink 1965 Fink M, Klein DF, Kramer JC. Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders. Psychopharmacologia 1965;7:27-36. Links Fleischhacker 1995 Fleischhacker W. Broadening treatment perspectives of schizophrenia: a clinical update on seroquel. 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 - Oct 4; Venice, Italy. 1995. Fleming 1958 Fleming B, Currie J. Investigation of a new compound, B.W.203, and of Chlorpromazine in the treatment of psychosis. British Journal of Psychiatry 1958;104:749-57. Links Foote 1958 Foote E. Combined Chlorpromazine and Reserpine in the treatment of chronic psychotics. British Journal of Psychiatry 1958;104:201-5. Links Forrest 1967 Forrest GL, Bortner TW, Bakker CB. The role of personality variables in response to chlorpromazine, dextroamphetamine and placebo. Journal of Psychiatric Research 1967;5:281-8. Links Freed 1956 Freed H, Peifer CA. Treatment of hyperkinetic emotionally disturbed children with prolonged administration of chlorpromazine. American Journal of Psychiatry 1956;113:22. Links Freedman 1965 Freedman N, Engelhardt D, Mann D, Margolis R, London S. Communication of body complaints and paranoid symptom change under conditions of phenothiazine treatment. Journal of Personality and Social Psychology 1965;1(4):310-8. Links Freeman 1956 Freeman H, Arnold AL, Cline HS. Effects of chlorpromazine and reserpine in chronic schizophrenic patients. Diseases of the Nervous System 1956;17:213-9. Links Freeman H, Cline HS. Effects of chlorpromazine on chronic lobotomized schizophrenic patients. A.M.A. Archives of Neurology and Psychiatry 1956;76:500-7. Links Freeman 1973 Freeman Harry. A double blind comparison of mesoridazine and chlorpromazine in chronic schizophrenics. Diseases of the Nervous System 1973;34(6):289-93. [MedLine: 74114021]. Links Friedhoff 1960 Friedhoff A, Alpert M. The effect of chlorpromazine on the variability of motor task performance in schizophrenics. Journal of Nervous and Mental Disease 1960;131:110-6. Links Fromm 1956 Fromm GH, Forsberg IA. Controlled study on the value of chlorpromazine in allaying anxiety. Diseases of the Nervous System 1956;17:16-9. Links Gaitz 1955 Gaitz C M, Roy H, Thompson W, Kimbell I, Mullen A J, Pokorny A D. Evaluation of Chlorpromazine in Comparison with other Methods of treatments of hospitalized psychiatric patients, using the lorr multidimensional scale for rating psychiatric patients. Psychiatric Research Reports 1955;1:1984. Links Galbrecht 1968 Galbrecht CR, Klett CJ. Predicting response to phenothiazines: the right drug for the right patient. Journal of Nervous and Mental Disease 1968;147:173-83. Links Galdi 1988 Galdi J, Bonato RR. Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics. Canadian Journal of Psychiatry 1988;33:816-8. Links Gallant 1963 Gallant D, Bishop M, Steele C, Noblin CD. The relationship between serotonin antagonism and tranquilizing activity. American Journal of Psychiatry 1963;119:882. Links Gallant 1967 Gallant DM, Bishop MP, O'Meallie L. BL-KR140: a controlled evaluation in chronic schizophrenic patients previously stabilized on chlorpromazine. Current Therapeutic Research 1967;9:447-50. Links Gardner 1955 Gardner MJ, Hawkins HM, Judah LN, Murphree OD. Objective measurement of psychiatric changes produced by chlorpromazine and reserpine in chronic schizophrenia. Psychiatric Research Reports 1955;1:77-83. Links Gardos 1968 Gardos G, Rapkin RM, DiMascio A. Trifluoperazine and chlorpromazine in combination and individually. Current Therapeutic Research Clinical and Experimental 1968;10(12):609-12. [MedLine: 69054114]. Links Gardos 1976 Gardos G, Cole J O. Maintenance antipsychotic therapy: is the cure worse than the disease?. American Journal of Psychiatry 1976;133:32-6. Links Garfield 1962 Garfield SL, Helper MM, Wilcott RC, Muffly R. Effects of chlorpromazine on behaviour in emotionally disturbed children. Journal of Nervous and Mental Diseases 1962;135:147-54. Links Garmezy 1969 Garmezy N. Effects of censure and chlorpromazine on visual discrimination behavior of schizophrenic and alcoholic patients. Proceedings of the Annual Convention of the American Psychological Association 1969;4(2):491-2. Links Gauthier 1967 Gauthier R, Hillel J, Bordeleau J M, Tetreault L. Comparative study of trifluperidol and trifluoperazine in the treatment of acute schizophrenia. Union Medicale du Canada 1967;96:936-43. Links Gendron 1973 Gendron JL, Zimmermann RL, Schiele BC. A double blind comparison of AL 1021 and chlorpromazine in hospitalized schizophrenics. Current Therapeutic Research 1973;15(6):333-6. Links Gibbs 1956 Gibbs JJ, Wilkens B, Lauterbach CG. A controlled clinical psychiatric study of chlorpromazine. Journal of Clinical and Experimental Psychopathology 1957;18:269-83. Links Gibbs JJ, Wilkens B, Lauterbach CG. A controlled clinical psychiatric study of the drug chlorpromazine. American Journal of Psychiatry 1956;113:254-5. Links Gilgash 1957 Gilgash CA. Effects of Thorazine on Wechsler scores of adult catatonic schizophrenics. Psychological Reports 1957;3:561-4. Links Goldberg 1968 Goldberg SC, Mattsson NB. Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System 1968;29(5):S153-8. [MedLine: 68399894]. Links Goldberg 1970 Goldberg GJ, Brooke G, Townsend HR, Brahma RK, Hill GB. A comparison of oxypertine and chlorpromazine in chronic schizophrenia. Acta Psychiatrica Scandinavica 1970;46(2):126-35. [MedLine: 71030938]. Links Goldberg 1972 Goldberg S, Frosch W, Drossman A, Schooler N, Johnson G. Prediction of response to phenothiazines in schizophrenia. A crossvalidation study. Archives of General Psychiatry 1972;26:367-73. Links Goldman 1955 Goldman D. Treatment of psychotic states with chlorpromazine. Journal of the American Medical Association 1955;157:1274-8. Links Good 1958 Good WW, Sterling M, Holtzman WH. Termination of chlorpromazine with schizophrenic patients. American Journal of Psychiatry 1958;115:443-8. Links Mefferd RB, Labrosse EH, Gawienowski AM, Williams RJ. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. Journal of Nervous and Mental Diseases 1958;127:167-79. Links Goodwin-Austin 1971 Godwin-Austen RB, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. British Medical Journal 1971;4(778):25-6. Links Goyne 1958 Goyne J B, Groebner E, Pueblita M. Clinical Research - Vesperin-Chlorpromazine Therapy. Scientific Papers of the 114th Annual Meeting of the American Psychiatric Association. 1958:104-5. Graupner 1972 Graupner OK, Kalman EV. Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments [Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)]. Psychopharmacologia 1972;27(4):343-7. [MedLine: 73085373]. Links Green 1996 Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology 1996;128(1):67-73. Links Green 1998 Green JF, King DJ. Antisaccade and no-saccade distractibilty with chlorpromazine and lorazepam. Schizophrenia Research 1998;29(1,2):117. Links Greenberg 1966 Greenberg LM, Roth S. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. American Journal of Psychiatry 1966;123:221-6. Links Griffiths 1979 Griffiths RR, Bigelow G, Liebson I. Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. Journal of Pharmacology and Experimental Therapeutics 1979;210:301-10. Links Guy 1978 Guy W, Petrie W, Cleary P. The incidence of treatment emergent symptoms under chlorpromazine and placebo conditions. Psychopharmacology Bulletin 1978;14:22-4. Links Hammond 1978 Hammond NV, Gruzelier JH. Laterality, attention and rate effects in the auditory temporal discrimination of chronic schizophrenics - the effect of treatment with chlorpromazine. Quarterly Journal of Experimental Psychology 1978;30:91-103. Links Hamner 1996 Hamner MB, Arvanitis LA, Miller BG, Link CGG, Hong WW. Plasma prolactin in schizophrenia subjects treated with seroquel (TM) (ICI 204,636). Psychopharmacology Bulletin 1996;32(1):107-10. [MedLine: 96267998]. Links Hankoff 1960 Hankoff L, Engelhardt D, Freedman N, Mann D, Margolis R. Denial of illness in schizophrenic outpatients: effects of psychopharmacological treatment. Archives of General Psychiatry 1960;3:657-64. Links Hanlon 1958 Hanlon T E, Kurland A A, Esquibel A J, Ota K Y. A Comparative Study of Chlorpromazine and Triflupromazine in the Management of the Chronic Hospitalized Psychotic Patient. Journal of Nervous and Mental Diseases 1958;127:17-20. Links Hanlon 1960 Hanlon TE, Wiener G, Kurland AA. The psychiatric physician and the phenothiazine tranquilizers. Journal of Nervous and Mental Diseases 1960;130:67-71. Links Harper 1976 Harper P, Chacon C. Work performance versus clinical assessment in the evaluation of phenothiazine therapy. British Journal of Clinical Pharmacology 1976;3:50-5. Links Hartley 1978 Hartley L, Henry T, Couper-Smartt J. Chlorpromazine and serial reaction performance. British Journal of Psychology 1978;69:271-6. Links Hartley 1987 Hartley LR, Coxon L, Spencer J. Pharmacological effects on lateralized behavior. Current Psychology Research and Reviews 1987;6:301-12. Links Hartley 1989 Hartley LR, Strother N, Arnold PK, Mulligan B. Lateralization of emotional expression under a neuroleptic drug. Physiology and Behavior 1989;45:917-21. Links Hartley 1991 Hartley LR, Ireland LK, Arnold PK, Spencer J. Chlorpromazine and the lateralisation of the perception of emotion. Physiology and Behavior 1991;50:881-5. Links Hartmann 1973 Hartmann E, Cravens J. The effects of long term administration of psychotrophic drugs on human sleep. IV. The effects of chlorpromazine. Psychopharmacologia 1973;33:203-18. Links Haskell 1974 Haskell DS, McNair DM, Fisher S, Kahn RJ. A controlled outpatient trial of perphenazine-amitriptyline and chlorpromazine. Journal of Clinical Pharmacology 1974;14:536-42. Links Heilizer 1959 Heilizer F. The effects of chlorpromazine upon psychomotor and psychiatric behavior of chronic schizophrenic patients. Journal of Nervous and Mental Disease 1959;128:358-64. Links Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. Journal of Clinical and Experimental Psychopathology 1959;20:53-7. Links Hekimian 1967 Hekimian LJ, Friedhoff AJ. A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients. Diseases of the Nervous System 1967;28:675-8. Links Herrera 1988 Herrera JN, Sramek JJ, Costa JF, Roy S, High potency neuroleptics and violence in schizophrenics. Journal of Nervous and Mental Disease 1988;176(9):558-61. Links Herrmann 1991a Herrmann WM, Scharer E, Delini-Stula A. Predictive value of pharmaco electroencephalography in early human pharmacological evaluations of psychoactive drugs - first example - Savoxepine. Pharmacopsychiatry 1991;24:196-205. Links Herrmann 1991b Herrmann WM, Scharer E, Wendt G, Delini-Stula A. Pharmaco EEG profile of maroxepine - third example to discuss the predictive value of pharmaco electroencephalography in early human pharmacological evaluations of psychoactive drugs. Pharmacopsychiatry 1991;24:214-24. Links Herz 1991 Herz M, Glazer W, Mostert M, Sheard M, Szymanski H, Hafez H, Mirza M, Vana J. Intermittent versus maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry 1991;48:333-9. Links Hoffer 1975 Hoffer J. Megavitamin treatment of schizophrenia. Canadian Psychiatric Association Journal 1975;20:492-5. Links Hogarty 1976 Hogarty G E, Ulrich R F, Mussare F, Aristigueta N. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Diseases of the Nervous System 1976;37:494-500. Links Hollis 1968 Hollis JH. Chlorpromazine: direct measurement of differential behavioral effect. Science 1968;159:1487-9. Links Hollister 1955 Hollister LE, Jones KP, Brownfield B, Johnson F. Chlorpromazine alone and with reserpine. California Medicine 1955;83:218-21. Links Hollister LE, Traub L, Beckman WG. Psychiatric use of reserpine and chlorpromazine: results of double-blind studies. In: Kline NS editor(s). Psychopharmacology. Washington DC: AAAS, 1956:65-74. Holt 1984 Holt RJ. Neuroleptic drug-induced changes in platelet levels. Journal of Clinical Psychopharmacology 1984;4:130-2. Links Hong 1996a Hong W, Arvanitis L. Reduction of the positive symptoms of schizophrenia by '(ICI 204,636): results from phase II and III clinical trials. 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands. 1996. Hong 1996b Hong WW, Arvanitis LA. The atypical profile of '(ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands. 1996. Hopkin 1954 Hopkin DA. Action of chlorpromazine and promethazine. British Medical Journal 1954;1:1036. Links Horenstein 1957 Horenstein. Resperpine and chlorpromazine in hyperactive mental defectives. American Journal of Mental Deficiency 1957:525-29. Links Hrushka 1966 Hrushka M, Bruck M, Hsu J J. Therapeutic effects of different modes of chlorpromazine administration. Diseases of the Nervous System 1966;27:522-7. Links Huang 1967 Huang CL, Hirano K. The effect of antipyretic analgesics on the metabolism of chlorpromazine in man. Biochemical Pharmacology 1967;16:2023-6. Links Hughes 1967 Hughes JS, Little JC. An appraisal of the continuing practice of prescribing tranquillizing drugs for long-stay psychiatric patients. British Journal of Psychiatry 1967;113:867-73. Links Hurst 1960 Hurst L. Chlorpromazine and Pecazine in chronic schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1960;106:726-31. Links Hurst 1996 Hurst BC, Link C. A comparison of the tolerance profile of seroquel with typical neuroleptics and placebo. Xth World Congress of Psychiatry. Madrid, Spain. Madrid, Spain: August 23-28, 1996. Hussar 1969 Hussar AE, Bragg DG. The effect of chlorpromazine on the swallowing function in chronic schizophrenic patients. American Journal of Psychiatry 1969;126:570-3. Links Itil 1968 Itil T, Shapiro D, Fink M. Differentiation of psychotropic drugs by quantitative EEG analysis. Agressologie 1968;9:267-80. Links Itil 1971 Itil TM, Ulett GA, Fukuda T. Quantitative pharmaco-electroencephalography in early evaluation of psychotropic drugs. Folia Psychiatrica et Neurologica Japonica 1971;25:195-202. Links Johnstone 1978 Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978;1(8069):848-51. [MedLine: 78155245]. Links Jones 1969 Jones IH. Drugs and motor activity in chronic schizophrenia. British Journal of Psychiatry 1969;115:851-6. Links Jones 1971 Jones IH, Pikler N. Effects of chlorpromazine and trifluoperazine on the activity of chronic schizophrenics. British Journal of Psychiatry 1971;119:545-6. Links Joseph 1979 Joseph MH, Baker HF, Johnstone EC, Crow TJ. 3-Methoxy-4-hydroxyphenylglycol excretion in acutely schizophrenic patients during a controlled clinical trial of the isomers of flupenthixol. Psychopharmacology 1979;64(1):35-40. [MedLine: 80013695]. Links Joshi 1980 Joshi VG, Nagesh R, Eswaran S, Nagesh R, Pai M, Mathews G, Mallick PN. Vitamins B1, B6, and B12 in the adjunctive treatment of schizophrenia - further studies to examine the effect of reduction of chlorpromazine dosage. Journal of Orthomolecular Psychiatry 1980;11:45-9. Links Kabes 1982 Kabes J, Sikora J, Pisvejc J, Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. International Pharmacopsychiatry 1982;17(3):185-92. [MedLine: 83056096]. Links Kammerer 1968 Kammerer M, Wartel R, Gurfein L, Weil J, Wysoki V, Gelb F. Clinical experimentation with desipramine with statistical control [Experimentation clinique de la desipramine avec controle statistique]. Annales Medico-psychologiques 1968;1:109-13. Links Kaplan 1974 Kaplan J, Dawson S, Vaughan T, Green R, Wyatt RJ. Effect of prolonged chlorpromazine administration on the sleep of chronic schizophrenics. Archives of General Psychiatry 1974;31:62-6. Links Keskiner 1970 Keskiner A, Itil TM, Todt N. A comparative study of butaperazine, chlorpromazine and placebo in chronic schizophrenics. Psychosomatics 1970;11:120-6. Links Kim 1960 Kim K. Responses to treatment-refractory chronic schizophrenics to chlorpromazine with concurrent adrenocortical steroid. American Journal of Psychiatry 1960;116:1023-4. Links Kimbell 1971 Kimbell I Jr, Winkelman GW, Hughes WM. Comparison of thioridazine and chlorpromazine in doctor's choice research design. Clinical Pharmacology and Therapeutics 1971;12:825-32. Links King 1959 King PD, Weinberger W. Comparison of proclorperazine and chlorpromazine in hospitalized chronic schizophrenics. American Journal of Psychiatry 1959;115:1026-7. [MedLine: 69202908]. Links King 1994 King DJ. Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatrica Scandinavica Supplementum 1994;89(380):53-8. Links Kinross-Wright 1954 Kinross-Wright V. Chlorpromazine - a major advance in psychiatric treatment. Postgraduate Medicine 1954:297-300. Links Klein 1974 Klein RH, Lynn EJ, Axelrod H, Dluhy J. Self-administration of medication by psychiatric inpatients. Journal of Nervous and Mental Disease 1974;158:450-5. Links Kopell 1968 Kopell BS, Wittner WK. The effects of chlorpromazine and methamphetamine on visual signal-from-noise detection. Journal of Nervous and Mental Disease 1968;147:418-24. Links Kordas 1968 Kordas S, Kazamias N, Georgas J, Papadokostakis J. Clopenthixol: a controlled trial in chronic hospitalised schizophrenic patients. British Journal of Psychiatry 1968;114:833-6. Links Kornetsky 1957 Kornetsky C, Humphries O. Relationship between effects of a number of centrally acting drugs and personality. Archives of Neurology and Psychiatry 1957;77:325-7. Links Kornetsky C, Humphries O, Evarts EV. Comparison of psychological effects of certain centrally acting drugs in man. Archives of Neurology and Psychiatry 1957;77:318-24. Links Primac DW, Mirsky AF, Rosvold HE. Effects of centrally acting drugs on two tests of brain damage. Archives of Neurology and Psychiatry 1957;77:328-32. Links Kornetsky 1958 Kornetsky C, Humphries O. Psychological effects of centrally acting drugs in man. Journal of Mental Science 1958;104:1093-9. Links Mirsky AF, Primac DW, Bates R. The effects of chlorpromazine and secobarbital on the C.P.T. Journal of Nervous and Mental Diseases 1959;128:12-7. Links Kornetsky 1959 Kornetsky C, Pettit M, Wynne R, Evarts EV. A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenic patients. Journal of Mental Science 1959;105:190-8. Links Korol 1965 Korol B, Lang WJ, Brown ML, Gershon S. Effects of chronic chlorpromazine administration on systemic arterial pressure in schizophrenic patients: relationship of body position to blood pressure. Clinical Pharmacology and Therapeutics 1965;6:587-91. Links Kovitz 1955 Kovitz B, Carter JT, Addison WP. A comparison of chlorpromazine and reserpine in chronic psychosis. Archives of Neurology and Psychiatry 1955;74:467-71. Links Kramer 1975 Kramer M, Roth T, Goldstein S, Ryan MS, Blackwell B. A double-blind evaluation of metiapine in hospitalized acute schizophrenics. Current Therapeutic Research 1975;18:839-48. Links Kugler 1980 Kugler BT, Gruzelier JH. The influence of chlorpromazine and amylobarbitone on the recovery limb of the electrodermal response. Psychiatry Research 1980;2:75-84. Links Kupfer 1971 Kupfer DJ, Wyatt RJ, Synder F, Davis JM. Chlorpromazine and sleep in psychiatric patients. Archives of General Psychiatry 1971;24:185-9. Links Kurland 1981 Kurland AA, Nagaraju A. Viloxazine and the depressed schizophrenic - methodological issues. Journal of Clinical Pharmacology 1981;21(1):37-41. [MedLine: 81168674]. Links Lampe 1969 Lampe WT. A double blind study of clomacran. Current Therapeutic Research 1969;11:300-6. Links Latz 1965 Latz A, Kornetsky C. The effects of chlorpromazine and secobarbital under two conditions of reinforcement on the performance of chronic schizophrenic subjects. Psychopharmacologia 1965;7:77-88. Links Laurian 1981 Laurian S, Le PK, Baumann P, Perey M, Gaillard JM. Relationship between plasma-levels of chlorpromazine and effects on EEG and evoked potentials in healthy volunteers. Pharmacopsychiatria 1981;14:199-204. Links Leff 1971 Leff JP. Influence of selection of patients on results of clinical trials. British Medical Journal 1973;4:156-8. Links Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. British Medical Journal 1971;3:599-604. Links Leszek 1991 Leszek J, Inglot AD, Cantell K, Wasik A. Natural human leukocyte interferon in the treatment of schizophrenia. European Journal of Psychiatry 1991;5(1):55-63. Links Levin 1959 Levin ML. A comparison of the effects of phenobarbital, promethazine, chlorpromazine, and placebo upon mental hospital patients. Journal of Consulting Psychology 1959;23:167-70. Links Levine 1997 Levine J, Caspi N, Laufer N. Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients. Schizophrenia Research 1997;26(1):55-63. [MedLine: 98017426]. Links Levita 1961 Levita E. Effects of chlorpromazine and promazine on perseveration. Journal of General Psychology 1961;65:181-7. Links Lewis 1973 Lewis PJ, James NM. Haloperidol and chlorpromazine - a double-blind cross-over trial and clinical study in children and adolescents. Australian and New Zealand Journal of Psychiatry 1973;7:59-65. Links Liberman 1973 Liberman RP, Davis J, Moon W, Moore J. Research design for analyzing drug-environment-behavior interactions. Journal of Nervous and Mental Diseases 1973;156:432-9. Links Little 1958 Little JC. A double-blind controlled comparison of the effects of Chlorpromazine, Barbiturate and a placebo in 142 chronic psychotic in-patients. British Journal of Psychiatry 1958;4:334-49. Links Loranger 1968 Loranger AW. Treatment of acute mental disorders with an adrenal steroid. British Journal of Psychiatry 1968;114:843-4. Links Lorr 1961 Lorr M, McNair DM, Weinstein GJ, Michaux WW, Raskin A. Meprobamate and chlorpromazine in psychotherapy. Some effects on anxiety and hostility of outpatients. Archives of General Psychiatry 1961;4:381-9. Links Lyberi 1956 Lyberi G, S L Last. The Use of Chlorpromazine As An Activating Agent. Electroencephalography and Clinical Neurophysiology 1956:711-12. Links Maculans 1964 Maculans GA. Comparison of diazepam, chlorprothixine and chlorpromazine in chronic schizophrenic patients. Diseases of the Nervous System 1964;25:164-8. Links Mahal 1976 Mahal AS, Ramu NG, Chaturvedi DD. Double blind controlled study of brahmyadiyoga and tagara in the management of various types of unmada (schizophrenia). Indian Journal of Psychiatry 1976;18(4):283-92. Links Majewski 1968 Majewski J, Stempurska K. Results of treatment of schizophrenic psychoses with neuroleptics combined with subcomatic insulin [Wyniki leczenia psychoz schizofrenicznych neuroleptykami skojarzonymi z insulina podspiaczkowa]. Psychiatria Polska 1968;2(1):37-42. [MedLine: 68366839]. Links Marjerrison 1969 Marjerrison G, Keogh RP. Integrated EEG variability - drug effects in acute schizophrenics. Canadian Psychiatric Association Journal 1969;14:403-5. Links Marrazzi 1972 Marrazzi AS, Woodruff S, Kennedy D. Perceptual challenge to measure illness and therapy. American Journal of Psychiatry 1972;128:886-90. Links Mason-Browne 1957 Mason-Browne NL. Perphenazine - a drug modifying consciousness. American Journal of Psychiatry 1957;114:173-4. Links Mason-Browne NL, Borthwick JW. Effect of perphenazine (Trilafon) on modification of crude consciousness. Diseases of the Nervous System 1957;18:300-6. Links Mathur 1981 Mathur S, Hall JN. Phenothiazine withdrawal in schizophrenics in a hostel (letter). British Journal of Psychiatry 1981;138:271-2. Links Mattila 1994 Mattila MJ, Vanakoski J, Mattila Evenden ME, Karonen SL. Suriclone enhances the actions of chlorpromazine on human psychomotor performance but not on memory or plasma prolactin in healthy subjects. European Journal of Clinical Pharmacology 1994;46:215-20. Links McClelland 1990 McClelland GR, Cooper SM, Pilgrim AJ. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. British Journal of Clinical Pharmacology 1990;30:795-803. Links Melnyk 1966 Melnyk WT, Worthington AG, Laverty SG. Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic in-patients. Canadian Psychiatric Association Journal 1966;11(5):410-3. Links Merry 1957 Merry J, Pargiter MB, Munro H. Chlorpromazine and chronic neurotic tension. American Journal of Psychiatry 1957;113:988-90. Links Michaux 1966 Kurland AA, Bethon GD, Michaux MH, Agallianos DD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings. Journal of New Drugs 1966;6:80-95. Links Michaux MH, Kurland AA, Agallianos DD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. Current Therapeutic Research, Clinical and Experimental 1966;8(supplement):117-52. Links Millar 1963 Millar J. A trial of fluphenazine in schizophrenia. British Journal of Psychiatry 1963;109:428-32. [MedLine: 74100099]. Links Milne 1960 Milne H, Fowler DB. A clinical trial of Largactil (chlorpromazine), Stemeticl (prochlorperazine) and Veractil (methotrimeprazine). British Journal of Psychiatry 1960;106:1105-10. Links Milton 1978 Milton F, Patwa VK, Hafner RJ. Confrontation versus belief modification in persistently deluded patients. British Journal of Medical Psychology 1978;51:127-30. Links Mitchell 1956 Mitchell P. Chlorpromazine in the treatment of the chronic disturbed schizophrenic patient. British Journal of Psychiatry 1956;102:151-4. Links Mitchell 1960 Mitchell LE, Zax M. Psychological response to chlorpromazine in a group of psychiatric patients. Journal of Clinical Psychology 1960;16:440-2. Links Monteleone 1999 Monteleone P, Tortorella A, Borriello R, Cassandro P, Maj M. Prolactin hyperresponsiveness to D fenfluramine in drug free schizophrenic patients: a placebo controlled study. Biological Psychiatry 1999;45(12):1606-11. [MedLine: 99304410]. Links Morgenstern 1960 Morgenstern FV, Funk IC, Holt WL. Comparative short-term evaluation of triflupromazine hydrochloride, chlorpromazine hyrochloride, and placebo in acutely disturbed patients. New York State Journal of medicine 1960;60:254-8. Links Morton 1968 Morton MR. A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry 1968;124:1585-8. Links Moss 1958 Moss CS, Jensen RE, Morrow W, Freund HG. Specific behavioural changes produced by chlorpromazine in chronic schizophrenia. American Journal of Psychiatry 1958;115:449-51. Links Neal 1969 Neal CD, Collis MP, Imlah NW. A comparative trial of oxypertine and chlorpromazine in chronic schizophrenia. Current Therapeutic Research - Clinical and Experimental 1969;11:367-78. Links Newbold 1956 Newbold, Steed. The Use of Chlorpromazine in Psychotherapy. Journal of Nervous and Mental Diseases 1956. Links Okuma 1979 Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe S. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology Berlin 1981;73:95-6. Links Orzack 1969 Orzack MH, Taylor CL, Kornetsky C. A comparison of the behavioral effects of periodic administration of chlorpromazine and a &amp;quot;sustained-release&amp;quot; form of chlorpromazine. Clinical Pharamacology and Therapeutics 1969;10(2):258-64. [MedLine: 69143232]. Links Osmakova 1972 Os'makova EI. Use of psychological methods for studying the particular psychotropic action of various psychopharmacologic drugs [Primenenie psikhologicheskikh metodik dlia issledovaniia sobstvenno psikhotropnogo deistviia nekotorykh psikhofarmakologic heskikh sredtsv]. Zhurnal Nevropatologii i Psikhiatrii 1972;72:1705-8. Links Rojo-Sierra M, Alonso J, D&amp;#237;ez E, Giner J, Lloret E. [Aportaci&amp;#243;n sobre el espectro psicofarmacoter&amp;#225;pico del R P. 19 366 y R P. 19 552]. 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Ciudad de Mexico, Mexico. 1971. Pai 2001 Pai Y-M, Yu S-C, Lin C-C. Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study. Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA. Marathon Multimedia, 2001. Paredes 1966 Paredes A, Baumgold J, Pugh LA, Ragland R. Clinical judgment in the assessment of psychopharmacological effects. Journal of Nervous and Mental Disease 1966;142(2):153-60. Links Park 1981 Park S, Hardesty AS, Garcia E. Effects of triiodothyronine and chlorpromazine combination treatment in schizophrenia. Current Therapeutic Research - Clinical and Experimental 1981;29:929-35. Links Pasamanick 1967 Pasamanick B, Scarpitti FR, Dinitz S. Schizophrenics in the community: an experimental study in the prevention of hospitalization. New York: Appleton-Century-Crofts, 1967. Patterson 1981 Patterson T, Venables PH. Bilateral skin conductance and the pupillary light dark reflex - manipulation by chlorpromazine, haloperidol, scopolamine, and placebo. Psychopharmacology 1981;73:63-9. Links Peet 1980 Peet M, Middlemiss DN, Yates RA. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients [letter]. Lancet 1980;2:978. Links Pennington 1957 Pennington V. A two-year comparative study of ataraxics in neuropsychiatric patients. Journal of the American Geriatric Association 1957;5:42-9. Links Pietzcker 1978 Pietzcker A. Long-term medication in schizophrenia [Langzeitmedikation bei schizophrenen Kranken]. Nervenarzt 1978;49:518-33. Links Pigache 1973 Pigache RM. The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine. Schizophrenia Research 1993;10:39-50. Links Pigache RM, Norris HN. Measurement of drug action in schizophrenia. Clinical Science 1973;44:28P. Links Pigache 1993 Pigache RM. Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two-year longitudinal study. Schizophrenia Research 1993;10:51-9. Links Platz 1967 Platz AR, Klett CJ, Caffey EMJ. Selective drug action related to chronic schizophrenic subtype. (A comparative study of carphenazine, chlorpromazine, and trifluoperazine). Diseases of the Nervous System 1967;28:601-5. Links Pleasure 1956 Pleasure H. Chlorpromazine (Thorazine) for mental illness in the presence of pulmonary tuberculosis. Psychiatry Quarterly 1956;30:23-30. Links Pollack 1956 Pollack, B. The effect of chlorpromazine on the return rate of 250 patients released from the Rochester State Hospital. American Journal of Psychiatry 1956;112:937. Links Pollard 1959 Pollard JC. Combined Effects of Chlorpromazine and Meprobamate in Chronically Disturbed Psychotic Patients. Diseases of the Nervous System 1959;20:427-9. Links Quigley 1996 Quigley N, Morgan D, Idzikowski C, King DJ. The effect of chlorpromazine and benzhexol on memory and psychomotor function in healthy volunteers. Journal of Psychopharmacology 1996;10:146-52. Links Quinn 1960 Quinn PJG, Johnston J, Latner G, Kiloh LG. A comparative controlled trial of methotrimeprazine ('veractil') in chronic schizophrenia. British Journal of Psychiatry 1960;106:161-70. Links Raaska 2000 Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. European Journal of Clinical Pharmacology 2000;56(8):585-9. [MedLine: 21026257]. Links Ragland 1968 Ragland R, Clark ML, Ray TS, Paredes A, Costiloe JP, Segal B, Wolf S. The evaluation of chlorpromazine therapy in chronic schizophrenic women. A replicated experiment. Journal of Chronic Diseases 1968;21:445-60. Links Raja 2000 Raja M, Azzoni A. Second generation antipsychotics in the emergency care setting. A prospective naturalistic study. General Hospital Psychiatry 2000;22(2):107-14. [MedLine: 20283566]. Links Rappaport 1967 Rappaport M. Competing voice messages. Effects of message load and drugs on the ability of acute schizophrenics to attend. Archives of General Psychiatry 1967;17:97-103. Links Rappaport 1968 Rappaport M. Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background. Journal of Nervous and Mental Disease 1968;146:404-11. Links Rathod 1958 Rathod N, Rees L. A controlled study of the prognostic significance of autonomic responses in the chlorpromazine treatment of disturbed psychotic patients. British Journal of Psychiatry 1958;104:705-12. Links Raymond 1957 Raymond MJ, Lucas CJ, Beesley ML, O'Connell BA, Fraser Roberts JA. A trial of five tranquillizing drugs in psychoneurosis. British Medical Journal 1957;2:63-6. Links Remr 1970 Remr J. The effects of chlorpromazine on fine psychomotor performance with a simultaneous secondary task in schizophrenics. Activitas Nervosa Superior 1971;13:179. Links Remr J. The effects of chlorpromazine on some components of psychomotor performance in schizophrenics. Activitas Nervosa Superior 1970;12:253-4. Links Rifkin 1978 Rifkin A, Quitkin F, Kane J, Struve F, Klein DF. Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. Archives of General Psychiatry 1978;35(4):483-9. [MedLine: 79081577]. Links Rinaldi 1956 Rinaldi F, Rudy L, Himwich HE. Clinical evaluation of azacyclonol, chlorpromazine, and reserpine on a group of chronic psychotic patients. American Journal of Psychiatry 1956;112:678-83. Links Rivera-Calimlim 1973 Rivera Calimlim L, Castaneda L, Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clinical Pharmacology and Therapeutics 1973;14:978-86. Links Rosen 1972 Rosen B, Engelhardt DM, Freedman N, Margolis R, Rudorfer L, Paley HM. Prediction of psychiatric hospitalization. II. The Hospitalization Proneness Scale: a cross-validation. Journal of Nervous and Mental Disease 1972;80:271-4. Links Rosenheck 2000 Rosenheck R, Cramer J, Jurgis G, Perlick D, Xu W, Thomas J, Henderson W, Charney D. Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. Journal of Clinical Psychiatry 2000;61(9):671-6. Links Rosner 1955 Rosner H, Levine S, Hess H, Kaye H. A comparative study of the effect on anxiety of chlorpromazine, reserpine, phenobarbital, and a placebo. Journal of Nervous and Mental Diseases 1955;122:505-12. Links Rudy 1957 Rudy L, Himwich H, Tasher DC. Clinical evaluation of two phenothiazine compounds Promazine and Mepazine. American Journal of Psychiatry 1957;113:979-83. Links Rudy 1958 Rudy L, Rinaldi E, Himwich H, Tuteur W, Glotzer J. Trifluoperazine in the treatment of psychotic patients. American Journal of Psychiatry 1958;115:364-5. Links Sainz 1955 Sainz A. Chlorpromazine in psychiatric disorders. Prescriber 1955;2(2):14. [MedLine: 20283566]. Links Saletu 1972 Saletu B, Saletu M, Itil T. Effect of minor and major tranquilizers on somatosensory evoked potentials. Psychopharmacologia 1972;24:347-58. Links Salisbury 1957 Salisbury BJ, Hare EH. Ritalin and Chlorpromazine in chronic schizophrenia: a controlled clinical trial. British Journal of Psychiatry 1957;103:830-4. Links Schiele 1959 Schiele BC, Mendelsohn RM, Penman AS, Schofield W. Comparison of low and high dosage procedures in chlorpromazine therapy. Psychiatric Quarterly 1959;33:252-9. Links Schmidt 1957 Schmidt KE. Combined treatment with chlorpromazine and reserpine: an attempt at quantitative assessments in chronic schizophrenic patients. British Journal of Psychiatry 1957;103:200-8. Links Schooler 1976 Sakalis G, Chan TL, Sathananthan G, Schooler N, Goldberg S, Gershon S. Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. Communucations in Psychopharmacology 1977;1:157-66. Links Schooler NR, Sakalis G, Chan TL. Chlorpromazine metabolism and clinical response in acute schizophrenia - a preliminary report. Psychopharmacology Bulletin 1975;11:30-3. Links Schooler NR, Sakalis G, Chan TL, Gershon S, Goldberg SC, Collins P. Chlorpromazine metabolism and clinical response in acute schizophrenia - a preliminary report. Pharmacokinetics of psychoactive drugs. 1976:199-219. Seager 1955 Seager CP. Chlorpromazine in treatment of elderly psychotic women. British Medical Journal 1955;1:882-5. Links Serafetinides 1973 Serafetinides EA. Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry 1973;8:214-6. Links Shaskan 1975 Becker RE, Shaskan EG. Platelet monoamine oxidase activity in schizophrenic patients. American Journal of Psychiatry 1977;134:512-7. Links Shaskan EG, Becker RE. Blood platelet monoamine oxidase activity in anergic schizophrenics. National Institute of Drug Abuse Research Monograph Services 1975:29-35. Links Shaskan EG, Becker RE. Platelet monoamine oxidase in schizophrenics. Nature 1975;253:659-60. Links Shawver 1959 Shawver JR, Gorham DR, Leskin LW, Good WW, Kabnick DE. Comparison of chlorpromazine and reserpine in maintenance drug therapy. Diseases of the Nervous System 1959;20:452-7. Links Shopsin 1978 Shopsin B, Klein H, Aronson M. Clozapine: double-blind control trial in the treatment of acute schizophrenia. Psychopharmacology Bulletin 1978;14:12-4. Links Shopsin 1979 Honigfeld G, Patin J, Singer J. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Advances in Therapy 1984;1:77-97. Links Shopsin B, Klein H, Aaronson M, Collora M. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients. Archives of General Psychiatry 1979;36:657-64. Links Silver 2000 Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. International Clinical Psychopharmacology 2000;15(5):257-61. [MedLine: 20445223]. Links Simopoulos 1971 Simopoulos AM, Pinto A, Uhlenhuth EH, Mcgee J. Old wine in new bottles: decreased hostility in chronic psychotic inpatients treated with diphenylhydantoin (Dilantin). 5th World Congress of Psychiatry. Ciudad de Mexico. Ciudad de Mexico: 1971:abstract 1077. Simpson 1974 Simpson GM, Varga E, Reiss M, Cooper TB, Bergner PE, Lee JH. Bioequivalency of generic and brand-named chlorpromazine. Clinical Pharmacology and Therapeutics 1974;15:631-41. Links Simpson 1980 Simpson GM, Cooper TB, Bark N, Sud I, Lee JH. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Archives of General Psychiatry 1980;37:205-8. Links Singh 1974 Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Diseases of the Nervous System 1976;37:191-6. Links Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Journal of the Bronx State Hospital 1974;2:173-83. Links Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benzotropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Psychopharmacologia 1975;43:103-13. Links Singh MM, Kay SR. Therapeutic reversal with benztropine in schizophrenics: practical and theoretical significance. Journal of Nervous and Mental Disease 1975;160:258-66. Links Singh 1990 Singh H, Hunt JI, Vitiello B, Simpson GM. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Journal of Clinical Psychiatry 1990;51:319-21. Links Small 1987 Small J, Milstein V, Small IF, Miller MJ, Kellams JJ, Corsaro CJ. Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia. Clinical Electroencephalography 1987;18:124-35. Links Smith 1958 Smith JA, Christian D, Rutherford A, Mansfield E. A comparison of triflupromazine (Vesprin), chlorpromazine and placebo in 85 chronic patients. American Journal of Psychiatry 1958;115:253-4. Links Smith 1960 Smith ME. A comparative controlled study with chlordiazepoxide. American Journal of Psychiatry 1960;117:362-3. Links Smith 1967 Smith K, Surphlis WRP, Gynther MD, Shimkunas AM. ECT-chlorpromazine and chlorpromazine compared in the treatment of schizophrenia. Journal of Nervous and Mental Disease 1967;144:284-90. Links Sommerness 1957 Sommerness MD, Lucero RJ, Hamlon JS, Mahowald AM. Chlorpromazine: a controlled study with highly disturbed patients. Diseases of the Nervous System 1957;18:16-20. Links South-East 1961 South-East Region (Scotland) Therapeutic Trials Committee. Controlled trial of Prochlorperazine (Stemetil) in schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1961;107:514-22. [MedLine: 87204515]. Links Soyka 1968 * Soyka D. The effect of psychopharmacological drugs and other central nervous system effecting drugs on experimental nystagmus [Die Wirkung von Psychopharmaka und anderen zentral wirksamen substanzen auf den experimentellen Nystagmus]. Fortschritte Der Neurologie, Psychiatrie Und Ihrer Grenzgebiete 1968;36:526-39. Links Spiegel 1967 Spiegel DE, Keith-Spiegel P. The effects of carphenazine, trifluoperazine and chlorpromazine on ward behavior, physiological functioning and psychological test scores in chronic schizophrenic patients. Journal of Nervous and Mental Diseases 1967;144:111-6. Links Spohn 1974 Spohn HE, Lacoursiere RB, Williams RO. The effect of chlorpromazine on visual information processing in normal subjects. Journal of Nervous and Mental Disease 1974;159:198-204. Links Sugerman 1964 Pfeiffer CC, Goldstein L, Murphree HB, Sugerman AA. Time-series frequency analysis, and electrogenesis of the EEGs of normals and psychotics before and after drugs. American Journal of Psychiatry 1965;122:1147-55. Links Sugerman AA, Goldstein L, Murphree HB, Pfieffer CC, Jenney EH. EEG and behavioural changes in schizophrenia. Archives of General Psychiatry 1964;10:340-4. Links Syvalahti 1997 Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, Dahl ML, Salokangas RK. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. Journal of International Medical Research 1997;25(1):24-32. [MedLine: 97179384]. Links Talbot 1964 Talbot DR. Are tranquilizer combinations more effective than a single tranquilizer?. American Journal of Psychiatry 1964;121:597-600. Links Tassis 1959 Tassis JA. Full Coma Insulin therapy, Chlorpromazine and Electoconvulsive Treatment. A control study of 600 Schizophrenic patients. Medical journal of Malaya 1959;14:135-43. Links Teja 1975 Teja JS, Grey WH, Clum JM, Warren C. Tranquilizers or anti-depressants for chronic schizophrenics: a long-term study. Australian and New Zealand Journal of Psychiatry 1975;9:241-7. Links Tenenblatt 1956 Tenenblatt SS, Spagno A. A controlled study of chlorpromazine therapy in chronic psychotic patients. Journal of Clinical &amp;amp; Experimental Psychopathology 1956;17:81-92. Links Terminska 1989 Terminska K, Mrowiec W. [Badanie porownawcze wplywu perazyny, flufenazyny, trifluoroperazyny, chloropromazny i haloperydolu na objawy pierwotne i deficytowe pierwszego zachorowania na schizofrenie paranoidalna]. Psychiatria Polska 1989;23:24-30. Links Tetreault 1969 Tetreault L, Bordeleau JM, Albert JM, Rajotte P. Comparative study of fluphenazine ethanate, fluphenazine bichlorhydrate and placebos in chronic schizophrenics [Etude comparative de l'enanthate de fluphenazine, du bichlorhydrate de fluphenazine et du placebo chez le schizophrene chronique]. Canadian Psychiatric Association Journal 1969;14(2):191-8. [MedLine: 69202908]. Links Thorpe 1956 Thorpe J, Baker A. A research method to assess a new tranquillizing drug. British Journal of Psychiatry 1956;102:790-5. Links Tourlentes 1958 Tourlentes T L, Hunsicker A L, Hurd D E. Chlorpromazine and Communication Processes. A.M.A. Archives of Neurology and Psychiatry 1958;79:468-73. Links Troshinsky 1962 Troshinsky CH, Aaronson HG, Stone RK. Maintenance phenothiazines in aftercare of schizophrenic patients. Pennsylvania Psychiatric Bulletin 1962;2:11-5. Links Turner 1956 Turner M, Berard, E, Turner N, Franco N. Changes in the Electroencephalogram, the Electrodermogram, and the Electromyogram Provoked by Chlorpromazine in Man. Abstracts of World Medicine 1956;20:177. Links Turner 1966 Turner P. A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency. Journal of Pharmacy and Pharmacology 1966;18:836. Links Urquhart 1959 Urquhart R, Forrest AD. Clinical trial of promazine hydrochloride and acetylpromazine in chronic schizophrenic patients. British Journal of Psychiatry 1959;105:260-4. Links Van Praag 1975 van Praag HM, Dols LC, Schut T. Biochemical versus psychopathological action profile of neuroleptics. A comparative study of chlorpromazine and oxypertine in acute psychotic disorders. Comprehensive Psychiatry 1975;16:255-63. Links van Praag HM, Korf J. The dopamine hypothesis of schizophrenia. Some direct observations. In: van Praag HM editor(s). On the origin of schizophrenic psychoses. Amsterdam: De Erven Bohn BV, 1975:81-98. Vestre 1961 Vestre ND. An experimental study of the effects of chlorpromazine on association learning in schizophrenic patients. Dissertation Abstracts 1961:2374. Vinar 1973 Vinar O. Whom do neuroleptic drugs help?. Psychopharmacology, Sexual Disorders and Drug Abuse. Amsterdam, Netherlands: North-Holland, 1973:247-56. Volavka 1983 Volavka J, Hui KS, Anderson B, Nemes Z, O'Donnell J, Lajtha A. Short-lived effect of (des-tyr)-gamma-endorphin in schizophrenia. Psychiatry Research 1983;10:243-52. Links Warner 1996 Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatrica Scandinavica 1996;93:311-3. Links Weir 1968 Weir TW, Kernohan GA, MacKay DN. The use of pericyazine and chlorpromazine with disturbed mentally subnormal patients. British Journal of Psychiatry 1968;114:111-2. Links Welbel 1980 Welbel L. [Roznice w dziallaniu klinicznym niektorych neuroleptykow]. Psychiatria Polska 1980;14:113-8. Links Whitehead 1958 Whitehead WA, Thune LE. The effects of chlorpromazine on learning in chronic psychotics. Journal of Consulting Psychology 1958;22:379-83. Links Wilcott 1962 Wilcott RC, Helper MM, Garfield SL. Some Psychophysiological Effects of Chlorpromazine on Emotionally Disturbed Children. Journal of Nervous and Mental Diseases 1962;135:233-8. Links Wilson 1961 Wilson IC, McKay J, Sandifer MG. A double-blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia. British Journal of Psychiatry 1961;107:90-9. Links Winkelman 1957 Winkelman N W. An Appraisal of Chlorpromazine. General Principles for Administration of Chlorpromazine, Based on Experience with 1,090 Patients. American Journal of Psychiatry 1957. Links Winter 1956 Winter WD, Frederickson WK. The short-term effects of chlorpromazine on psychiatric patients. Journal of Consulting Psychology 1956;20:431-4. Links Wode-Helgodt 1977 Wode-Helgodt B, Eneroth P, Fyro B, Gullberg B, Sedvall G. Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatrica Scandinavica 1977;56:280-93. Links Wold 1959 Wold PN. A long term evaluation of chlorpromazine in six chronic schizophrenic patients. American Journal of Psychiatry 1959;116:461-2. Links Wolpert 1969 Wolpert A, Yaryura TJA, White L, Merlis S. Triiodothyronine and phenothiazines in schizophrenia. Diseases of the Nervous System 1969;30(7):487-9. [MedLine: 69288496]. Links Wyatt 1997 Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychological Medicine 1997;27:261-8. Links Yorkston 1977 Yorkston NJ, Zaki SA, Pitcher DR, Gruzelier JH, Hollander D, Sergeant HG. Propranolol as an adjunct to the treatment of schizophrenia. Lancet 1977;2:575-8. Links Yuan-guang 1994 Yuan-Guang C, Guang-rong X, Jing Ping Z. A study on the relationship between the chlorprmazine plasma levels and clinical response to chlorpromazine administrations in the schizophrenics. Chinese Journal of Neurology and Psychiatry 1994;27(3):153-5. Links Zeller 1956 Zeller WW, Graffagnino PN, Cullen CF, Rietman HJ. Use of chlorpromazine and reserpine in the treatment of emotional disorders. Journal of the American Medical Association 1956;160:179-84. Links References to studies awaiting assessment Magner 1974 Magner O, Moller S. The blood pressure lowering effect of chlorpromazine and methylperon (Buronil) [Blodtryksnedsaettende effekt af kllrpromazin og metylperon (Buronil)]. Ugeskrift for Laeger 1974;136:809-11. Links Rojo-Sierra 1971 Rojo-Sierra M, Alonso J, D&amp;#237;ez E, Giner J, Lloret E. [Aportaci&amp;#243;n sobre el espectro psicofarmacoter&amp;#225;pico del R P. 19 366 y R P. 19 552]. 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Ciudad de Mexico, Mexico. 1971:495-6. Vinar 1976 Vinar O, Taussigova D. Schizophrenic syndromes improving without neuroleptic drug treatment [Schizofrenni syndromy zlepsujici se bez neurolepticke lecby]. Ceskoslovenska Psychiatrie 1976;72(3):176-81. [MedLine: 77001715]. Links Yagi 1976 Yagi G. A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Rinsho Hyoka (Clinical Evaluation) 1976;4(3):351-403. Links Additional references Ahmed 1998 Ahmed I, Soares K, Seifas R, Adams CE. Randomised controlled trials in Archives of General Psychiatry (1959-1995): a prevalence study. Archives of General Psychiatry 1998;55(8):754-5. References to studies included in this review Abrams 1958 {published data only} Abrams J. Chlorpromazine in the treatment of chronic schizophrenia. Diseases of the Nervous System 1958;19:20-8. Links Baker 1959 {published data only} Baker JP. A controlled trial of ethylcrotonylurea. British Journal of Psychiatry 1959;105:852-62. Links Ban 1975 {published data only} Ban TA, Lehmann HE, Sterlin C, Climan M. Comprehensive clinical studies with thiothixene. Diseases of the Nervous System 1975;36:473-7. Links Bishop 1963 {published data only} Bishop M, Gallant DM. Behavioral toxicity associated with benzquinamide (Quantril) therapy in schizophrenic patients. American Journal of Psychiatry 1963;120:180-1. Links Borison 1991 {published data only} Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin 1991;27:103-6. Links Borison RL, Dren AT, Diamond BI. Sigma receptor antagonism and antipsychotic actions in schizophrenic patients. European Journal of Pharmacology 1990;183:2323. Links Chouinard 1990 {published data only} Chouinard G. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatria Scandinavica Supplementum 1990;358:111-9. Links Clark 1961 {published data only} Clark ML, Ray T, Paredes A, Costiloe J, Chappell J, Hagans J, Wolf S. Chlorpromazine in chronic schizophrenic women. I. Experimental design and effects at maximum point of treatment. Psychopharmacologia 1961;2:107-36. Links Clark ML, Ray TS, Ragland RE. Chlorpromazine in chronic schizophrenic women: rate of onset and rate of dissipation of drug effects. Psychosomatic Medicine 1963;25:212-17. Links Ray TS, Ragland RE, Clark ML. Chlorpromazine in chronic schizophrenic women: comparison of differential effects on various psychological modalities during and after treatment. Journal of Nervous and Mental Diseases 1964;138:348-53. Links Clark 1967 {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, Wolf S. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosomatic Medicine 1967;29:634-42. Links Clark 1968a {published data only} Clark ML, Huber WK, Kyriakopoulos AA, Ray TS, Colmore JP, Ramsey HR. Evaluation of trifluperidol in chronic schizophrenia. Psychopharmacologia 1968;12:193-203. Links Clark 1968b {published data only} Clark ML, Ray TS, Huber WK, Willis D, Ramsey HR. Evaluation of butaperazine in chronic schizophrenia. Clinical Pharmacology and Therapeutics 1968;97:57-64. Links Clark 1970a {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. Clinical Pharmacology and Therapeutics 1970;11:680-8. Links Serafetinides EA, Willis D, Clark ML. The EEG effects of chemically and clinically dissimilar antipsychotics: molindone vs. chlorpromazine. International Pharmacopsychiatry 1971;6:77-82. Links Clark 1970b {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark M, Ramsey H, Rahhal D, Serafetinides E, Wood F, Costiloe J. Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships. Archives of General Psychiatry 1972;27:479-83. Links Clark ML, Ramsey HR, Ragland RE, Rahhal DK, Serafetinides EA, Costiloe JP. Chlorpromazine in chronic schizophrenia - behavioral dose-response relationships. Psychopharmacologia 1970;18:260-70. Links Serafetinides EA, Willis D, Clark ML. EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking. Biological Psychiatry 1972;4:251-6. Links Clark 1971 {published data only} Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP. Drug treatment in newly admitted schizophrenic patients. Archives of General Psychiatry 1971;25:404-9. Links Clark 1972 {published data only} Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972;33:783-91. Links Serafetinides EA, Willis D, Clark ML. The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects. International Pharmacopsychiatry 1971;6:38-44. Links Clark 1977 {published data only} Clark ML, Paredes A, Costiloe JP, Wood F. Evaluation of butaclamol in chronic schizophrenic patients. Journal of Clinical Pharmacology 1977;17:529-36. Links Cohen 1968 {published data only} Cohen M, Freedman N, Englehardt DM. Family interaction patterns, drug treatment, and change in social aggression. Archives of General Psychiatry 1968;19(1):50-6. Links Graupner OK, Kalman EV. Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments [Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)]. Psychopharmacologia 1972;27(4):343-7. [MedLine: 73085373]. Links Cole 1964 {published data only} * Cole JO, Goldberg SC, Klerman GL National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 1964;10:246-61. Links Goldberg S, Klerman G, Cole J. Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. British Journal of Psychiatry 1965;111:120-33. Links Goldberg SC, Mattsson NB. Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System 1968;29:153-8. Links Cooper 2000 {published and unpublished data} Cooper SJ, Butler A, Tweed J, Welch CP. Zotepine in the treatment of chronic schizophrenia. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria: September 13-17, 1997. Cooper SJ, Raniwalla J, Welch C. Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo. XXth Collegium Internationale Neuro-psychopharmacologicum. Melbourne, Australia. Melbourne, Australia: 1996. * Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C. A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica 2000;101(3):218-25. [MedLine: 20184895]. Links Cooper SJ, Tweed J, Raniwalla J, Welch C. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Unpublished manuscript 1996. Cooper SJ, Welch CP. A comparison of zotepine and chlorpromazine on BPRS subscores. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria: September 13-17, 1997. Dean 1958 {published data only} Dean EF, Buker S. Schizophrenia treated with and without chlorpromazine. Rocky Mountain Medical Journal 1958;55:47-50. Links Engelhardt 1960 {published data only} Engelhardt D, Freedman N, Rosen B, Mann D, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. Archives of General Psychiatry 1964;11:162-9. Links Engelhardt DM, Freedman N, Glick BS, Hankoff LD, Mann D, Margolis R. Prevention of psychiatric hospitalization with use of psychopharmacological agents. Journal of the American Medical Association 1960;173:147-9. Links Engelhardt DM, Margolis RA, Rudorfer L, Paley HM. Physician bias and the double-blind. Archives of General Psychiatry 1969;20(3):315-20. Links Engelhardt DM, Rosen B, Freedman N, Mann D, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure. Journal of the American Medical Association 1963;186:981-3. Links Engelhardt DM, Rosen B, Freedman N, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization - a reevaluation. Archives of General Psychiatry 1967;16:98-101. Links Freedman N, Cutler R, Engelhardt DM, Margolis R. On the modification of paranoid symptomatology. Journal of Nervous and Mental Disease 1967;144:29-36. Links Freedman N, Cutler R, Engelhardt DM, Margolis R. On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines. Journal of Nervous and Mental Disease 1970;150:68-76. Links Rosen B, Engelhardt DM, Freedman N. The hospitalization proneness scale as a predictor of response to phenothiazine treatment. Journal of Nervous and Mental Disease 1968;6:476-80. Links Fink 1963 {published data only} Belmont I, Pollack M, Willner A, Klein D, Fink M. The effects of imipramine and chlorpromazine on perceptual analytic ability, perceptual analytic responsivity and memory as revealed in rorschach responses. Journal of Nervous and Mental Disease 1963;137(1):42-50. Links * Fink M, Pollack M, Klein DF, Blumberg AG, Belmont I, Karp E, Kramer JC, Willner A. Comparative studies of chlorpromazine and imipramine. I. Drug discriminating patterns. Neuropsychopharmacology 1963;3:370-2. Links Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Archives of General Psychiatry 1967;16:118-26. Links Klein DF. Psychiatric diagnosis and a typology of clinical drug effects. Psychopharmacologia 1968;13:359-86. Links Klein DF, Honigfeld G, Feldman S. Prediction of drug effect by diagnostic decision tree. Diseases of the Nervous System 1968;29:159-87. Links Levenstein S, Klein DF, Pollack M. Follow up study of formerly hospitalized voluntary psychiatric patients: the first two years. American Journal of Psychiatry 1966;122:1102-8. Links Fleming 1959 {published data only} Fleming B, Spencer A, Whitelaw E. A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis. British Journal of Psychiatry 1959;105:349-58. Links Grygier 1958 {published data only} Grygier P, Waters MA. Chlorpromazine used with an intensive occupational therapy program. A.M.A. Archives of Neurology and Psychiatry 1958;79:697-705. Links Hall 1955 {published data only} Hall RA, Dunlap DJ. A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics. Journal of Nervous and Mental Disease 1955;122:301-14. Links Hollister LE, Hall RA. Phenothiazine derivatives and morphologic changes in the liver. American Journal of Psychiatry 1966;123:211-2. Links Hamill 1975 {published data only} Hamill WT, Fontana AF. The immediate effects of chlorpromazine in newly admitted schizophrenic patients. American Journal of Psychiatry 1975;132:1023-6. Links Hamilton 1960 {published data only} Hamilton M, Smith A, Lapidus HR, Cadogan EP. A controlled trial of Thiopropazate Dihydrochloride (Dartalan), Chlorpromazine and occupational therapy in chronic schizophrenics. British Journal of Psychiatry 1960;106:40-55. Links Hine 1958 {published data only} Hine FR. Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic. Journal of Nervous and Mental Diseases 1958;127:220-7. Links Hogarty 1973 {published data only} Goldberg S, Schooler N, Hogarty G, Roper M. Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry 1977;34:171-84. Links Hogarty G, Goldberg S. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Archives of General Psychiatry 1973;28:54-64. Links Hogarty G, Goldberg S, Schooler N. Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients. Archives of General Psychiatry 1974;31:609-18. Links Hogarty G, Goldberg S, Schooler N, Ulrich R. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Archives of General Psychiatry 1974;31:603-8. Links Hogarty G, Ulrich R. Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry 1977;34:297-301. Links Hogarty GE, Munetz MR. Pharmacogenic depression among outpatient schizophrenic patients - a failure to substantiate. Journal of Clinical Psychopharmacology 1984;4:17-24. Links Klein 1973 {published data only} Klein D, Rosen B. Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients. Archives of General Psychiatry 1973;29:480-5. Links Kurland 1961 {published data only} Kurland AA, Hanlon TE, Tatom MH, Ota KY, Simopoulos AL. The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness. Journal of Nervous and Mental Disease 1961;133:1-18. Links Kurland AA, Hanlon TE, Tatom MH, Simopoulos AL. Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations. Journal of Nervous and Mental Disease 1961;132:61-74. Links Kurland AA, Nilsson GL, Hanlon TE. Pre-admission drug treatment of state psychiatric hospital patients. American Journal of Psychiatry 1959;115:1028-9. Links Kurland AA, Sutherland GF. The phenothiazine tranquilizers - their neurological complications and significance. Psychosomatics 1960;1:192-4. Links Letemendia 1967 {published data only} Letemendia F, Harris AD. Chlorpromazine and the untreated chronic schizophrenic: a long-term trial. British Journal of Psychiatry 1967;113:950-8. Links Nishikawa 1982 {published data only} Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology 1982;77:301-4. Links Payne 1960 {published data only} Payne P. A Comparison of Trifluopromazine, Chlorpromazine and a Placebo in Twenty-one Chronic Schizophrenic Patients. Manitoba Medical Review 1960:196-8. Links Peet 1981 {published data only} Peet M, Bethell M, Coates A, Khamnee A, Hall P, Cooper S, King D, Yates R. Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo. British Journal of Psychiatry 1981;139:105-11. Links Prien 1968 {published data only} Crane GE. Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie 1968;2:209-18. Links De Long SL. Incidence and significance of chlorpromazine-induced eye changes. Diseases of the Nervous System 1968;29:19-22. Links Gardos G, Cole JO, LaBrie RA. A 12-year follow-up study of chronic schizophrenics. Hospital and Community Psychiatry 1982;33:983-4. Links Mandel A, Gross M. Agranulocyctosis and phenothiazines. Diseases of the Nervous System 1968:32-6. Links Prien R, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group. Archives of General Psychiatry 1968;18:482-95. Links Prien R, DeLong S, Cole J, Levine J. Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry 1970;23:464-8. Links Prien RF, Cole JO, Belkin NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry 1968;115:679-86. Links Prien RF, Levine J, Cole JO. Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System 1970;31:739-45. Links Rappaport 1978 {published data only} Rappaport M, Hopkins HK, Hall K, Belleza T, Silverman J. Are there schizophrenics for whom drugs may be unnecessary or contraindicated?. International Pharmacopsychiatry 1978;13:100-11. Links Reardon 1966 {published data only} Reardon JD, Abrams S. Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System 1966;27:265-70. Links Reschke 1974 {published data only} Reschke RW. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Diseases of the Nervous System 1974;35:112-5. Links Saretsky 1966 {published data only} Saretsky T. Effects of chlorpromazine on primary-process thought manifestations. Journal of Abnormal Psychology 1966;71:247-52. Links Schiele 1961 {published data only} Schiele BC, Vestre ND, Stein KE. A comparison of thioridazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients. Journal of Clinical and Experiemental Psychopathology 1961;22:151-62. Links Serafetinides 1972 {published data only} Serafetinides EA, Clark ML. Psychological effects of single dose antipsychotic medication. Biological Psychiatry 1973;7:263-7. Links Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Diseases 1972;154:31-42. Links Serafetinides EA, Willis D. A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry 1973;8:245-7. Links Serafetinides EA, Willis D, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Diseases 1972;155:366-9. Links Shepherd 1956 {published data only} Shepherd M, Watt DC. A controlled clinical study of chlorpromazine and reserpine. Journal of Neurology, Neurosurgery and Psychiatry 1956;19:232-5. Links Simon 1958 {published data only} Simon W, Wirt AL, Wirt RD, Halloran AV. Long-term follow-up study of schizophrenic patients. Archives of General Psychiatry 1965;12:510-5. Links Simon W, Wirt R, Wirt A, Halloran A, Hinckley R, Lund J, Hopkins GW. A controlled study of the short-term differential treatment of schizophrenia. American Journal of Psychiatry 1958;114:1077-86. Links Smith 1961 {published data only} Smith ME. A clinical study of chlorpromazine and chlordiazepoxide. Connecticut State Medical Journal 1961;25:153-7. Links Somerville 1960 {published data only} Somerville DM, Cohen PH, Graves GD. Phenothiazine side-effects. Comparison of two major tranquillizers. British Journal of Psychiatry 1960;106:1417-24. Links Spohn 1977 {published data only} Spohn H, Lacoursiere R, Thompson K, Coyne L. Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Archives of General Psychiatry 1977;34(6):633-44. Links Tetreault 1969a {published data only} Tetreault L. Comparative study of two drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques 1969;22:221-8. Links Tetreault L, Bordeleau JM, Gauthier R, Vulpe M, Lapointe L. Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients. Diseases of the Nervous System 1969;30(2):74-84. Links Vaughan 1955 {published data only} Vaughan GF, Leiberman DM, Cook LC. Chlorpromazine in psychiatry. Lancet 1955;1:1083-7. Links Walsh 1959 {published data only} Walsh GP, Walton D, Black DA. The relative efficacy of &amp;quot;Vespral&amp;quot; and chlorpromazine in the treatment of a group of chronic schizophrenic patients. British Journal of Psychiatry 1959;105:199-209. Links Zuoze 1986 {published data only} Zuoze L, Youjun W, Shuzhong Z, Anguo H, Yuande C. Therapeutic effect of He-Ne laser irradiation of Point Erman in schizophrenic auditory hallucination - a clinical assessment. Journal of Traditional Chinese Medicine 1986;6:253-6. Links References to studies excluded from this review Abse 1960 Abse WD, Dahlstrom WG, Tolley AG. Evaluation of tranquilizing drugs in the management of acute mental disturbance. American Journal of Psychiatry 1960;117:973-80. Links Acker 1965 Acker CW. An exploration of the autonomic effects of phenothiazines. Psychopharmacologia 1965;7:150-8. Links Affleck 1966 Affleck DC, Eaton MT, Mansfield E. The action of a medication and the physician's expectations. Nebraska State Medical Journal 1966;51:331-4. Links Agarwal 1985 Agarwal AK, Winny GC. Role of ECT phenothiazine combination in schizophrenia. Indian Journal of Psychiatry 1985;27:233-6. Links Akimoto 1966 Akimoto H, Shimazaki T, Shibata N, Sato Y, Takahashi R. Current status of pharmacotherapy in schizophrenia. Folia Psychiatrica et Neurologica Japonica 1966;20(1):1-8. [MedLine: 67213329]. Links Alpert 1966 Alpert M, Hekimian LJ, Frosch WA. Evaluation of treatment with recorded interviews. American Journal of Psychiatry 1966;122:1258-64. Links Alpert 1978 Alpert M, Friedhoff A, Marcos L, Diamond F. Paradoxical reaction to L-dopa in schizophrenic patients. American Journal of Psychiatry 1978;135:1329-32. Links Alson 1964 Alson E, Hastings K. The use of adjective check lists with psychotic patients: the problem of pseudo-responses. Journal of Clinical Psychology 1964;20(4):462-3. Links Aman 1985 Aman MG, Singh NN. Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment. Journal of Mental Deficiency Research 1985;29(2):187-95. [MedLine: 85293054]. Links Amin 1977 Amin MM, Ban TA, Lehmann HE. A standard-controlled clinical study with benzquinamide in the treatment of chronic schizophrenic patients. Psychopharmacology Bulletin 1977;13:20-1. Links Ananth 1972 Ananth JV, Vacaflor L, Kekhwa G, Sterlin C, Ban TA. Nicotinic acid in the treatment of newly admitted schizophrenic patients: a placebo-controlled study. Internationale Zeitschrift Fur Klinische Pharmakologie Therapie und Toxikologie 1972;5(4):406-10. [MedLine: 72239308]. Links Andrews 1976 Andrews P, Hall JN, Snaith RP. A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. British Journal of Psychiatry 1976;128:451-5. Links Ashcroft 1961 Ashcroft GW, MacDougall EJ, Barker PA. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1961;107:287-93. [MedLine: 72239308]. Links Ayers 1984 Ayers T, Liberman RP, Wallace CJ. Subjective response to antipsychotic drugs: failure to replicate predictions of outcome. Journal of Clinical Psychopharmacology 1984;4:89-93. Links Azima 1954 Azima H, Ogle W. Effects of Largactil in mental syndomes. Canadian Medical Association Journal 1954;71:116-21. Links Bagadia 1981 Bagadia VN, Shah LP, Pradhan PV, Doshi J, Abhyankar R. Evaluation of cognitive effects of ECT: preliminary observations. Indian Journal of Psychiatry 1981;23:324-9. Links Ban 1977 Ban TA, Lehmann HE, Deutsch M. Negative findings with megavitamins in schizophrenic patients - preliminary report. Communications in Psychopharmacology 1977;1:119-22. Links Hoffer, J. Megavitamin treatment of schizophrenia. Canadian Psychiatric Association Journal 1975;20:492-5. Links Beech 1990 Beech A, Powell TJ, McWilliam J, Claridge GS. The effect of a small dose of chlorpromazine on a measure of 'cognitive inhibition'. Personality and Individual Differences 1990;11:1141-5. Links Benaim 1960 Benaim S. The effect of chlorpromazine on the incidence of epileptic phenomena during insulin coma therapy: A statistical investigation. Journal of Mental Science 1960;106:317-21. Links Bennett 1956 Bennett A, Ford F, Turk RE. Clinical investigation of chlorpromazine and reserpine in private psychiatric practice. American Journal of Psychiatry 1956;112:782-7. Links Blumberg 1964 Blumberg AG, Klein DF, Pollack M. Effects of chlorpromazine and imipramine on systolic blood pressure in psychiatric patients: Relationships to age, diagnosis and initial blood pressure. Journal of Psychiatric Research 1964;2(1):51-60. Links Blumberg 1969 Blumberg AG, Klein DF. Chlorpromazine-procyclidine and imipramine: effects on thyroid function in psychiatric patients. Clinical Pharmacology and Therapeutics 1969;10:350-4. Links Boullin 1975 Boullin DJ, Woods HF, Grimes RP, Grahame-Smith DG, Wiles D, Gelder MG, Kolakowska T. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. British Journal of Clinical Pharmacology 1975;2:29-35. Links Bowes 1956 Bowes, HA. The ataractic drugs: the present position of chlorpromazine, frenquel, pacatal, and reserpine in the psychiatric hospital. American Journal of Psychiatry 1956;113:530-9. Links Bressler 1971 Bressler B, Friedel RO. A comparison between chlorpromazine and thiothixene in a Veterans Administration Hospital population. Psychosomatics 1971;12:275-7. Links Brizer 1985 Brizer DA, Hartman N, Sweeney J, Millman RB. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. American Journal of Psychiatry 1985;142(9):1106-7. Links Burnett 1975 Burnett GB, Little SR, Graham N, Forrest AD. The assessment of thiothixene in chronic schizophrenia. A double-blind controlled trial. Diseases of the Nervous System 1975;36:625-9. Links Cabrera Gomez 1994 Cabrera Gomez JA, Cordero Gutierrez JR, Fernandez Lopez O, Reyes Gutierrez B, Romero Garcia K, Simon Consuegra J, Feas Cruz. Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon. Biotherapy 1994;7(1):27-37. Links Caffey 1963 * Caffey E, Forrest I, Frank T, Klett CJ. Phenothiazine excretion in chronic schizophrenics. American Journal of Psychiatry 1963;120:578-82. Links Caffey EM, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, Rothstein C. Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases 1964;17(4):347-58. Links Caffey 1975 Caffey EMJ, Prien RF. Practical considerations on treatment with antipsychotic preparations [Prakticheskie soobrazheniia o lechenii antipsikhoticheskimi preparatami]. Zhurnal Nevropatologii i Psikhiatrii 1975;75:1399-401. Links Campbell 1972 Campbell M, Fish B, Shapiro T, Floyd A. Acute responses of schizophrenic children to a sedative and a 'stimulating' neuroleptic: a pharmacologic yardstick. Current Therapeutic Research 1972;14:759-66. Links Campbell M, Fish B, Shapiro T, Floyd A. Thiothixene in young disturbed children. A pilot study. Archives of General Psychiatry 1970;23:70-2. Links Cardone 1969 Cardone S, Olson R. Chlorpromazine and body image. Effects on chronic schizophrenics. Archives of General Psychiatry 1969;20:576-82. Links Carrillo 1971 Carrillo C. Pharmacologlal treatment of the emotionally unstable character disorder. Vth World Congress of Psychiatry. Ciudad de Mexico. 1971. Casey 1960 Casey JF, Bennet IF, Lindley CJ, Hollister LE, Gordon MH, Springer NN. Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Archives of General Psychiatry 1960;2:210-20. Links Casey 1961 Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM. Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry 1961;117:997-1003. Links Chacon 1972 Chacon C, Harper P. Clinical and work performance variables in phenothiazine therapy of schizophrenia. Acta Psychiatrica Scandinavica 1973;49:65-76. Links Chacon Carlos, Harper P, Harvey GF. Work study in the assessment of the effects of phenothiazines in schizophrenia. Comprehensive Psychiatry 1972;13(6):549-54. [MedLine: 73051431]. Links Childers 1961 Childers RT, Therrien R. A comparison of the effectiveness of triluoperazine and chlorpromazine in schizophrenia. American Journal of Psychiatry 1961;118:552-4. Links Chouinard 1977 Chouinard G, Annable L, Kolivakis TN. Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology 1977;17(2-3):162-7. [MedLine: 77094284]. Links Chouinard-G 1983 Chouinard-G, Annable-L. Fluspirilene in the treatment of newly admitted schizophrenic patients. Psychopharmacology Bulletin 1983;19(1):136-8. Links Claghorn 1983 Claghorn J, Abuzzahab F, Wang R, Larson C, Gelenberg A, Klerman G, Tuason V, Steinbook R. The current status of Clozapine. Psychopharmacology Bulletin 1983;19:138-40. Links Clark 1970c Clark ML, Serafetinides EA, Wise JB, Colmore JP. Ocular pigment deposits: drug-induced false-positives. Journal of the American Medical Association 1970;214:2339. Links Clark 1970d Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark 1975 Clark ML, Kaul PN. A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. In: Gottschalk LA, Merlis S editor(s). Pharmacokinetics of psychoactive drugs. New York: Spectrum Publications, 1976:191-7. Clark ML, Kaul PN. A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. Psychopharmacology Bulletin 1975;11:28-30. Links Clark ML, Kaul PN, Whitfield LR. Chlorpromazine kinetics and clinical response. Psychopharmacology Bulletin 1978;14:43-5. Links Cole 1967 Cole JO, Schooler NR. Differences in clinical effects of three phenothiazines in &amp;quot;acute&amp;quot; schizophrenia. Diseases of the Nervous System 1967;28:369-83. Links Coons 1962 Coons WH, Boyd BA, White JG. Chlorpromazine, trifluoperazine and placebo with long term mental hospital patients. Canadian Psychiatric Association Journal 1962;7:159-63. [MedLine: 62022417]. Links Cowden 1956 Cowden RC, Zax M, Hague JR, Finney RC. Chlorpromazine: alone and as an adjunct to group psychotherapy in the treatment of psychiatric patients. American Journal of Psychiatry 1956;4:898-902. Links Crane 1970 Crane GE. High doses of trifluperazine and tardive dyskinesia. Archives of Neurology 1970;22(2):176-80. [MedLine: 70065772]. Links Crane 1971 Crane GE. Persistence of neurological symptoms due to neuroleptic drugs. American Journal of Psychiatry 1971;127:1407-10. Links Crow 1986 Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. II. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986;148:120-7. Links Johnstone EC, Crow TJ, Johnson AL, MacMillan JF. The Northwick Park study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. British Journal of Psychiatry 1986;148:115-20. Links MacMillan JF, Crow TJ, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. III. Short-term outcome in trial entrants and trial eligible patients. British Journal of Psychiatry 1986;148:128-33. Links Curry 1972 Curry SH, Adamson L. Double-blind trial of fluphenazine decanoate. Lancet 1972;2:543-4. Links Cutler 1957 Cutler RP, Monroe JJ, Anderson TE. Effects of &amp;quot;tranquilizers&amp;quot; upon pathological activity in psychotic patients: II. Reserpine. Archives of Neurology and Psychiatry 1957;78:61-8. Links Dally 1966 Dally P, Sargant W. Treatment and outcome of anorexia nervosa. British Medical Journal 1966;2:793-5. Links Danion 1992 Danion JM, Peretti S, Grange D, Bilik M, Imbs JL, Singer L. Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers. Psychopharmacology 1992;108(3):345-51. [MedLine: 92396807]. Links Daston 1958 Daston PG. Stylus maze performance of chronic schizophrenics taking chlorpromazine. Journal of Consulting Psychology 1958;22(5):384. Links Daston 1959 Daston PG. Effects of two phenothiazine drugs on concentrative attention span of chronic schizophrenics. Journal of Clinical Psychology 1959;15:106-9. Links Davies 1973 Davies AL, O'Leary J. The use of chlorpromazine in schizophrenia. Nursing Times 1973;69:1694-5. Links Dean 1967 Dean G. Mefenamic acid and chlorpromazine in porphyria variegata. South African Medical Journal 1967;41:925-7. Links Den 2000 Den Boer JA, Vahlne J O, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Human Psychopharmacology 2000;15(3):179-89. Links Denber 1955 Denber HCB, Merlis S. Studies on Mescaline. VI. Therapeutic Aspects of the Mescaline-Chlorpromazine Combination. Journal of Nervous and Mental Diseases 1955;122:463. Links Denber 1956 Denber H, Bird EG. Chlorpromazine in the treatment of mental illness. III. The problem of depression. American Journal of Psychiatry 1956;112:1021. Links Denber 1957 Denber HCB. Chlorpromazine-diethazine in the treatment of depression. Diseases of the Nervous System 1957;18:76-9. Links Desager 1988 Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF. Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology Berlin 1988;96:63-6. Links Douglas 1969 Douglas KW, Hindley JP. A comparison of mesoridazine and chlorpromazine in chronic psychiatric patients. Journal of Clinical Pharmacology and The Journal of New Drugs 1969;9:176-82. Links Downing 1963 Downing RW, Ebert JN, Shubrooks SJ. Effect of phenothiazines on the thinking of acute schizophrenics. Perceptual and Motor Skills 1963;17(2):511-20. Links Dube 1981 Dube S, Sethi B. Efficacy of lithium in schizophrenia. Indian Journal of Psychiatry 1981;23(2):193-9. Links Eitan 1991 Eitan N, Levin Y, Ben-Artzi E, Levy A, Neumann M. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica 1992;85:74-6. Links Ekdawi 1966 Ekdawi MY, Fowke R. A controlled trial of anti-parkinson drugs in drug-induced parkinsonism. British Journal of Psychiatry 1966;112(487):633-6. Links Elkes 1954 Elkes J, Elkes C. Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients. British Medical Journal 1954;2:560-5. Links Feldman 1956 Feldman PE, Lacy BS, Walker AE, Garrez NJ. A controlled, blind study of effects of thorazine on psychotic behavior. Bulletin of the Menninger Clinic 1956;20:25-47. Links Fink 1958 Fink M, Shaw R, Gross GE, Coleman FS. Comparative study of chlorpromazine and insulin coma in therapy of psychosis. Journal of the American Medical Association 1958;166(15):1846-50. Links Fink 1965 Fink M, Klein DF, Kramer JC. Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders. Psychopharmacologia 1965;7:27-36. Links Fleischhacker 1995 Fleischhacker W. Broadening treatment perspectives of schizophrenia: a clinical update on seroquel. 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 - Oct 4; Venice, Italy. 1995. Fleming 1958 Fleming B, Currie J. Investigation of a new compound, B.W.203, and of Chlorpromazine in the treatment of psychosis. British Journal of Psychiatry 1958;104:749-57. Links Foote 1958 Foote E. Combined Chlorpromazine and Reserpine in the treatment of chronic psychotics. British Journal of Psychiatry 1958;104:201-5. Links Forrest 1967 Forrest GL, Bortner TW, Bakker CB. The role of personality variables in response to chlorpromazine, dextroamphetamine and placebo. Journal of Psychiatric Research 1967;5:281-8. Links Freed 1956 Freed H, Peifer CA. Treatment of hyperkinetic emotionally disturbed children with prolonged administration of chlorpromazine. American Journal of Psychiatry 1956;113:22. Links Freedman 1965 Freedman N, Engelhardt D, Mann D, Margolis R, London S. Communication of body complaints and paranoid symptom change under conditions of phenothiazine treatment. Journal of Personality and Social Psychology 1965;1(4):310-8. Links Freeman 1956 Freeman H, Arnold AL, Cline HS. Effects of chlorpromazine and reserpine in chronic schizophrenic patients. Diseases of the Nervous System 1956;17:213-9. Links Freeman H, Cline HS. Effects of chlorpromazine on chronic lobotomized schizophrenic patients. A.M.A. Archives of Neurology and Psychiatry 1956;76:500-7. Links Freeman 1973 Freeman Harry. A double blind comparison of mesoridazine and chlorpromazine in chronic schizophrenics. Diseases of the Nervous System 1973;34(6):289-93. [MedLine: 74114021]. Links Friedhoff 1960 Friedhoff A, Alpert M. The effect of chlorpromazine on the variability of motor task performance in schizophrenics. Journal of Nervous and Mental Disease 1960;131:110-6. Links Fromm 1956 Fromm GH, Forsberg IA. Controlled study on the value of chlorpromazine in allaying anxiety. Diseases of the Nervous System 1956;17:16-9. Links Gaitz 1955 Gaitz C M, Roy H, Thompson W, Kimbell I, Mullen A J, Pokorny A D. Evaluation of Chlorpromazine in Comparison with other Methods of treatments of hospitalized psychiatric patients, using the lorr multidimensional scale for rating psychiatric patients. Psychiatric Research Reports 1955;1:1984. Links Galbrecht 1968 Galbrecht CR, Klett CJ. Predicting response to phenothiazines: the right drug for the right patient. Journal of Nervous and Mental Disease 1968;147:173-83. Links Galdi 1988 Galdi J, Bonato RR. Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics. Canadian Journal of Psychiatry 1988;33:816-8. Links Gallant 1963 Gallant D, Bishop M, Steele C, Noblin CD. The relationship between serotonin antagonism and tranquilizing activity. American Journal of Psychiatry 1963;119:882. Links Gallant 1967 Gallant DM, Bishop MP, O'Meallie L. BL-KR140: a controlled evaluation in chronic schizophrenic patients previously stabilized on chlorpromazine. Current Therapeutic Research 1967;9:447-50. Links Gardner 1955 Gardner MJ, Hawkins HM, Judah LN, Murphree OD. Objective measurement of psychiatric changes produced by chlorpromazine and reserpine in chronic schizophrenia. Psychiatric Research Reports 1955;1:77-83. Links Gardos 1968 Gardos G, Rapkin RM, DiMascio A. Trifluoperazine and chlorpromazine in combination and individually. Current Therapeutic Research Clinical and Experimental 1968;10(12):609-12. [MedLine: 69054114]. Links Gardos 1976 Gardos G, Cole J O. Maintenance antipsychotic therapy: is the cure worse than the disease?. American Journal of Psychiatry 1976;133:32-6. Links Garfield 1962 Garfield SL, Helper MM, Wilcott RC, Muffly R. Effects of chlorpromazine on behaviour in emotionally disturbed children. Journal of Nervous and Mental Diseases 1962;135:147-54. Links Garmezy 1969 Garmezy N. Effects of censure and chlorpromazine on visual discrimination behavior of schizophrenic and alcoholic patients. Proceedings of the Annual Convention of the American Psychological Association 1969;4(2):491-2. Links Gauthier 1967 Gauthier R, Hillel J, Bordeleau J M, Tetreault L. Comparative study of trifluperidol and trifluoperazine in the treatment of acute schizophrenia. Union Medicale du Canada 1967;96:936-43. Links Gendron 1973 Gendron JL, Zimmermann RL, Schiele BC. A double blind comparison of AL 1021 and chlorpromazine in hospitalized schizophrenics. Current Therapeutic Research 1973;15(6):333-6. Links Gibbs 1956 Gibbs JJ, Wilkens B, Lauterbach CG. A controlled clinical psychiatric study of chlorpromazine. Journal of Clinical and Experimental Psychopathology 1957;18:269-83. Links Gibbs JJ, Wilkens B, Lauterbach CG. A controlled clinical psychiatric study of the drug chlorpromazine. American Journal of Psychiatry 1956;113:254-5. Links Gilgash 1957 Gilgash CA. Effects of Thorazine on Wechsler scores of adult catatonic schizophrenics. Psychological Reports 1957;3:561-4. Links Goldberg 1968 Goldberg SC, Mattsson NB. Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System 1968;29(5):S153-8. [MedLine: 68399894]. Links Goldberg 1970 Goldberg GJ, Brooke G, Townsend HR, Brahma RK, Hill GB. A comparison of oxypertine and chlorpromazine in chronic schizophrenia. Acta Psychiatrica Scandinavica 1970;46(2):126-35. [MedLine: 71030938]. Links Goldberg 1972 Goldberg S, Frosch W, Drossman A, Schooler N, Johnson G. Prediction of response to phenothiazines in schizophrenia. A crossvalidation study. Archives of General Psychiatry 1972;26:367-73. Links Goldman 1955 Goldman D. Treatment of psychotic states with chlorpromazine. Journal of the American Medical Association 1955;157:1274-8. Links Good 1958 Good WW, Sterling M, Holtzman WH. Termination of chlorpromazine with schizophrenic patients. American Journal of Psychiatry 1958;115:443-8. Links Mefferd RB, Labrosse EH, Gawienowski AM, Williams RJ. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. Journal of Nervous and Mental Diseases 1958;127:167-79. Links Goodwin-Austin 1971 Godwin-Austen RB, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. British Medical Journal 1971;4(778):25-6. Links Goyne 1958 Goyne J B, Groebner E, Pueblita M. Clinical Research - Vesperin-Chlorpromazine Therapy. Scientific Papers of the 114th Annual Meeting of the American Psychiatric Association. 1958:104-5. Graupner 1972 Graupner OK, Kalman EV. Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments [Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)]. Psychopharmacologia 1972;27(4):343-7. [MedLine: 73085373]. Links Green 1996 Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology 1996;128(1):67-73. Links Green 1998 Green JF, King DJ. Antisaccade and no-saccade distractibilty with chlorpromazine and lorazepam. Schizophrenia Research 1998;29(1,2):117. Links Greenberg 1966 Greenberg LM, Roth S. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. American Journal of Psychiatry 1966;123:221-6. Links Griffiths 1979 Griffiths RR, Bigelow G, Liebson I. Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. Journal of Pharmacology and Experimental Therapeutics 1979;210:301-10. Links Guy 1978 Guy W, Petrie W, Cleary P. The incidence of treatment emergent symptoms under chlorpromazine and placebo conditions. Psychopharmacology Bulletin 1978;14:22-4. Links Hammond 1978 Hammond NV, Gruzelier JH. Laterality, attention and rate effects in the auditory temporal discrimination of chronic schizophrenics - the effect of treatment with chlorpromazine. Quarterly Journal of Experimental Psychology 1978;30:91-103. Links Hamner 1996 Hamner MB, Arvanitis LA, Miller BG, Link CGG, Hong WW. Plasma prolactin in schizophrenia subjects treated with seroquel (TM) (ICI 204,636). Psychopharmacology Bulletin 1996;32(1):107-10. [MedLine: 96267998]. Links Hankoff 1960 Hankoff L, Engelhardt D, Freedman N, Mann D, Margolis R. Denial of illness in schizophrenic outpatients: effects of psychopharmacological treatment. Archives of General Psychiatry 1960;3:657-64. Links Hanlon 1958 Hanlon T E, Kurland A A, Esquibel A J, Ota K Y. A Comparative Study of Chlorpromazine and Triflupromazine in the Management of the Chronic Hospitalized Psychotic Patient. Journal of Nervous and Mental Diseases 1958;127:17-20. Links Hanlon 1960 Hanlon TE, Wiener G, Kurland AA. The psychiatric physician and the phenothiazine tranquilizers. Journal of Nervous and Mental Diseases 1960;130:67-71. Links Harper 1976 Harper P, Chacon C. Work performance versus clinical assessment in the evaluation of phenothiazine therapy. British Journal of Clinical Pharmacology 1976;3:50-5. Links Hartley 1978 Hartley L, Henry T, Couper-Smartt J. Chlorpromazine and serial reaction performance. British Journal of Psychology 1978;69:271-6. Links Hartley 1987 Hartley LR, Coxon L, Spencer J. Pharmacological effects on lateralized behavior. Current Psychology Research and Reviews 1987;6:301-12. Links Hartley 1989 Hartley LR, Strother N, Arnold PK, Mulligan B. Lateralization of emotional expression under a neuroleptic drug. Physiology and Behavior 1989;45:917-21. Links Hartley 1991 Hartley LR, Ireland LK, Arnold PK, Spencer J. Chlorpromazine and the lateralisation of the perception of emotion. Physiology and Behavior 1991;50:881-5. Links Hartmann 1973 Hartmann E, Cravens J. The effects of long term administration of psychotrophic drugs on human sleep. IV. The effects of chlorpromazine. Psychopharmacologia 1973;33:203-18. Links Haskell 1974 Haskell DS, McNair DM, Fisher S, Kahn RJ. A controlled outpatient trial of perphenazine-amitriptyline and chlorpromazine. Journal of Clinical Pharmacology 1974;14:536-42. Links Heilizer 1959 Heilizer F. The effects of chlorpromazine upon psychomotor and psychiatric behavior of chronic schizophrenic patients. Journal of Nervous and Mental Disease 1959;128:358-64. Links Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. Journal of Clinical and Experimental Psychopathology 1959;20:53-7. Links Hekimian 1967 Hekimian LJ, Friedhoff AJ. A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients. Diseases of the Nervous System 1967;28:675-8. Links Herrera 1988 Herrera JN, Sramek JJ, Costa JF, Roy S, High potency neuroleptics and violence in schizophrenics. Journal of Nervous and Mental Disease 1988;176(9):558-61. Links Herrmann 1991a Herrmann WM, Scharer E, Delini-Stula A. Predictive value of pharmaco electroencephalography in early human pharmacological evaluations of psychoactive drugs - first example - Savoxepine. Pharmacopsychiatry 1991;24:196-205. Links Herrmann 1991b Herrmann WM, Scharer E, Wendt G, Delini-Stula A. Pharmaco EEG profile of maroxepine - third example to discuss the predictive value of pharmaco electroencephalography in early human pharmacological evaluations of psychoactive drugs. Pharmacopsychiatry 1991;24:214-24. Links Herz 1991 Herz M, Glazer W, Mostert M, Sheard M, Szymanski H, Hafez H, Mirza M, Vana J. Intermittent versus maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry 1991;48:333-9. Links Hoffer 1975 Hoffer J. Megavitamin treatment of schizophrenia. Canadian Psychiatric Association Journal 1975;20:492-5. Links Hogarty 1976 Hogarty G E, Ulrich R F, Mussare F, Aristigueta N. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Diseases of the Nervous System 1976;37:494-500. Links Hollis 1968 Hollis JH. Chlorpromazine: direct measurement of differential behavioral effect. Science 1968;159:1487-9. Links Hollister 1955 Hollister LE, Jones KP, Brownfield B, Johnson F. Chlorpromazine alone and with reserpine. California Medicine 1955;83:218-21. Links Hollister LE, Traub L, Beckman WG. Psychiatric use of reserpine and chlorpromazine: results of double-blind studies. In: Kline NS editor(s). Psychopharmacology. Washington DC: AAAS, 1956:65-74. Holt 1984 Holt RJ. Neuroleptic drug-induced changes in platelet levels. Journal of Clinical Psychopharmacology 1984;4:130-2. Links Hong 1996a Hong W, Arvanitis L. Reduction of the positive symptoms of schizophrenia by '(ICI 204,636): results from phase II and III clinical trials. 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands. 1996. Hong 1996b Hong WW, Arvanitis LA. The atypical profile of '(ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands. 1996. Hopkin 1954 Hopkin DA. Action of chlorpromazine and promethazine. British Medical Journal 1954;1:1036. Links Horenstein 1957 Horenstein. Resperpine and chlorpromazine in hyperactive mental defectives. American Journal of Mental Deficiency 1957:525-29. Links Hrushka 1966 Hrushka M, Bruck M, Hsu J J. Therapeutic effects of different modes of chlorpromazine administration. Diseases of the Nervous System 1966;27:522-7. Links Huang 1967 Huang CL, Hirano K. The effect of antipyretic analgesics on the metabolism of chlorpromazine in man. Biochemical Pharmacology 1967;16:2023-6. Links Hughes 1967 Hughes JS, Little JC. An appraisal of the continuing practice of prescribing tranquillizing drugs for long-stay psychiatric patients. British Journal of Psychiatry 1967;113:867-73. Links Hurst 1960 Hurst L. Chlorpromazine and Pecazine in chronic schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1960;106:726-31. Links Hurst 1996 Hurst BC, Link C. A comparison of the tolerance profile of seroquel with typical neuroleptics and placebo. Xth World Congress of Psychiatry. Madrid, Spain. Madrid, Spain: August 23-28, 1996. Hussar 1969 Hussar AE, Bragg DG. The effect of chlorpromazine on the swallowing function in chronic schizophrenic patients. American Journal of Psychiatry 1969;126:570-3. Links Itil 1968 Itil T, Shapiro D, Fink M. Differentiation of psychotropic drugs by quantitative EEG analysis. Agressologie 1968;9:267-80. Links Itil 1971 Itil TM, Ulett GA, Fukuda T. Quantitative pharmaco-electroencephalography in early evaluation of psychotropic drugs. Folia Psychiatrica et Neurologica Japonica 1971;25:195-202. Links Johnstone 1978 Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978;1(8069):848-51. [MedLine: 78155245]. Links Jones 1969 Jones IH. Drugs and motor activity in chronic schizophrenia. British Journal of Psychiatry 1969;115:851-6. Links Jones 1971 Jones IH, Pikler N. Effects of chlorpromazine and trifluoperazine on the activity of chronic schizophrenics. British Journal of Psychiatry 1971;119:545-6. Links Joseph 1979 Joseph MH, Baker HF, Johnstone EC, Crow TJ. 3-Methoxy-4-hydroxyphenylglycol excretion in acutely schizophrenic patients during a controlled clinical trial of the isomers of flupenthixol. Psychopharmacology 1979;64(1):35-40. [MedLine: 80013695]. Links Joshi 1980 Joshi VG, Nagesh R, Eswaran S, Nagesh R, Pai M, Mathews G, Mallick PN. Vitamins B1, B6, and B12 in the adjunctive treatment of schizophrenia - further studies to examine the effect of reduction of chlorpromazine dosage. Journal of Orthomolecular Psychiatry 1980;11:45-9. Links Kabes 1982 Kabes J, Sikora J, Pisvejc J, Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. International Pharmacopsychiatry 1982;17(3):185-92. [MedLine: 83056096]. Links Kammerer 1968 Kammerer M, Wartel R, Gurfein L, Weil J, Wysoki V, Gelb F. Clinical experimentation with desipramine with statistical control [Experimentation clinique de la desipramine avec controle statistique]. Annales Medico-psychologiques 1968;1:109-13. Links Kaplan 1974 Kaplan J, Dawson S, Vaughan T, Green R, Wyatt RJ. Effect of prolonged chlorpromazine administration on the sleep of chronic schizophrenics. Archives of General Psychiatry 1974;31:62-6. Links Keskiner 1970 Keskiner A, Itil TM, Todt N. A comparative study of butaperazine, chlorpromazine and placebo in chronic schizophrenics. Psychosomatics 1970;11:120-6. Links Kim 1960 Kim K. Responses to treatment-refractory chronic schizophrenics to chlorpromazine with concurrent adrenocortical steroid. American Journal of Psychiatry 1960;116:1023-4. Links Kimbell 1971 Kimbell I Jr, Winkelman GW, Hughes WM. Comparison of thioridazine and chlorpromazine in doctor's choice research design. Clinical Pharmacology and Therapeutics 1971;12:825-32. Links King 1959 King PD, Weinberger W. Comparison of proclorperazine and chlorpromazine in hospitalized chronic schizophrenics. American Journal of Psychiatry 1959;115:1026-7. [MedLine: 69202908]. Links King 1994 King DJ. Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatrica Scandinavica Supplementum 1994;89(380):53-8. Links Kinross-Wright 1954 Kinross-Wright V. Chlorpromazine - a major advance in psychiatric treatment. Postgraduate Medicine 1954:297-300. Links Klein 1974 Klein RH, Lynn EJ, Axelrod H, Dluhy J. Self-administration of medication by psychiatric inpatients. Journal of Nervous and Mental Disease 1974;158:450-5. Links Kopell 1968 Kopell BS, Wittner WK. The effects of chlorpromazine and methamphetamine on visual signal-from-noise detection. Journal of Nervous and Mental Disease 1968;147:418-24. Links Kordas 1968 Kordas S, Kazamias N, Georgas J, Papadokostakis J. Clopenthixol: a controlled trial in chronic hospitalised schizophrenic patients. British Journal of Psychiatry 1968;114:833-6. Links Kornetsky 1957 Kornetsky C, Humphries O. Relationship between effects of a number of centrally acting drugs and personality. Archives of Neurology and Psychiatry 1957;77:325-7. Links Kornetsky C, Humphries O, Evarts EV. Comparison of psychological effects of certain centrally acting drugs in man. Archives of Neurology and Psychiatry 1957;77:318-24. Links Primac DW, Mirsky AF, Rosvold HE. Effects of centrally acting drugs on two tests of brain damage. Archives of Neurology and Psychiatry 1957;77:328-32. Links Kornetsky 1958 Kornetsky C, Humphries O. Psychological effects of centrally acting drugs in man. Journal of Mental Science 1958;104:1093-9. Links Mirsky AF, Primac DW, Bates R. The effects of chlorpromazine and secobarbital on the C.P.T. Journal of Nervous and Mental Diseases 1959;128:12-7. Links Kornetsky 1959 Kornetsky C, Pettit M, Wynne R, Evarts EV. A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenic patients. Journal of Mental Science 1959;105:190-8. Links Korol 1965 Korol B, Lang WJ, Brown ML, Gershon S. Effects of chronic chlorpromazine administration on systemic arterial pressure in schizophrenic patients: relationship of body position to blood pressure. Clinical Pharmacology and Therapeutics 1965;6:587-91. Links Kovitz 1955 Kovitz B, Carter JT, Addison WP. A comparison of chlorpromazine and reserpine in chronic psychosis. Archives of Neurology and Psychiatry 1955;74:467-71. Links Kramer 1975 Kramer M, Roth T, Goldstein S, Ryan MS, Blackwell B. A double-blind evaluation of metiapine in hospitalized acute schizophrenics. Current Therapeutic Research 1975;18:839-48. Links Kugler 1980 Kugler BT, Gruzelier JH. The influence of chlorpromazine and amylobarbitone on the recovery limb of the electrodermal response. Psychiatry Research 1980;2:75-84. Links Kupfer 1971 Kupfer DJ, Wyatt RJ, Synder F, Davis JM. Chlorpromazine and sleep in psychiatric patients. Archives of General Psychiatry 1971;24:185-9. Links Kurland 1981 Kurland AA, Nagaraju A. Viloxazine and the depressed schizophrenic - methodological issues. Journal of Clinical Pharmacology 1981;21(1):37-41. [MedLine: 81168674]. Links Lampe 1969 Lampe WT. A double blind study of clomacran. Current Therapeutic Research 1969;11:300-6. Links Latz 1965 Latz A, Kornetsky C. The effects of chlorpromazine and secobarbital under two conditions of reinforcement on the performance of chronic schizophrenic subjects. Psychopharmacologia 1965;7:77-88. Links Laurian 1981 Laurian S, Le PK, Baumann P, Perey M, Gaillard JM. Relationship between plasma-levels of chlorpromazine and effects on EEG and evoked potentials in healthy volunteers. Pharmacopsychiatria 1981;14:199-204. Links Leff 1971 Leff JP. Influence of selection of patients on results of clinical trials. British Medical Journal 1973;4:156-8. Links Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. British Medical Journal 1971;3:599-604. Links Leszek 1991 Leszek J, Inglot AD, Cantell K, Wasik A. Natural human leukocyte interferon in the treatment of schizophrenia. European Journal of Psychiatry 1991;5(1):55-63. Links Levin 1959 Levin ML. A comparison of the effects of phenobarbital, promethazine, chlorpromazine, and placebo upon mental hospital patients. Journal of Consulting Psychology 1959;23:167-70. Links Levine 1997 Levine J, Caspi N, Laufer N. Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients. Schizophrenia Research 1997;26(1):55-63. [MedLine: 98017426]. Links Levita 1961 Levita E. Effects of chlorpromazine and promazine on perseveration. Journal of General Psychology 1961;65:181-7. Links Lewis 1973 Lewis PJ, James NM. Haloperidol and chlorpromazine - a double-blind cross-over trial and clinical study in children and adolescents. Australian and New Zealand Journal of Psychiatry 1973;7:59-65. Links Liberman 1973 Liberman RP, Davis J, Moon W, Moore J. Research design for analyzing drug-environment-behavior interactions. Journal of Nervous and Mental Diseases 1973;156:432-9. Links Little 1958 Little JC. A double-blind controlled comparison of the effects of Chlorpromazine, Barbiturate and a placebo in 142 chronic psychotic in-patients. British Journal of Psychiatry 1958;4:334-49. Links Loranger 1968 Loranger AW. Treatment of acute mental disorders with an adrenal steroid. British Journal of Psychiatry 1968;114:843-4. Links Lorr 1961 Lorr M, McNair DM, Weinstein GJ, Michaux WW, Raskin A. Meprobamate and chlorpromazine in psychotherapy. Some effects on anxiety and hostility of outpatients. Archives of General Psychiatry 1961;4:381-9. Links Lyberi 1956 Lyberi G, S L Last. The Use of Chlorpromazine As An Activating Agent. Electroencephalography and Clinical Neurophysiology 1956:711-12. Links Maculans 1964 Maculans GA. Comparison of diazepam, chlorprothixine and chlorpromazine in chronic schizophrenic patients. Diseases of the Nervous System 1964;25:164-8. Links Mahal 1976 Mahal AS, Ramu NG, Chaturvedi DD. Double blind controlled study of brahmyadiyoga and tagara in the management of various types of unmada (schizophrenia). Indian Journal of Psychiatry 1976;18(4):283-92. Links Majewski 1968 Majewski J, Stempurska K. Results of treatment of schizophrenic psychoses with neuroleptics combined with subcomatic insulin [Wyniki leczenia psychoz schizofrenicznych neuroleptykami skojarzonymi z insulina podspiaczkowa]. Psychiatria Polska 1968;2(1):37-42. [MedLine: 68366839]. Links Marjerrison 1969 Marjerrison G, Keogh RP. Integrated EEG variability - drug effects in acute schizophrenics. Canadian Psychiatric Association Journal 1969;14:403-5. Links Marrazzi 1972 Marrazzi AS, Woodruff S, Kennedy D. Perceptual challenge to measure illness and therapy. American Journal of Psychiatry 1972;128:886-90. Links Mason-Browne 1957 Mason-Browne NL. Perphenazine - a drug modifying consciousness. American Journal of Psychiatry 1957;114:173-4. Links Mason-Browne NL, Borthwick JW. Effect of perphenazine (Trilafon) on modification of crude consciousness. Diseases of the Nervous System 1957;18:300-6. Links Mathur 1981 Mathur S, Hall JN. Phenothiazine withdrawal in schizophrenics in a hostel (letter). British Journal of Psychiatry 1981;138:271-2. Links Mattila 1994 Mattila MJ, Vanakoski J, Mattila Evenden ME, Karonen SL. Suriclone enhances the actions of chlorpromazine on human psychomotor performance but not on memory or plasma prolactin in healthy subjects. European Journal of Clinical Pharmacology 1994;46:215-20. Links McClelland 1990 McClelland GR, Cooper SM, Pilgrim AJ. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. British Journal of Clinical Pharmacology 1990;30:795-803. Links Melnyk 1966 Melnyk WT, Worthington AG, Laverty SG. Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic in-patients. Canadian Psychiatric Association Journal 1966;11(5):410-3. Links Merry 1957 Merry J, Pargiter MB, Munro H. Chlorpromazine and chronic neurotic tension. American Journal of Psychiatry 1957;113:988-90. Links Michaux 1966 Kurland AA, Bethon GD, Michaux MH, Agallianos DD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings. Journal of New Drugs 1966;6:80-95. Links Michaux MH, Kurland AA, Agallianos DD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. Current Therapeutic Research, Clinical and Experimental 1966;8(supplement):117-52. Links Millar 1963 Millar J. A trial of fluphenazine in schizophrenia. British Journal of Psychiatry 1963;109:428-32. [MedLine: 74100099]. Links Milne 1960 Milne H, Fowler DB. A clinical trial of Largactil (chlorpromazine), Stemeticl (prochlorperazine) and Veractil (methotrimeprazine). British Journal of Psychiatry 1960;106:1105-10. Links Milton 1978 Milton F, Patwa VK, Hafner RJ. Confrontation versus belief modification in persistently deluded patients. British Journal of Medical Psychology 1978;51:127-30. Links Mitchell 1956 Mitchell P. Chlorpromazine in the treatment of the chronic disturbed schizophrenic patient. British Journal of Psychiatry 1956;102:151-4. Links Mitchell 1960 Mitchell LE, Zax M. Psychological response to chlorpromazine in a group of psychiatric patients. Journal of Clinical Psychology 1960;16:440-2. Links Monteleone 1999 Monteleone P, Tortorella A, Borriello R, Cassandro P, Maj M. Prolactin hyperresponsiveness to D fenfluramine in drug free schizophrenic patients: a placebo controlled study. Biological Psychiatry 1999;45(12):1606-11. [MedLine: 99304410]. Links Morgenstern 1960 Morgenstern FV, Funk IC, Holt WL. Comparative short-term evaluation of triflupromazine hydrochloride, chlorpromazine hyrochloride, and placebo in acutely disturbed patients. New York State Journal of medicine 1960;60:254-8. Links Morton 1968 Morton MR. A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry 1968;124:1585-8. Links Moss 1958 Moss CS, Jensen RE, Morrow W, Freund HG. Specific behavioural changes produced by chlorpromazine in chronic schizophrenia. American Journal of Psychiatry 1958;115:449-51. Links Neal 1969 Neal CD, Collis MP, Imlah NW. A comparative trial of oxypertine and chlorpromazine in chronic schizophrenia. Current Therapeutic Research - Clinical and Experimental 1969;11:367-78. Links Newbold 1956 Newbold, Steed. The Use of Chlorpromazine in Psychotherapy. Journal of Nervous and Mental Diseases 1956. Links Okuma 1979 Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe S. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology Berlin 1981;73:95-6. Links Orzack 1969 Orzack MH, Taylor CL, Kornetsky C. A comparison of the behavioral effects of periodic administration of chlorpromazine and a &amp;quot;sustained-release&amp;quot; form of chlorpromazine. Clinical Pharamacology and Therapeutics 1969;10(2):258-64. [MedLine: 69143232]. Links Osmakova 1972 Os'makova EI. Use of psychological methods for studying the particular psychotropic action of various psychopharmacologic drugs [Primenenie psikhologicheskikh metodik dlia issledovaniia sobstvenno psikhotropnogo deistviia nekotorykh psikhofarmakologic heskikh sredtsv]. Zhurnal Nevropatologii i Psikhiatrii 1972;72:1705-8. Links Rojo-Sierra M, Alonso J, D&amp;#237;ez E, Giner J, Lloret E. [Aportaci&amp;#243;n sobre el espectro psicofarmacoter&amp;#225;pico del R P. 19 366 y R P. 19 552]. 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Ciudad de Mexico, Mexico. 1971. Pai 2001 Pai Y-M, Yu S-C, Lin C-C. Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study. Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA. Marathon Multimedia, 2001. Paredes 1966 Paredes A, Baumgold J, Pugh LA, Ragland R. Clinical judgment in the assessment of psychopharmacological effects. Journal of Nervous and Mental Disease 1966;142(2):153-60. Links Park 1981 Park S, Hardesty AS, Garcia E. Effects of triiodothyronine and chlorpromazine combination treatment in schizophrenia. Current Therapeutic Research - Clinical and Experimental 1981;29:929-35. Links Pasamanick 1967 Pasamanick B, Scarpitti FR, Dinitz S. Schizophrenics in the community: an experimental study in the prevention of hospitalization. New York: Appleton-Century-Crofts, 1967. Patterson 1981 Patterson T, Venables PH. Bilateral skin conductance and the pupillary light dark reflex - manipulation by chlorpromazine, haloperidol, scopolamine, and placebo. Psychopharmacology 1981;73:63-9. Links Peet 1980 Peet M, Middlemiss DN, Yates RA. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients [letter]. Lancet 1980;2:978. Links Pennington 1957 Pennington V. A two-year comparative study of ataraxics in neuropsychiatric patients. Journal of the American Geriatric Association 1957;5:42-9. Links Pietzcker 1978 Pietzcker A. Long-term medication in schizophrenia [Langzeitmedikation bei schizophrenen Kranken]. Nervenarzt 1978;49:518-33. Links Pigache 1973 Pigache RM. The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine. Schizophrenia Research 1993;10:39-50. Links Pigache RM, Norris HN. Measurement of drug action in schizophrenia. Clinical Science 1973;44:28P. Links Pigache 1993 Pigache RM. Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two-year longitudinal study. Schizophrenia Research 1993;10:51-9. Links Platz 1967 Platz AR, Klett CJ, Caffey EMJ. Selective drug action related to chronic schizophrenic subtype. (A comparative study of carphenazine, chlorpromazine, and trifluoperazine). Diseases of the Nervous System 1967;28:601-5. Links Pleasure 1956 Pleasure H. Chlorpromazine (Thorazine) for mental illness in the presence of pulmonary tuberculosis. Psychiatry Quarterly 1956;30:23-30. Links Pollack 1956 Pollack, B. The effect of chlorpromazine on the return rate of 250 patients released from the Rochester State Hospital. American Journal of Psychiatry 1956;112:937. Links Pollard 1959 Pollard JC. Combined Effects of Chlorpromazine and Meprobamate in Chronically Disturbed Psychotic Patients. Diseases of the Nervous System 1959;20:427-9. Links Quigley 1996 Quigley N, Morgan D, Idzikowski C, King DJ. The effect of chlorpromazine and benzhexol on memory and psychomotor function in healthy volunteers. Journal of Psychopharmacology 1996;10:146-52. Links Quinn 1960 Quinn PJG, Johnston J, Latner G, Kiloh LG. A comparative controlled trial of methotrimeprazine ('veractil') in chronic schizophrenia. British Journal of Psychiatry 1960;106:161-70. Links Raaska 2000 Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. European Journal of Clinical Pharmacology 2000;56(8):585-9. [MedLine: 21026257]. Links Ragland 1968 Ragland R, Clark ML, Ray TS, Paredes A, Costiloe JP, Segal B, Wolf S. The evaluation of chlorpromazine therapy in chronic schizophrenic women. A replicated experiment. Journal of Chronic Diseases 1968;21:445-60. Links Raja 2000 Raja M, Azzoni A. Second generation antipsychotics in the emergency care setting. A prospective naturalistic study. General Hospital Psychiatry 2000;22(2):107-14. [MedLine: 20283566]. Links Rappaport 1967 Rappaport M. Competing voice messages. Effects of message load and drugs on the ability of acute schizophrenics to attend. Archives of General Psychiatry 1967;17:97-103. Links Rappaport 1968 Rappaport M. Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background. Journal of Nervous and Mental Disease 1968;146:404-11. Links Rathod 1958 Rathod N, Rees L. A controlled study of the prognostic significance of autonomic responses in the chlorpromazine treatment of disturbed psychotic patients. British Journal of Psychiatry 1958;104:705-12. Links Raymond 1957 Raymond MJ, Lucas CJ, Beesley ML, O'Connell BA, Fraser Roberts JA. A trial of five tranquillizing drugs in psychoneurosis. British Medical Journal 1957;2:63-6. Links Remr 1970 Remr J. The effects of chlorpromazine on fine psychomotor performance with a simultaneous secondary task in schizophrenics. Activitas Nervosa Superior 1971;13:179. Links Remr J. The effects of chlorpromazine on some components of psychomotor performance in schizophrenics. Activitas Nervosa Superior 1970;12:253-4. Links Rifkin 1978 Rifkin A, Quitkin F, Kane J, Struve F, Klein DF. Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. Archives of General Psychiatry 1978;35(4):483-9. [MedLine: 79081577]. Links Rinaldi 1956 Rinaldi F, Rudy L, Himwich HE. Clinical evaluation of azacyclonol, chlorpromazine, and reserpine on a group of chronic psychotic patients. American Journal of Psychiatry 1956;112:678-83. Links Rivera-Calimlim 1973 Rivera Calimlim L, Castaneda L, Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clinical Pharmacology and Therapeutics 1973;14:978-86. Links Rosen 1972 Rosen B, Engelhardt DM, Freedman N, Margolis R, Rudorfer L, Paley HM. Prediction of psychiatric hospitalization. II. The Hospitalization Proneness Scale: a cross-validation. Journal of Nervous and Mental Disease 1972;80:271-4. Links Rosenheck 2000 Rosenheck R, Cramer J, Jurgis G, Perlick D, Xu W, Thomas J, Henderson W, Charney D. Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. Journal of Clinical Psychiatry 2000;61(9):671-6. Links Rosner 1955 Rosner H, Levine S, Hess H, Kaye H. A comparative study of the effect on anxiety of chlorpromazine, reserpine, phenobarbital, and a placebo. Journal of Nervous and Mental Diseases 1955;122:505-12. Links Rudy 1957 Rudy L, Himwich H, Tasher DC. Clinical evaluation of two phenothiazine compounds Promazine and Mepazine. American Journal of Psychiatry 1957;113:979-83. Links Rudy 1958 Rudy L, Rinaldi E, Himwich H, Tuteur W, Glotzer J. Trifluoperazine in the treatment of psychotic patients. American Journal of Psychiatry 1958;115:364-5. Links Sainz 1955 Sainz A. Chlorpromazine in psychiatric disorders. Prescriber 1955;2(2):14. [MedLine: 20283566]. Links Saletu 1972 Saletu B, Saletu M, Itil T. Effect of minor and major tranquilizers on somatosensory evoked potentials. Psychopharmacologia 1972;24:347-58. Links Salisbury 1957 Salisbury BJ, Hare EH. Ritalin and Chlorpromazine in chronic schizophrenia: a controlled clinical trial. British Journal of Psychiatry 1957;103:830-4. Links Schiele 1959 Schiele BC, Mendelsohn RM, Penman AS, Schofield W. Comparison of low and high dosage procedures in chlorpromazine therapy. Psychiatric Quarterly 1959;33:252-9. Links Schmidt 1957 Schmidt KE. Combined treatment with chlorpromazine and reserpine: an attempt at quantitative assessments in chronic schizophrenic patients. British Journal of Psychiatry 1957;103:200-8. Links Schooler 1976 Sakalis G, Chan TL, Sathananthan G, Schooler N, Goldberg S, Gershon S. Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. Communucations in Psychopharmacology 1977;1:157-66. Links Schooler NR, Sakalis G, Chan TL. Chlorpromazine metabolism and clinical response in acute schizophrenia - a preliminary report. Psychopharmacology Bulletin 1975;11:30-3. Links Schooler NR, Sakalis G, Chan TL, Gershon S, Goldberg SC, Collins P. Chlorpromazine metabolism and clinical response in acute schizophrenia - a preliminary report. Pharmacokinetics of psychoactive drugs. 1976:199-219. Seager 1955 Seager CP. Chlorpromazine in treatment of elderly psychotic women. British Medical Journal 1955;1:882-5. Links Serafetinides 1973 Serafetinides EA. Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry 1973;8:214-6. Links Shaskan 1975 Becker RE, Shaskan EG. Platelet monoamine oxidase activity in schizophrenic patients. American Journal of Psychiatry 1977;134:512-7. Links Shaskan EG, Becker RE. Blood platelet monoamine oxidase activity in anergic schizophrenics. National Institute of Drug Abuse Research Monograph Services 1975:29-35. Links Shaskan EG, Becker RE. Platelet monoamine oxidase in schizophrenics. Nature 1975;253:659-60. Links Shawver 1959 Shawver JR, Gorham DR, Leskin LW, Good WW, Kabnick DE. Comparison of chlorpromazine and reserpine in maintenance drug therapy. Diseases of the Nervous System 1959;20:452-7. Links Shopsin 1978 Shopsin B, Klein H, Aronson M. Clozapine: double-blind control trial in the treatment of acute schizophrenia. Psychopharmacology Bulletin 1978;14:12-4. Links Shopsin 1979 Honigfeld G, Patin J, Singer J. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Advances in Therapy 1984;1:77-97. Links Shopsin B, Klein H, Aaronson M, Collora M. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients. Archives of General Psychiatry 1979;36:657-64. Links Silver 2000 Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. International Clinical Psychopharmacology 2000;15(5):257-61. [MedLine: 20445223]. Links Simopoulos 1971 Simopoulos AM, Pinto A, Uhlenhuth EH, Mcgee J. Old wine in new bottles: decreased hostility in chronic psychotic inpatients treated with diphenylhydantoin (Dilantin). 5th World Congress of Psychiatry. Ciudad de Mexico. Ciudad de Mexico: 1971:abstract 1077. Simpson 1974 Simpson GM, Varga E, Reiss M, Cooper TB, Bergner PE, Lee JH. Bioequivalency of generic and brand-named chlorpromazine. Clinical Pharmacology and Therapeutics 1974;15:631-41. Links Simpson 1980 Simpson GM, Cooper TB, Bark N, Sud I, Lee JH. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Archives of General Psychiatry 1980;37:205-8. Links Singh 1974 Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Diseases of the Nervous System 1976;37:191-6. Links Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Journal of the Bronx State Hospital 1974;2:173-83. Links Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benzotropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Psychopharmacologia 1975;43:103-13. Links Singh MM, Kay SR. Therapeutic reversal with benztropine in schizophrenics: practical and theoretical significance. Journal of Nervous and Mental Disease 1975;160:258-66. Links Singh 1990 Singh H, Hunt JI, Vitiello B, Simpson GM. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Journal of Clinical Psychiatry 1990;51:319-21. Links Small 1987 Small J, Milstein V, Small IF, Miller MJ, Kellams JJ, Corsaro CJ. Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia. Clinical Electroencephalography 1987;18:124-35. Links Smith 1958 Smith JA, Christian D, Rutherford A, Mansfield E. A comparison of triflupromazine (Vesprin), chlorpromazine and placebo in 85 chronic patients. American Journal of Psychiatry 1958;115:253-4. Links Smith 1960 Smith ME. A comparative controlled study with chlordiazepoxide. American Journal of Psychiatry 1960;117:362-3. Links Smith 1967 Smith K, Surphlis WRP, Gynther MD, Shimkunas AM. ECT-chlorpromazine and chlorpromazine compared in the treatment of schizophrenia. Journal of Nervous and Mental Disease 1967;144:284-90. Links Sommerness 1957 Sommerness MD, Lucero RJ, Hamlon JS, Mahowald AM. Chlorpromazine: a controlled study with highly disturbed patients. Diseases of the Nervous System 1957;18:16-20. Links South-East 1961 South-East Region (Scotland) Therapeutic Trials Committee. Controlled trial of Prochlorperazine (Stemetil) in schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1961;107:514-22. [MedLine: 87204515]. Links Soyka 1968 * Soyka D. The effect of psychopharmacological drugs and other central nervous system effecting drugs on experimental nystagmus [Die Wirkung von Psychopharmaka und anderen zentral wirksamen substanzen auf den experimentellen Nystagmus]. Fortschritte Der Neurologie, Psychiatrie Und Ihrer Grenzgebiete 1968;36:526-39. Links Spiegel 1967 Spiegel DE, Keith-Spiegel P. The effects of carphenazine, trifluoperazine and chlorpromazine on ward behavior, physiological functioning and psychological test scores in chronic schizophrenic patients. Journal of Nervous and Mental Diseases 1967;144:111-6. Links Spohn 1974 Spohn HE, Lacoursiere RB, Williams RO. The effect of chlorpromazine on visual information processing in normal subjects. Journal of Nervous and Mental Disease 1974;159:198-204. Links Sugerman 1964 Pfeiffer CC, Goldstein L, Murphree HB, Sugerman AA. Time-series frequency analysis, and electrogenesis of the EEGs of normals and psychotics before and after drugs. American Journal of Psychiatry 1965;122:1147-55. Links Sugerman AA, Goldstein L, Murphree HB, Pfieffer CC, Jenney EH. EEG and behavioural changes in schizophrenia. Archives of General Psychiatry 1964;10:340-4. Links Syvalahti 1997 Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, Dahl ML, Salokangas RK. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. Journal of International Medical Research 1997;25(1):24-32. [MedLine: 97179384]. Links Talbot 1964 Talbot DR. Are tranquilizer combinations more effective than a single tranquilizer?. American Journal of Psychiatry 1964;121:597-600. Links Tassis 1959 Tassis JA. Full Coma Insulin therapy, Chlorpromazine and Electoconvulsive Treatment. A control study of 600 Schizophrenic patients. Medical journal of Malaya 1959;14:135-43. Links Teja 1975 Teja JS, Grey WH, Clum JM, Warren C. Tranquilizers or anti-depressants for chronic schizophrenics: a long-term study. Australian and New Zealand Journal of Psychiatry 1975;9:241-7. Links Tenenblatt 1956 Tenenblatt SS, Spagno A. A controlled study of chlorpromazine therapy in chronic psychotic patients. Journal of Clinical &amp;amp; Experimental Psychopathology 1956;17:81-92. Links Terminska 1989 Terminska K, Mrowiec W. [Badanie porownawcze wplywu perazyny, flufenazyny, trifluoroperazyny, chloropromazny i haloperydolu na objawy pierwotne i deficytowe pierwszego zachorowania na schizofrenie paranoidalna]. Psychiatria Polska 1989;23:24-30. Links Tetreault 1969 Tetreault L, Bordeleau JM, Albert JM, Rajotte P. Comparative study of fluphenazine ethanate, fluphenazine bichlorhydrate and placebos in chronic schizophrenics [Etude comparative de l'enanthate de fluphenazine, du bichlorhydrate de fluphenazine et du placebo chez le schizophrene chronique]. Canadian Psychiatric Association Journal 1969;14(2):191-8. [MedLine: 69202908]. Links Thorpe 1956 Thorpe J, Baker A. A research method to assess a new tranquillizing drug. British Journal of Psychiatry 1956;102:790-5. Links Tourlentes 1958 Tourlentes T L, Hunsicker A L, Hurd D E. Chlorpromazine and Communication Processes. A.M.A. Archives of Neurology and Psychiatry 1958;79:468-73. Links Troshinsky 1962 Troshinsky CH, Aaronson HG, Stone RK. Maintenance phenothiazines in aftercare of schizophrenic patients. Pennsylvania Psychiatric Bulletin 1962;2:11-5. Links Turner 1956 Turner M, Berard, E, Turner N, Franco N. Changes in the Electroencephalogram, the Electrodermogram, and the Electromyogram Provoked by Chlorpromazine in Man. Abstracts of World Medicine 1956;20:177. Links Turner 1966 Turner P. A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency. Journal of Pharmacy and Pharmacology 1966;18:836. Links Urquhart 1959 Urquhart R, Forrest AD. Clinical trial of promazine hydrochloride and acetylpromazine in chronic schizophrenic patients. British Journal of Psychiatry 1959;105:260-4. Links Van Praag 1975 van Praag HM, Dols LC, Schut T. Biochemical versus psychopathological action profile of neuroleptics. A comparative study of chlorpromazine and oxypertine in acute psychotic disorders. Comprehensive Psychiatry 1975;16:255-63. Links van Praag HM, Korf J. The dopamine hypothesis of schizophrenia. Some direct observations. In: van Praag HM editor(s). On the origin of schizophrenic psychoses. Amsterdam: De Erven Bohn BV, 1975:81-98. Vestre 1961 Vestre ND. An experimental study of the effects of chlorpromazine on association learning in schizophrenic patients. Dissertation Abstracts 1961:2374. Vinar 1973 Vinar O. Whom do neuroleptic drugs help?. Psychopharmacology, Sexual Disorders and Drug Abuse. Amsterdam, Netherlands: North-Holland, 1973:247-56. Volavka 1983 Volavka J, Hui KS, Anderson B, Nemes Z, O'Donnell J, Lajtha A. Short-lived effect of (des-tyr)-gamma-endorphin in schizophrenia. Psychiatry Research 1983;10:243-52. Links Warner 1996 Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatrica Scandinavica 1996;93:311-3. Links Weir 1968 Weir TW, Kernohan GA, MacKay DN. The use of pericyazine and chlorpromazine with disturbed mentally subnormal patients. British Journal of Psychiatry 1968;114:111-2. Links Welbel 1980 Welbel L. [Roznice w dziallaniu klinicznym niektorych neuroleptykow]. Psychiatria Polska 1980;14:113-8. Links Whitehead 1958 Whitehead WA, Thune LE. The effects of chlorpromazine on learning in chronic psychotics. Journal of Consulting Psychology 1958;22:379-83. Links Wilcott 1962 Wilcott RC, Helper MM, Garfield SL. Some Psychophysiological Effects of Chlorpromazine on Emotionally Disturbed Children. Journal of Nervous and Mental Diseases 1962;135:233-8. Links Wilson 1961 Wilson IC, McKay J, Sandifer MG. A double-blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia. British Journal of Psychiatry 1961;107:90-9. Links Winkelman 1957 Winkelman N W. An Appraisal of Chlorpromazine. General Principles for Administration of Chlorpromazine, Based on Experience with 1,090 Patients. American Journal of Psychiatry 1957. Links Winter 1956 Winter WD, Frederickson WK. The short-term effects of chlorpromazine on psychiatric patients. Journal of Consulting Psychology 1956;20:431-4. Links Wode-Helgodt 1977 Wode-Helgodt B, Eneroth P, Fyro B, Gullberg B, Sedvall G. Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatrica Scandinavica 1977;56:280-93. Links Wold 1959 Wold PN. A long term evaluation of chlorpromazine in six chronic schizophrenic patients. American Journal of Psychiatry 1959;116:461-2. Links Wolpert 1969 Wolpert A, Yaryura TJA, White L, Merlis S. Triiodothyronine and phenothiazines in schizophrenia. Diseases of the Nervous System 1969;30(7):487-9. [MedLine: 69288496]. Links Wyatt 1997 Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychological Medicine 1997;27:261-8. Links Yorkston 1977 Yorkston NJ, Zaki SA, Pitcher DR, Gruzelier JH, Hollander D, Sergeant HG. Propranolol as an adjunct to the treatment of schizophrenia. Lancet 1977;2:575-8. Links Yuan-guang 1994 Yuan-Guang C, Guang-rong X, Jing Ping Z. A study on the relationship between the chlorprmazine plasma levels and clinical response to chlorpromazine administrations in the schizophrenics. Chinese Journal of Neurology and Psychiatry 1994;27(3):153-5. Links Zeller 1956 Zeller WW, Graffagnino PN, Cullen CF, Rietman HJ. Use of chlorpromazine and reserpine in the treatment of emotional disorders. Journal of the American Medical Association 1956;160:179-84. Links References to studies awaiting assessment Magner 1974 Magner O, Moller S. The blood pressure lowering effect of chlorpromazine and methylperon (Buronil) [Blodtryksnedsaettende effekt af kllrpromazin og metylperon (Buronil)]. Ugeskrift for Laeger 1974;136:809-11. Links Rojo-Sierra 1971 Rojo-Sierra M, Alonso J, D&amp;#237;ez E, Giner J, Lloret E. [Aportaci&amp;#243;n sobre el espectro psicofarmacoter&amp;#225;pico del R P. 19 366 y R P. 19 552]. 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Ciudad de Mexico, Mexico. 1971:495-6. Vinar 1976 Vinar O, Taussigova D. Schizophrenic syndromes improving without neuroleptic drug treatment [Schizofrenni syndromy zlepsujici se bez neurolepticke lecby]. Ceskoslovenska Psychiatrie 1976;72(3):176-81. [MedLine: 77001715]. Links Yagi 1976 Yagi G. A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Rinsho Hyoka (Clinical Evaluation) 1976;4(3):351-403. Links Additional references Ahmed 1998 Ahmed I, Soares K, Seifas R, Adams CE. Randomised controlled trials in Archives of General Psychiatry (1959-1995): a prevalence study. Archives of General Psychiatry 1998;55(8):754-5. References to studies included in this review Abrams 1958 {published data only} Abrams J. Chlorpromazine in the treatment of chronic schizophrenia. Diseases of the Nervous System 1958;19:20-8. Links Baker 1959 {published data only} Baker JP. A controlled trial of ethylcrotonylurea. British Journal of Psychiatry 1959;105:852-62. Links Ban 1975 {published data only} Ban TA, Lehmann HE, Sterlin C, Climan M. Comprehensive clinical studies with thiothixene. Diseases of the Nervous System 1975;36:473-7. Links Bishop 1963 {published data only} Bishop M, Gallant DM. Behavioral toxicity associated with benzquinamide (Quantril) therapy in schizophrenic patients. American Journal of Psychiatry 1963;120:180-1. Links Borison 1991 {published data only} Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin 1991;27:103-6. Links Borison RL, Dren AT, Diamond BI. Sigma receptor antagonism and antipsychotic actions in schizophrenic patients. European Journal of Pharmacology 1990;183:2323. Links Chouinard 1990 {published data only} Chouinard G. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatria Scandinavica Supplementum 1990;358:111-9. Links Clark 1961 {published data only} Clark ML, Ray T, Paredes A, Costiloe J, Chappell J, Hagans J, Wolf S. Chlorpromazine in chronic schizophrenic women. I. Experimental design and effects at maximum point of treatment. Psychopharmacologia 1961;2:107-36. Links Clark ML, Ray TS, Ragland RE. Chlorpromazine in chronic schizophrenic women: rate of onset and rate of dissipation of drug effects. Psychosomatic Medicine 1963;25:212-17. Links Ray TS, Ragland RE, Clark ML. Chlorpromazine in chronic schizophrenic women: comparison of differential effects on various psychological modalities during and after treatment. Journal of Nervous and Mental Diseases 1964;138:348-53. Links Clark 1967 {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, Wolf S. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosomatic Medicine 1967;29:634-42. Links Clark 1968a {published data only} Clark ML, Huber WK, Kyriakopoulos AA, Ray TS, Colmore JP, Ramsey HR. Evaluation of trifluperidol in chronic schizophrenia. Psychopharmacologia 1968;12:193-203. Links Clark 1968b {published data only} Clark ML, Ray TS, Huber WK, Willis D, Ramsey HR. Evaluation of butaperazine in chronic schizophrenia. Clinical Pharmacology and Therapeutics 1968;97:57-64. Links Clark 1970a {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. Clinical Pharmacology and Therapeutics 1970;11:680-8. Links Serafetinides EA, Willis D, Clark ML. The EEG effects of chemically and clinically dissimilar antipsychotics: molindone vs. chlorpromazine. International Pharmacopsychiatry 1971;6:77-82. Links Clark 1970b {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark M, Ramsey H, Rahhal D, Serafetinides E, Wood F, Costiloe J. Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships. Archives of General Psychiatry 1972;27:479-83. Links Clark ML, Ramsey HR, Ragland RE, Rahhal DK, Serafetinides EA, Costiloe JP. Chlorpromazine in chronic schizophrenia - behavioral dose-response relationships. Psychopharmacologia 1970;18:260-70. Links Serafetinides EA, Willis D, Clark ML. EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking. Biological Psychiatry 1972;4:251-6. Links Clark 1971 {published data only} Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP. Drug treatment in newly admitted schizophrenic patients. Archives of General Psychiatry 1971;25:404-9. Links Clark 1972 {published data only} Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972;33:783-91. Links Serafetinides EA, Willis D, Clark ML. The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects. International Pharmacopsychiatry 1971;6:38-44. Links Clark 1977 {published data only} Clark ML, Paredes A, Costiloe JP, Wood F. Evaluation of butaclamol in chronic schizophrenic patients. Journal of Clinical Pharmacology 1977;17:529-36. Links Cohen 1968 {published data only} Cohen M, Freedman N, Englehardt DM. Family interaction patterns, drug treatment, and change in social aggression. Archives of General Psychiatry 1968;19(1):50-6. Links Graupner OK, Kalman EV. Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments [Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)]. Psychopharmacologia 1972;27(4):343-7. [MedLine: 73085373]. Links Cole 1964 {published data only} * Cole JO, Goldberg SC, Klerman GL National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 1964;10:246-61. Links Goldberg S, Klerman G, Cole J. Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. British Journal of Psychiatry 1965;111:120-33. Links Goldberg SC, Mattsson NB. Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System 1968;29:153-8. Links Cooper 2000 {published and unpublished data} Cooper SJ, Butler A, Tweed J, Welch CP. Zotepine in the treatment of chronic schizophrenia. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria: September 13-17, 1997. Cooper SJ, Raniwalla J, Welch C. Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo. XXth Collegium Internationale Neuro-psychopharmacologicum. Melbourne, Australia. Melbourne, Australia: 1996. * Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C. A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica 2000;101(3):218-25. [MedLine: 20184895]. Links Cooper SJ, Tweed J, Raniwalla J, Welch C. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Unpublished manuscript 1996. Cooper SJ, Welch CP. A comparison of zotepine and chlorpromazine on BPRS subscores. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria: September 13-17, 1997. Dean 1958 {published data only} Dean EF, Buker S. Schizophrenia treated with and without chlorpromazine. Rocky Mountain Medical Journal 1958;55:47-50. Links Engelhardt 1960 {published data only} Engelhardt D, Freedman N, Rosen B, Mann D, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. Archives of General Psychiatry 1964;11:162-9. Links Engelhardt DM, Freedman N, Glick BS, Hankoff LD, Mann D, Margolis R. Prevention of psychiatric hospitalization with use of psychopharmacological agents. Journal of the American Medical Association 1960;173:147-9. Links Engelhardt DM, Margolis RA, Rudorfer L, Paley HM. Physician bias and the double-blind. Archives of General Psychiatry 1969;20(3):315-20. Links Engelhardt DM, Rosen B, Freedman N, Mann D, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure. Journal of the American Medical Association 1963;186:981-3. Links Engelhardt DM, Rosen B, Freedman N, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization - a reevaluation. Archives of General Psychiatry 1967;16:98-101. Links Freedman N, Cutler R, Engelhardt DM, Margolis R. On the modification of paranoid symptomatology. Journal of Nervous and Mental Disease 1967;144:29-36. Links Freedman N, Cutler R, Engelhardt DM, Margolis R. On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines. Journal of Nervous and Mental Disease 1970;150:68-76. Links Rosen B, Engelhardt DM, Freedman N. The hospitalization proneness scale as a predictor of response to phenothiazine treatment. Journal of Nervous and Mental Disease 1968;6:476-80. Links Fink 1963 {published data only} Belmont I, Pollack M, Willner A, Klein D, Fink M. The effects of imipramine and chlorpromazine on perceptual analytic ability, perceptual analytic responsivity and memory as revealed in rorschach responses. Journal of Nervous and Mental Disease 1963;137(1):42-50. Links * Fink M, Pollack M, Klein DF, Blumberg AG, Belmont I, Karp E, Kramer JC, Willner A. Comparative studies of chlorpromazine and imipramine. I. Drug discriminating patterns. Neuropsychopharmacology 1963;3:370-2. Links Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Archives of General Psychiatry 1967;16:118-26. Links Klein DF. Psychiatric diagnosis and a typology of clinical drug effects. Psychopharmacologia 1968;13:359-86. Links Klein DF, Honigfeld G, Feldman S. Prediction of drug effect by diagnostic decision tree. Diseases of the Nervous System 1968;29:159-87. Links Levenstein S, Klein DF, Pollack M. Follow up study of formerly hospitalized voluntary psychiatric patients: the first two years. American Journal of Psychiatry 1966;122:1102-8. Links Fleming 1959 {published data only} Fleming B, Spencer A, Whitelaw E. A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis. British Journal of Psychiatry 1959;105:349-58. Links Grygier 1958 {published data only} Grygier P, Waters MA. Chlorpromazine used with an intensive occupational therapy program. A.M.A. Archives of Neurology and Psychiatry 1958;79:697-705. Links Hall 1955 {published data only} Hall RA, Dunlap DJ. A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics. Journal of Nervous and Mental Disease 1955;122:301-14. Links Hollister LE, Hall RA. Phenothiazine derivatives and morphologic changes in the liver. American Journal of Psychiatry 1966;123:211-2. Links Hamill 1975 {published data only} Hamill WT, Fontana AF. The immediate effects of chlorpromazine in newly admitted schizophrenic patients. American Journal of Psychiatry 1975;132:1023-6. Links Hamilton 1960 {published data only} Hamilton M, Smith A, Lapidus HR, Cadogan EP. A controlled trial of Thiopropazate Dihydrochloride (Dartalan), Chlorpromazine and occupational therapy in chronic schizophrenics. British Journal of Psychiatry 1960;106:40-55. Links Hine 1958 {published data only} Hine FR. Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic. Journal of Nervous and Mental Diseases 1958;127:220-7. Links Hogarty 1973 {published data only} Goldberg S, Schooler N, Hogarty G, Roper M. Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry 1977;34:171-84. Links Hogarty G, Goldberg S. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Archives of General Psychiatry 1973;28:54-64. Links Hogarty G, Goldberg S, Schooler N. Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients. Archives of General Psychiatry 1974;31:609-18. Links Hogarty G, Goldberg S, Schooler N, Ulrich R. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Archives of General Psychiatry 1974;31:603-8. Links Hogarty G, Ulrich R. Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry 1977;34:297-301. Links Hogarty GE, Munetz MR. Pharmacogenic depression among outpatient schizophrenic patients - a failure to substantiate. Journal of Clinical Psychopharmacology 1984;4:17-24. Links Klein 1973 {published data only} Klein D, Rosen B. Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients. Archives of General Psychiatry 1973;29:480-5. Links Kurland 1961 {published data only} Kurland AA, Hanlon TE, Tatom MH, Ota KY, Simopoulos AL. The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness. Journal of Nervous and Mental Disease 1961;133:1-18. Links Kurland AA, Hanlon TE, Tatom MH, Simopoulos AL. Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations. Journal of Nervous and Mental Disease 1961;132:61-74. Links Kurland AA, Nilsson GL, Hanlon TE. Pre-admission drug treatment of state psychiatric hospital patients. American Journal of Psychiatry 1959;115:1028-9. Links Kurland AA, Sutherland GF. The phenothiazine tranquilizers - their neurological complications and significance. Psychosomatics 1960;1:192-4. Links Letemendia 1967 {published data only} Letemendia F, Harris AD. Chlorpromazine and the untreated chronic schizophrenic: a long-term trial. British Journal of Psychiatry 1967;113:950-8. Links Nishikawa 1982 {published data only} Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology 1982;77:301-4. Links Payne 1960 {published data only} Payne P. A Comparison of Trifluopromazine, Chlorpromazine and a Placebo in Twenty-one Chronic Schizophrenic Patients. Manitoba Medical Review 1960:196-8. Links Peet 1981 {published data only} Peet M, Bethell M, Coates A, Khamnee A, Hall P, Cooper S, King D, Yates R. Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo. British Journal of Psychiatry 1981;139:105-11. Links Prien 1968 {published data only} Crane GE. Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie 1968;2:209-18. Links De Long SL. Incidence and significance of chlorpromazine-induced eye changes. Diseases of the Nervous System 1968;29:19-22. Links Gardos G, Cole JO, LaBrie RA. A 12-year follow-up study of chronic schizophrenics. Hospital and Community Psychiatry 1982;33:983-4. Links Mandel A, Gross M. Agranulocyctosis and phenothiazines. Diseases of the Nervous System 1968:32-6. Links Prien R, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group. Archives of General Psychiatry 1968;18:482-95. Links Prien R, DeLong S, Cole J, Levine J. Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry 1970;23:464-8. Links Prien RF, Cole JO, Belkin NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry 1968;115:679-86. Links Prien RF, Levine J, Cole JO. Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System 1970;31:739-45. Links Rappaport 1978 {published data only} Rappaport M, Hopkins HK, Hall K, Belleza T, Silverman J. Are there schizophrenics for whom drugs may be unnecessary or contraindicated?. International Pharmacopsychiatry 1978;13:100-11. Links Reardon 1966 {published data only} Reardon JD, Abrams S. Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System 1966;27:265-70. Links Reschke 1974 {published data only} Reschke RW. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Diseases of the Nervous System 1974;35:112-5. Links Saretsky 1966 {published data only} Saretsky T. Effects of chlorpromazine on primary-process thought manifestations. Journal of Abnormal Psychology 1966;71:247-52. Links Schiele 1961 {published data only} Schiele BC, Vestre ND, Stein KE. A comparison of thioridazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients. Journal of Clinical and Experiemental Psychopathology 1961;22:151-62. Links Serafetinides 1972 {published data only} Serafetinides EA, Clark ML. Psychological effects of single dose antipsychotic medication. Biological Psychiatry 1973;7:263-7. Links Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Diseases 1972;154:31-42. Links Serafetinides EA, Willis D. A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry 1973;8:245-7. Links Serafetinides EA, Willis D, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Diseases 1972;155:366-9. Links Shepherd 1956 {published data only} Shepherd M, Watt DC. A controlled clinical study of chlorpromazine and reserpine. Journal of Neurology, Neurosurgery and Psychiatry 1956;19:232-5. Links Simon 1958 {published data only} Simon W, Wirt AL, Wirt RD, Halloran AV. Long-term follow-up study of schizophrenic patients. Archives of General Psychiatry 1965;12:510-5. Links Simon W, Wirt R, Wirt A, Halloran A, Hinckley R, Lund J, Hopkins GW. A controlled study of the short-term differential treatment of schizophrenia. American Journal of Psychiatry 1958;114:1077-86. Links Smith 1961 {published data only} Smith ME. A clinical study of chlorpromazine and chlordiazepoxide. Connecticut State Medical Journal 1961;25:153-7. Links Somerville 1960 {published data only} Somerville DM, Cohen PH, Graves GD. Phenothiazine side-effects. Comparison of two major tranquillizers. British Journal of Psychiatry 1960;106:1417-24. Links Spohn 1977 {published data only} Spohn H, Lacoursiere R, Thompson K, Coyne L. Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Archives of General Psychiatry 1977;34(6):633-44. Links Tetreault 1969a {published data only} Tetreault L. Comparative study of two drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques 1969;22:221-8. Links Tetreault L, Bordeleau JM, Gauthier R, Vulpe M, Lapointe L. Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients. Diseases of the Nervous System 1969;30(2):74-84. Links Vaughan 1955 {published data only} Vaughan GF, Leiberman DM, Cook LC. Chlorpromazine in psychiatry. Lancet 1955;1:1083-7. Links Walsh 1959 {published data only} Walsh GP, Walton D, Black DA. The relative efficacy of &amp;quot;Vespral&amp;quot; and chlorpromazine in the treatment of a group of chronic schizophrenic patients. British Journal of Psychiatry 1959;105:199-209. Links Zuoze 1986 {published data only} Zuoze L, Youjun W, Shuzhong Z, Anguo H, Yuande C. Therapeutic effect of He-Ne laser irradiation of Point Erman in schizophrenic auditory hallucination - a clinical assessment. Journal of Traditional Chinese Medicine 1986;6:253-6. Links References to studies excluded from this review Abse 1960 Abse WD, Dahlstrom WG, Tolley AG. Evaluation of tranquilizing drugs in the management of acute mental disturbance. American Journal of Psychiatry 1960;117:973-80. Links Acker 1965 Acker CW. An exploration of the autonomic effects of phenothiazines. Psychopharmacologia 1965;7:150-8. Links Affleck 1966 Affleck DC, Eaton MT, Mansfield E. The action of a medication and the physician's expectations. Nebraska State Medical Journal 1966;51:331-4. Links Agarwal 1985 Agarwal AK, Winny GC. Role of ECT phenothiazine combination in schizophrenia. Indian Journal of Psychiatry 1985;27:233-6. Links Akimoto 1966 Akimoto H, Shimazaki T, Shibata N, Sato Y, Takahashi R. Current status of pharmacotherapy in schizophrenia. Folia Psychiatrica et Neurologica Japonica 1966;20(1):1-8. [MedLine: 67213329]. Links Alpert 1966 Alpert M, Hekimian LJ, Frosch WA. Evaluation of treatment with recorded interviews. American Journal of Psychiatry 1966;122:1258-64. Links Alpert 1978 Alpert M, Friedhoff A, Marcos L, Diamond F. Paradoxical reaction to L-dopa in schizophrenic patients. American Journal of Psychiatry 1978;135:1329-32. Links Alson 1964 Alson E, Hastings K. The use of adjective check lists with psychotic patients: the problem of pseudo-responses. Journal of Clinical Psychology 1964;20(4):462-3. Links Aman 1985 Aman MG, Singh NN. Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment. Journal of Mental Deficiency Research 1985;29(2):187-95. [MedLine: 85293054]. Links Amin 1977 Amin MM, Ban TA, Lehmann HE. A standard-controlled clinical study with benzquinamide in the treatment of chronic schizophrenic patients. Psychopharmacology Bulletin 1977;13:20-1. Links Ananth 1972 Ananth JV, Vacaflor L, Kekhwa G, Sterlin C, Ban TA. Nicotinic acid in the treatment of newly admitted schizophrenic patients: a placebo-controlled study. Internationale Zeitschrift Fur Klinische Pharmakologie Therapie und Toxikologie 1972;5(4):406-10. [MedLine: 72239308]. Links Andrews 1976 Andrews P, Hall JN, Snaith RP. A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. British Journal of Psychiatry 1976;128:451-5. Links Ashcroft 1961 Ashcroft GW, MacDougall EJ, Barker PA. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1961;107:287-93. [MedLine: 72239308]. Links Ayers 1984 Ayers T, Liberman RP, Wallace CJ. Subjective response to antipsychotic drugs: failure to replicate predictions of outcome. Journal of Clinical Psychopharmacology 1984;4:89-93. Links Azima 1954 Azima H, Ogle W. Effects of Largactil in mental syndomes. Canadian Medical Association Journal 1954;71:116-21. Links Bagadia 1981 Bagadia VN, Shah LP, Pradhan PV, Doshi J, Abhyankar R. Evaluation of cognitive effects of ECT: preliminary observations. Indian Journal of Psychiatry 1981;23:324-9. Links Ban 1977 Ban TA, Lehmann HE, Deutsch M. Negative findings with megavitamins in schizophrenic patients - preliminary report. Communications in Psychopharmacology 1977;1:119-22. Links Hoffer, J. Megavitamin treatment of schizophrenia. Canadian Psychiatric Association Journal 1975;20:492-5. Links Beech 1990 Beech A, Powell TJ, McWilliam J, Claridge GS. The effect of a small dose of chlorpromazine on a measure of 'cognitive inhibition'. Personality and Individual Differences 1990;11:1141-5. Links Benaim 1960 Benaim S. The effect of chlorpromazine on the incidence of epileptic phenomena during insulin coma therapy: A statistical investigation. Journal of Mental Science 1960;106:317-21. Links Bennett 1956 Bennett A, Ford F, Turk RE. Clinical investigation of chlorpromazine and reserpine in private psychiatric practice. American Journal of Psychiatry 1956;112:782-7. Links Blumberg 1964 Blumberg AG, Klein DF, Pollack M. Effects of chlorpromazine and imipramine on systolic blood pressure in psychiatric patients: Relationships to age, diagnosis and initial blood pressure. Journal of Psychiatric Research 1964;2(1):51-60. Links Blumberg 1969 Blumberg AG, Klein DF. Chlorpromazine-procyclidine and imipramine: effects on thyroid function in psychiatric patients. Clinical Pharmacology and Therapeutics 1969;10:350-4. Links Boullin 1975 Boullin DJ, Woods HF, Grimes RP, Grahame-Smith DG, Wiles D, Gelder MG, Kolakowska T. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. British Journal of Clinical Pharmacology 1975;2:29-35. Links Bowes 1956 Bowes, HA. The ataractic drugs: the present position of chlorpromazine, frenquel, pacatal, and reserpine in the psychiatric hospital. American Journal of Psychiatry 1956;113:530-9. Links Bressler 1971 Bressler B, Friedel RO. A comparison between chlorpromazine and thiothixene in a Veterans Administration Hospital population. Psychosomatics 1971;12:275-7. Links Brizer 1985 Brizer DA, Hartman N, Sweeney J, Millman RB. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. American Journal of Psychiatry 1985;142(9):1106-7. Links Burnett 1975 Burnett GB, Little SR, Graham N, Forrest AD. The assessment of thiothixene in chronic schizophrenia. A double-blind controlled trial. Diseases of the Nervous System 1975;36:625-9. Links Cabrera Gomez 1994 Cabrera Gomez JA, Cordero Gutierrez JR, Fernandez Lopez O, Reyes Gutierrez B, Romero Garcia K, Simon Consuegra J, Feas Cruz. Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon. Biotherapy 1994;7(1):27-37. Links Caffey 1963 * Caffey E, Forrest I, Frank T, Klett CJ. Phenothiazine excretion in chronic schizophrenics. American Journal of Psychiatry 1963;120:578-82. Links Caffey EM, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, Rothstein C. Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases 1964;17(4):347-58. Links Caffey 1975 Caffey EMJ, Prien RF. Practical considerations on treatment with antipsychotic preparations [Prakticheskie soobrazheniia o lechenii antipsikhoticheskimi preparatami]. Zhurnal Nevropatologii i Psikhiatrii 1975;75:1399-401. Links Campbell 1972 Campbell M, Fish B, Shapiro T, Floyd A. Acute responses of schizophrenic children to a sedative and a 'stimulating' neuroleptic: a pharmacologic yardstick. Current Therapeutic Research 1972;14:759-66. Links Campbell M, Fish B, Shapiro T, Floyd A. Thiothixene in young disturbed children. A pilot study. Archives of General Psychiatry 1970;23:70-2. Links Cardone 1969 Cardone S, Olson R. Chlorpromazine and body image. Effects on chronic schizophrenics. Archives of General Psychiatry 1969;20:576-82. Links Carrillo 1971 Carrillo C. Pharmacologlal treatment of the emotionally unstable character disorder. Vth World Congress of Psychiatry. Ciudad de Mexico. 1971. Casey 1960 Casey JF, Bennet IF, Lindley CJ, Hollister LE, Gordon MH, Springer NN. Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Archives of General Psychiatry 1960;2:210-20. Links Casey 1961 Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM. Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry 1961;117:997-1003. Links Chacon 1972 Chacon C, Harper P. Clinical and work performance variables in phenothiazine therapy of schizophrenia. Acta Psychiatrica Scandinavica 1973;49:65-76. Links Chacon Carlos, Harper P, Harvey GF. Work study in the assessment of the effects of phenothiazines in schizophrenia. Comprehensive Psychiatry 1972;13(6):549-54. [MedLine: 73051431]. Links Childers 1961 Childers RT, Therrien R. A comparison of the effectiveness of triluoperazine and chlorpromazine in schizophrenia. American Journal of Psychiatry 1961;118:552-4. Links Chouinard 1977 Chouinard G, Annable L, Kolivakis TN. Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology 1977;17(2-3):162-7. [MedLine: 77094284]. Links Chouinard-G 1983 Chouinard-G, Annable-L. Fluspirilene in the treatment of newly admitted schizophrenic patients. Psychopharmacology Bulletin 1983;19(1):136-8. Links Claghorn 1983 Claghorn J, Abuzzahab F, Wang R, Larson C, Gelenberg A, Klerman G, Tuason V, Steinbook R. The current status of Clozapine. Psychopharmacology Bulletin 1983;19:138-40. Links Clark 1970c Clark ML, Serafetinides EA, Wise JB, Colmore JP. Ocular pigment deposits: drug-induced false-positives. Journal of the American Medical Association 1970;214:2339. Links Clark 1970d Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark 1975 Clark ML, Kaul PN. A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. In: Gottschalk LA, Merlis S editor(s). Pharmacokinetics of psychoactive drugs. New York: Spectrum Publications, 1976:191-7. Clark ML, Kaul PN. A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. Psychopharmacology Bulletin 1975;11:28-30. Links Clark ML, Kaul PN, Whitfield LR. Chlorpromazine kinetics and clinical response. Psychopharmacology Bulletin 1978;14:43-5. Links Cole 1967 Cole JO, Schooler NR. Differences in clinical effects of three phenothiazines in &amp;quot;acute&amp;quot; schizophrenia. Diseases of the Nervous System 1967;28:369-83. Links Coons 1962 Coons WH, Boyd BA, White JG. Chlorpromazine, trifluoperazine and placebo with long term mental hospital patients. Canadian Psychiatric Association Journal 1962;7:159-63. [MedLine: 62022417]. Links Cowden 1956 Cowden RC, Zax M, Hague JR, Finney RC. Chlorpromazine: alone and as an adjunct to group psychotherapy in the treatment of psychiatric patients. American Journal of Psychiatry 1956;4:898-902. Links Crane 1970 Crane GE. High doses of trifluperazine and tardive dyskinesia. Archives of Neurology 1970;22(2):176-80. [MedLine: 70065772]. Links Crane 1971 Crane GE. Persistence of neurological symptoms due to neuroleptic drugs. American Journal of Psychiatry 1971;127:1407-10. Links Crow 1986 Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. II. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986;148:120-7. Links Johnstone EC, Crow TJ, Johnson AL, MacMillan JF. The Northwick Park study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. British Journal of Psychiatry 1986;148:115-20. Links MacMillan JF, Crow TJ, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. III. Short-term outcome in trial entrants and trial eligible patients. British Journal of Psychiatry 1986;148:128-33. Links Curry 1972 Curry SH, Adamson L. Double-blind trial of fluphenazine decanoate. Lancet 1972;2:543-4. Links Cutler 1957 Cutler RP, Monroe JJ, Anderson TE. Effects of &amp;quot;tranquilizers&amp;quot; upon pathological activity in psychotic patients: II. Reserpine. Archives of Neurology and Psychiatry 1957;78:61-8. Links Dally 1966 Dally P, Sargant W. Treatment and outcome of anorexia nervosa. British Medical Journal 1966;2:793-5. Links Danion 1992 Danion JM, Peretti S, Grange D, Bilik M, Imbs JL, Singer L. Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers. Psychopharmacology 1992;108(3):345-51. [MedLine: 92396807]. Links Daston 1958 Daston PG. Stylus maze performance of chronic schizophrenics taking chlorpromazine. Journal of Consulting Psychology 1958;22(5):384. Links Daston 1959 Daston PG. Effects of two phenothiazine drugs on concentrative attention span of chronic schizophrenics. Journal of Clinical Psychology 1959;15:106-9. Links Davies 1973 Davies AL, O'Leary J. The use of chlorpromazine in schizophrenia. Nursing Times 1973;69:1694-5. Links Dean 1967 Dean G. Mefenamic acid and chlorpromazine in porphyria variegata. South African Medical Journal 1967;41:925-7. Links Den 2000 Den Boer JA, Vahlne J O, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Human Psychopharmacology 2000;15(3):179-89. Links Denber 1955 Denber HCB, Merlis S. Studies on Mescaline. VI. Therapeutic Aspects of the Mescaline-Chlorpromazine Combination. Journal of Nervous and Mental Diseases 1955;122:463. Links Denber 1956 Denber H, Bird EG. Chlorpromazine in the treatment of mental illness. III. The problem of depression. American Journal of Psychiatry 1956;112:1021. Links Denber 1957 Denber HCB. Chlorpromazine-diethazine in the treatment of depression. Diseases of the Nervous System 1957;18:76-9. Links Desager 1988 Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF. Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology Berlin 1988;96:63-6. Links Douglas 1969 Douglas KW, Hindley JP. A comparison of mesoridazine and chlorpromazine in chronic psychiatric patients. Journal of Clinical Pharmacology and The Journal of New Drugs 1969;9:176-82. Links Downing 1963 Downing RW, Ebert JN, Shubrooks SJ. Effect of phenothiazines on the thinking of acute schizophrenics. Perceptual and Motor Skills 1963;17(2):511-20. Links Dube 1981 Dube S, Sethi B. Efficacy of lithium in schizophrenia. Indian Journal of Psychiatry 1981;23(2):193-9. Links Eitan 1991 Eitan N, Levin Y, Ben-Artzi E, Levy A, Neumann M. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica 1992;85:74-6. Links Ekdawi 1966 Ekdawi MY, Fowke R. A controlled trial of anti-parkinson drugs in drug-induced parkinsonism. British Journal of Psychiatry 1966;112(487):633-6. Links Elkes 1954 Elkes J, Elkes C. Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients. British Medical Journal 1954;2:560-5. Links Feldman 1956 Feldman PE, Lacy BS, Walker AE, Garrez NJ. A controlled, blind study of effects of thorazine on psychotic behavior. Bulletin of the Menninger Clinic 1956;20:25-47. Links Fink 1958 Fink M, Shaw R, Gross GE, Coleman FS. Comparative study of chlorpromazine and insulin coma in therapy of psychosis. Journal of the American Medical Association 1958;166(15):1846-50. Links Fink 1965 Fink M, Klein DF, Kramer JC. Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders. Psychopharmacologia 1965;7:27-36. Links Fleischhacker 1995 Fleischhacker W. Broadening treatment perspectives of schizophrenia: a clinical update on seroquel. 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 - Oct 4; Venice, Italy. 1995. Fleming 1958 Fleming B, Currie J. Investigation of a new compound, B.W.203, and of Chlorpromazine in the treatment of psychosis. British Journal of Psychiatry 1958;104:749-57. Links Foote 1958 Foote E. Combined Chlorpromazine and Reserpine in the treatment of chronic psychotics. British Journal of Psychiatry 1958;104:201-5. Links Forrest 1967 Forrest GL, Bortner TW, Bakker CB. The role of personality variables in response to chlorpromazine, dextroamphetamine and placebo. Journal of Psychiatric Research 1967;5:281-8. Links Freed 1956 Freed H, Peifer CA. Treatment of hyperkinetic emotionally disturbed children with prolonged administration of chlorpromazine. American Journal of Psychiatry 1956;113:22. Links Freedman 1965 Freedman N, Engelhardt D, Mann D, Margolis R, London S. Communication of body complaints and paranoid symptom change under conditions of phenothiazine treatment. Journal of Personality and Social Psychology 1965;1(4):310-8. Links Freeman 1956 Freeman H, Arnold AL, Cline HS. Effects of chlorpromazine and reserpine in chronic schizophrenic patients. Diseases of the Nervous System 1956;17:213-9. Links Freeman H, Cline HS. Effects of chlorpromazine on chronic lobotomized schizophrenic patients. A.M.A. Archives of Neurology and Psychiatry 1956;76:500-7. Links Freeman 1973 Freeman Harry. A double blind comparison of mesoridazine and chlorpromazine in chronic schizophrenics. Diseases of the Nervous System 1973;34(6):289-93. [MedLine: 74114021]. Links Friedhoff 1960 Friedhoff A, Alpert M. The effect of chlorpromazine on the variability of motor task performance in schizophrenics. Journal of Nervous and Mental Disease 1960;131:110-6. Links Fromm 1956 Fromm GH, Forsberg IA. Controlled study on the value of chlorpromazine in allaying anxiety. Diseases of the Nervous System 1956;17:16-9. Links Gaitz 1955 Gaitz C M, Roy H, Thompson W, Kimbell I, Mullen A J, Pokorny A D. Evaluation of Chlorpromazine in Comparison with other Methods of treatments of hospitalized psychiatric patients, using the lorr multidimensional scale for rating psychiatric patients. Psychiatric Research Reports 1955;1:1984. Links Galbrecht 1968 Galbrecht CR, Klett CJ. Predicting response to phenothiazines: the right drug for the right patient. Journal of Nervous and Mental Disease 1968;147:173-83. Links Galdi 1988 Galdi J, Bonato RR. Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics. Canadian Journal of Psychiatry 1988;33:816-8. Links Gallant 1963 Gallant D, Bishop M, Steele C, Noblin CD. The relationship between serotonin antagonism and tranquilizing activity. American Journal of Psychiatry 1963;119:882. Links Gallant 1967 Gallant DM, Bishop MP, O'Meallie L. BL-KR140: a controlled evaluation in chronic schizophrenic patients previously stabilized on chlorpromazine. Current Therapeutic Research 1967;9:447-50. Links Gardner 1955 Gardner MJ, Hawkins HM, Judah LN, Murphree OD. Objective measurement of psychiatric changes produced by chlorpromazine and reserpine in chronic schizophrenia. Psychiatric Research Reports 1955;1:77-83. Links Gardos 1968 Gardos G, Rapkin RM, DiMascio A. Trifluoperazine and chlorpromazine in combination and individually. Current Therapeutic Research Clinical and Experimental 1968;10(12):609-12. [MedLine: 69054114]. Links Gardos 1976 Gardos G, Cole J O. Maintenance antipsychotic therapy: is the cure worse than the disease?. American Journal of Psychiatry 1976;133:32-6. Links Garfield 1962 Garfield SL, Helper MM, Wilcott RC, Muffly R. Effects of chlorpromazine on behaviour in emotionally disturbed children. Journal of Nervous and Mental Diseases 1962;135:147-54. Links Garmezy 1969 Garmezy N. Effects of censure and chlorpromazine on visual discrimination behavior of schizophrenic and alcoholic patients. Proceedings of the Annual Convention of the American Psychological Association 1969;4(2):491-2. Links Gauthier 1967 Gauthier R, Hillel J, Bordeleau J M, Tetreault L. Comparative study of trifluperidol and trifluoperazine in the treatment of acute schizophrenia. Union Medicale du Canada 1967;96:936-43. Links Gendron 1973 Gendron JL, Zimmermann RL, Schiele BC. A double blind comparison of AL 1021 and chlorpromazine in hospitalized schizophrenics. Current Therapeutic Research 1973;15(6):333-6. Links Gibbs 1956 Gibbs JJ, Wilkens B, Lauterbach CG. A controlled clinical psychiatric study of chlorpromazine. Journal of Clinical and Experimental Psychopathology 1957;18:269-83. Links Gibbs JJ, Wilkens B, Lauterbach CG. A controlled clinical psychiatric study of the drug chlorpromazine. American Journal of Psychiatry 1956;113:254-5. Links Gilgash 1957 Gilgash CA. Effects of Thorazine on Wechsler scores of adult catatonic schizophrenics. Psychological Reports 1957;3:561-4. Links Goldberg 1968 Goldberg SC, Mattsson NB. Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System 1968;29(5):S153-8. [MedLine: 68399894]. Links Goldberg 1970 Goldberg GJ, Brooke G, Townsend HR, Brahma RK, Hill GB. A comparison of oxypertine and chlorpromazine in chronic schizophrenia. Acta Psychiatrica Scandinavica 1970;46(2):126-35. [MedLine: 71030938]. Links Goldberg 1972 Goldberg S, Frosch W, Drossman A, Schooler N, Johnson G. Prediction of response to phenothiazines in schizophrenia. A crossvalidation study. Archives of General Psychiatry 1972;26:367-73. Links Goldman 1955 Goldman D. Treatment of psychotic states with chlorpromazine. Journal of the American Medical Association 1955;157:1274-8. Links Good 1958 Good WW, Sterling M, Holtzman WH. Termination of chlorpromazine with schizophrenic patients. American Journal of Psychiatry 1958;115:443-8. Links Mefferd RB, Labrosse EH, Gawienowski AM, Williams RJ. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. Journal of Nervous and Mental Diseases 1958;127:167-79. Links Goodwin-Austin 1971 Godwin-Austen RB, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. British Medical Journal 1971;4(778):25-6. Links Goyne 1958 Goyne J B, Groebner E, Pueblita M. Clinical Research - Vesperin-Chlorpromazine Therapy. Scientific Papers of the 114th Annual Meeting of the American Psychiatric Association. 1958:104-5. Graupner 1972 Graupner OK, Kalman EV. Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments [Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)]. Psychopharmacologia 1972;27(4):343-7. [MedLine: 73085373]. Links Green 1996 Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology 1996;128(1):67-73. Links Green 1998 Green JF, King DJ. Antisaccade and no-saccade distractibilty with chlorpromazine and lorazepam. Schizophrenia Research 1998;29(1,2):117. Links Greenberg 1966 Greenberg LM, Roth S. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. American Journal of Psychiatry 1966;123:221-6. Links Griffiths 1979 Griffiths RR, Bigelow G, Liebson I. Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. Journal of Pharmacology and Experimental Therapeutics 1979;210:301-10. Links Guy 1978 Guy W, Petrie W, Cleary P. The incidence of treatment emergent symptoms under chlorpromazine and placebo conditions. Psychopharmacology Bulletin 1978;14:22-4. Links Hammond 1978 Hammond NV, Gruzelier JH. Laterality, attention and rate effects in the auditory temporal discrimination of chronic schizophrenics - the effect of treatment with chlorpromazine. Quarterly Journal of Experimental Psychology 1978;30:91-103. Links Hamner 1996 Hamner MB, Arvanitis LA, Miller BG, Link CGG, Hong WW. Plasma prolactin in schizophrenia subjects treated with seroquel (TM) (ICI 204,636). Psychopharmacology Bulletin 1996;32(1):107-10. [MedLine: 96267998]. Links Hankoff 1960 Hankoff L, Engelhardt D, Freedman N, Mann D, Margolis R. Denial of illness in schizophrenic outpatients: effects of psychopharmacological treatment. Archives of General Psychiatry 1960;3:657-64. Links Hanlon 1958 Hanlon T E, Kurland A A, Esquibel A J, Ota K Y. A Comparative Study of Chlorpromazine and Triflupromazine in the Management of the Chronic Hospitalized Psychotic Patient. Journal of Nervous and Mental Diseases 1958;127:17-20. Links Hanlon 1960 Hanlon TE, Wiener G, Kurland AA. The psychiatric physician and the phenothiazine tranquilizers. Journal of Nervous and Mental Diseases 1960;130:67-71. Links Harper 1976 Harper P, Chacon C. Work performance versus clinical assessment in the evaluation of phenothiazine therapy. British Journal of Clinical Pharmacology 1976;3:50-5. Links Hartley 1978 Hartley L, Henry T, Couper-Smartt J. Chlorpromazine and serial reaction performance. British Journal of Psychology 1978;69:271-6. Links Hartley 1987 Hartley LR, Coxon L, Spencer J. Pharmacological effects on lateralized behavior. Current Psychology Research and Reviews 1987;6:301-12. Links Hartley 1989 Hartley LR, Strother N, Arnold PK, Mulligan B. Lateralization of emotional expression under a neuroleptic drug. Physiology and Behavior 1989;45:917-21. Links Hartley 1991 Hartley LR, Ireland LK, Arnold PK, Spencer J. Chlorpromazine and the lateralisation of the perception of emotion. Physiology and Behavior 1991;50:881-5. Links Hartmann 1973 Hartmann E, Cravens J. The effects of long term administration of psychotrophic drugs on human sleep. IV. The effects of chlorpromazine. Psychopharmacologia 1973;33:203-18. Links Haskell 1974 Haskell DS, McNair DM, Fisher S, Kahn RJ. A controlled outpatient trial of perphenazine-amitriptyline and chlorpromazine. Journal of Clinical Pharmacology 1974;14:536-42. Links Heilizer 1959 Heilizer F. The effects of chlorpromazine upon psychomotor and psychiatric behavior of chronic schizophrenic patients. Journal of Nervous and Mental Disease 1959;128:358-64. Links Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. Journal of Clinical and Experimental Psychopathology 1959;20:53-7. Links Hekimian 1967 Hekimian LJ, Friedhoff AJ. A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients. Diseases of the Nervous System 1967;28:675-8. Links Herrera 1988 Herrera JN, Sramek JJ, Costa JF, Roy S, High potency neuroleptics and violence in schizophrenics. Journal of Nervous and Mental Disease 1988;176(9):558-61. Links Herrmann 1991a Herrmann WM, Scharer E, Delini-Stula A. Predictive value of pharmaco electroencephalography in early human pharmacological evaluations of psychoactive drugs - first example - Savoxepine. Pharmacopsychiatry 1991;24:196-205. Links Herrmann 1991b Herrmann WM, Scharer E, Wendt G, Delini-Stula A. Pharmaco EEG profile of maroxepine - third example to discuss the predictive value of pharmaco electroencephalography in early human pharmacological evaluations of psychoactive drugs. Pharmacopsychiatry 1991;24:214-24. Links Herz 1991 Herz M, Glazer W, Mostert M, Sheard M, Szymanski H, Hafez H, Mirza M, Vana J. Intermittent versus maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry 1991;48:333-9. Links Hoffer 1975 Hoffer J. Megavitamin treatment of schizophrenia. Canadian Psychiatric Association Journal 1975;20:492-5. Links Hogarty 1976 Hogarty G E, Ulrich R F, Mussare F, Aristigueta N. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Diseases of the Nervous System 1976;37:494-500. Links Hollis 1968 Hollis JH. Chlorpromazine: direct measurement of differential behavioral effect. Science 1968;159:1487-9. Links Hollister 1955 Hollister LE, Jones KP, Brownfield B, Johnson F. Chlorpromazine alone and with reserpine. California Medicine 1955;83:218-21. Links Hollister LE, Traub L, Beckman WG. Psychiatric use of reserpine and chlorpromazine: results of double-blind studies. In: Kline NS editor(s). Psychopharmacology. Washington DC: AAAS, 1956:65-74. Holt 1984 Holt RJ. Neuroleptic drug-induced changes in platelet levels. Journal of Clinical Psychopharmacology 1984;4:130-2. Links Hong 1996a Hong W, Arvanitis L. Reduction of the positive symptoms of schizophrenia by '(ICI 204,636): results from phase II and III clinical trials. 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands. 1996. Hong 1996b Hong WW, Arvanitis LA. The atypical profile of '(ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands. 1996. Hopkin 1954 Hopkin DA. Action of chlorpromazine and promethazine. British Medical Journal 1954;1:1036. Links Horenstein 1957 Horenstein. Resperpine and chlorpromazine in hyperactive mental defectives. American Journal of Mental Deficiency 1957:525-29. Links Hrushka 1966 Hrushka M, Bruck M, Hsu J J. Therapeutic effects of different modes of chlorpromazine administration. Diseases of the Nervous System 1966;27:522-7. Links Huang 1967 Huang CL, Hirano K. The effect of antipyretic analgesics on the metabolism of chlorpromazine in man. Biochemical Pharmacology 1967;16:2023-6. Links Hughes 1967 Hughes JS, Little JC. An appraisal of the continuing practice of prescribing tranquillizing drugs for long-stay psychiatric patients. British Journal of Psychiatry 1967;113:867-73. Links Hurst 1960 Hurst L. Chlorpromazine and Pecazine in chronic schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1960;106:726-31. Links Hurst 1996 Hurst BC, Link C. A comparison of the tolerance profile of seroquel with typical neuroleptics and placebo. Xth World Congress of Psychiatry. Madrid, Spain. Madrid, Spain: August 23-28, 1996. Hussar 1969 Hussar AE, Bragg DG. The effect of chlorpromazine on the swallowing function in chronic schizophrenic patients. American Journal of Psychiatry 1969;126:570-3. Links Itil 1968 Itil T, Shapiro D, Fink M. Differentiation of psychotropic drugs by quantitative EEG analysis. Agressologie 1968;9:267-80. Links Itil 1971 Itil TM, Ulett GA, Fukuda T. Quantitative pharmaco-electroencephalography in early evaluation of psychotropic drugs. Folia Psychiatrica et Neurologica Japonica 1971;25:195-202. Links Johnstone 1978 Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978;1(8069):848-51. [MedLine: 78155245]. Links Jones 1969 Jones IH. Drugs and motor activity in chronic schizophrenia. British Journal of Psychiatry 1969;115:851-6. Links Jones 1971 Jones IH, Pikler N. Effects of chlorpromazine and trifluoperazine on the activity of chronic schizophrenics. British Journal of Psychiatry 1971;119:545-6. Links Joseph 1979 Joseph MH, Baker HF, Johnstone EC, Crow TJ. 3-Methoxy-4-hydroxyphenylglycol excretion in acutely schizophrenic patients during a controlled clinical trial of the isomers of flupenthixol. Psychopharmacology 1979;64(1):35-40. [MedLine: 80013695]. Links Joshi 1980 Joshi VG, Nagesh R, Eswaran S, Nagesh R, Pai M, Mathews G, Mallick PN. Vitamins B1, B6, and B12 in the adjunctive treatment of schizophrenia - further studies to examine the effect of reduction of chlorpromazine dosage. Journal of Orthomolecular Psychiatry 1980;11:45-9. Links Kabes 1982 Kabes J, Sikora J, Pisvejc J, Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. International Pharmacopsychiatry 1982;17(3):185-92. [MedLine: 83056096]. Links Kammerer 1968 Kammerer M, Wartel R, Gurfein L, Weil J, Wysoki V, Gelb F. Clinical experimentation with desipramine with statistical control [Experimentation clinique de la desipramine avec controle statistique]. Annales Medico-psychologiques 1968;1:109-13. Links Kaplan 1974 Kaplan J, Dawson S, Vaughan T, Green R, Wyatt RJ. Effect of prolonged chlorpromazine administration on the sleep of chronic schizophrenics. Archives of General Psychiatry 1974;31:62-6. Links Keskiner 1970 Keskiner A, Itil TM, Todt N. A comparative study of butaperazine, chlorpromazine and placebo in chronic schizophrenics. Psychosomatics 1970;11:120-6. Links Kim 1960 Kim K. Responses to treatment-refractory chronic schizophrenics to chlorpromazine with concurrent adrenocortical steroid. American Journal of Psychiatry 1960;116:1023-4. Links Kimbell 1971 Kimbell I Jr, Winkelman GW, Hughes WM. Comparison of thioridazine and chlorpromazine in doctor's choice research design. Clinical Pharmacology and Therapeutics 1971;12:825-32. Links King 1959 King PD, Weinberger W. Comparison of proclorperazine and chlorpromazine in hospitalized chronic schizophrenics. American Journal of Psychiatry 1959;115:1026-7. [MedLine: 69202908]. Links King 1994 King DJ. Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatrica Scandinavica Supplementum 1994;89(380):53-8. Links Kinross-Wright 1954 Kinross-Wright V. Chlorpromazine - a major advance in psychiatric treatment. Postgraduate Medicine 1954:297-300. Links Klein 1974 Klein RH, Lynn EJ, Axelrod H, Dluhy J. Self-administration of medication by psychiatric inpatients. Journal of Nervous and Mental Disease 1974;158:450-5. Links Kopell 1968 Kopell BS, Wittner WK. The effects of chlorpromazine and methamphetamine on visual signal-from-noise detection. Journal of Nervous and Mental Disease 1968;147:418-24. Links Kordas 1968 Kordas S, Kazamias N, Georgas J, Papadokostakis J. Clopenthixol: a controlled trial in chronic hospitalised schizophrenic patients. British Journal of Psychiatry 1968;114:833-6. Links Kornetsky 1957 Kornetsky C, Humphries O. Relationship between effects of a number of centrally acting drugs and personality. Archives of Neurology and Psychiatry 1957;77:325-7. Links Kornetsky C, Humphries O, Evarts EV. Comparison of psychological effects of certain centrally acting drugs in man. Archives of Neurology and Psychiatry 1957;77:318-24. Links Primac DW, Mirsky AF, Rosvold HE. Effects of centrally acting drugs on two tests of brain damage. Archives of Neurology and Psychiatry 1957;77:328-32. Links Kornetsky 1958 Kornetsky C, Humphries O. Psychological effects of centrally acting drugs in man. Journal of Mental Science 1958;104:1093-9. Links Mirsky AF, Primac DW, Bates R. The effects of chlorpromazine and secobarbital on the C.P.T. Journal of Nervous and Mental Diseases 1959;128:12-7. Links Kornetsky 1959 Kornetsky C, Pettit M, Wynne R, Evarts EV. A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenic patients. Journal of Mental Science 1959;105:190-8. Links Korol 1965 Korol B, Lang WJ, Brown ML, Gershon S. Effects of chronic chlorpromazine administration on systemic arterial pressure in schizophrenic patients: relationship of body position to blood pressure. Clinical Pharmacology and Therapeutics 1965;6:587-91. Links Kovitz 1955 Kovitz B, Carter JT, Addison WP. A comparison of chlorpromazine and reserpine in chronic psychosis. Archives of Neurology and Psychiatry 1955;74:467-71. Links Kramer 1975 Kramer M, Roth T, Goldstein S, Ryan MS, Blackwell B. A double-blind evaluation of metiapine in hospitalized acute schizophrenics. Current Therapeutic Research 1975;18:839-48. Links Kugler 1980 Kugler BT, Gruzelier JH. The influence of chlorpromazine and amylobarbitone on the recovery limb of the electrodermal response. Psychiatry Research 1980;2:75-84. Links Kupfer 1971 Kupfer DJ, Wyatt RJ, Synder F, Davis JM. Chlorpromazine and sleep in psychiatric patients. Archives of General Psychiatry 1971;24:185-9. Links Kurland 1981 Kurland AA, Nagaraju A. Viloxazine and the depressed schizophrenic - methodological issues. Journal of Clinical Pharmacology 1981;21(1):37-41. [MedLine: 81168674]. Links Lampe 1969 Lampe WT. A double blind study of clomacran. Current Therapeutic Research 1969;11:300-6. Links Latz 1965 Latz A, Kornetsky C. The effects of chlorpromazine and secobarbital under two conditions of reinforcement on the performance of chronic schizophrenic subjects. Psychopharmacologia 1965;7:77-88. Links Laurian 1981 Laurian S, Le PK, Baumann P, Perey M, Gaillard JM. Relationship between plasma-levels of chlorpromazine and effects on EEG and evoked potentials in healthy volunteers. Pharmacopsychiatria 1981;14:199-204. Links Leff 1971 Leff JP. Influence of selection of patients on results of clinical trials. British Medical Journal 1973;4:156-8. Links Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. British Medical Journal 1971;3:599-604. Links Leszek 1991 Leszek J, Inglot AD, Cantell K, Wasik A. Natural human leukocyte interferon in the treatment of schizophrenia. European Journal of Psychiatry 1991;5(1):55-63. Links Levin 1959 Levin ML. A comparison of the effects of phenobarbital, promethazine, chlorpromazine, and placebo upon mental hospital patients. Journal of Consulting Psychology 1959;23:167-70. Links Levine 1997 Levine J, Caspi N, Laufer N. Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients. Schizophrenia Research 1997;26(1):55-63. [MedLine: 98017426]. Links Levita 1961 Levita E. Effects of chlorpromazine and promazine on perseveration. Journal of General Psychology 1961;65:181-7. Links Lewis 1973 Lewis PJ, James NM. Haloperidol and chlorpromazine - a double-blind cross-over trial and clinical study in children and adolescents. Australian and New Zealand Journal of Psychiatry 1973;7:59-65. Links Liberman 1973 Liberman RP, Davis J, Moon W, Moore J. Research design for analyzing drug-environment-behavior interactions. Journal of Nervous and Mental Diseases 1973;156:432-9. Links Little 1958 Little JC. A double-blind controlled comparison of the effects of Chlorpromazine, Barbiturate and a placebo in 142 chronic psychotic in-patients. British Journal of Psychiatry 1958;4:334-49. Links Loranger 1968 Loranger AW. Treatment of acute mental disorders with an adrenal steroid. British Journal of Psychiatry 1968;114:843-4. Links Lorr 1961 Lorr M, McNair DM, Weinstein GJ, Michaux WW, Raskin A. Meprobamate and chlorpromazine in psychotherapy. Some effects on anxiety and hostility of outpatients. Archives of General Psychiatry 1961;4:381-9. Links Lyberi 1956 Lyberi G, S L Last. The Use of Chlorpromazine As An Activating Agent. Electroencephalography and Clinical Neurophysiology 1956:711-12. Links Maculans 1964 Maculans GA. Comparison of diazepam, chlorprothixine and chlorpromazine in chronic schizophrenic patients. Diseases of the Nervous System 1964;25:164-8. Links Mahal 1976 Mahal AS, Ramu NG, Chaturvedi DD. Double blind controlled study of brahmyadiyoga and tagara in the management of various types of unmada (schizophrenia). Indian Journal of Psychiatry 1976;18(4):283-92. Links Majewski 1968 Majewski J, Stempurska K. Results of treatment of schizophrenic psychoses with neuroleptics combined with subcomatic insulin [Wyniki leczenia psychoz schizofrenicznych neuroleptykami skojarzonymi z insulina podspiaczkowa]. Psychiatria Polska 1968;2(1):37-42. [MedLine: 68366839]. Links Marjerrison 1969 Marjerrison G, Keogh RP. Integrated EEG variability - drug effects in acute schizophrenics. Canadian Psychiatric Association Journal 1969;14:403-5. Links Marrazzi 1972 Marrazzi AS, Woodruff S, Kennedy D. Perceptual challenge to measure illness and therapy. American Journal of Psychiatry 1972;128:886-90. Links Mason-Browne 1957 Mason-Browne NL. Perphenazine - a drug modifying consciousness. American Journal of Psychiatry 1957;114:173-4. Links Mason-Browne NL, Borthwick JW. Effect of perphenazine (Trilafon) on modification of crude consciousness. Diseases of the Nervous System 1957;18:300-6. Links Mathur 1981 Mathur S, Hall JN. Phenothiazine withdrawal in schizophrenics in a hostel (letter). British Journal of Psychiatry 1981;138:271-2. Links Mattila 1994 Mattila MJ, Vanakoski J, Mattila Evenden ME, Karonen SL. Suriclone enhances the actions of chlorpromazine on human psychomotor performance but not on memory or plasma prolactin in healthy subjects. European Journal of Clinical Pharmacology 1994;46:215-20. Links McClelland 1990 McClelland GR, Cooper SM, Pilgrim AJ. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. British Journal of Clinical Pharmacology 1990;30:795-803. Links Melnyk 1966 Melnyk WT, Worthington AG, Laverty SG. Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic in-patients. Canadian Psychiatric Association Journal 1966;11(5):410-3. Links Merry 1957 Merry J, Pargiter MB, Munro H. Chlorpromazine and chronic neurotic tension. American Journal of Psychiatry 1957;113:988-90. Links Michaux 1966 Kurland AA, Bethon GD, Michaux MH, Agallianos DD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings. Journal of New Drugs 1966;6:80-95. Links Michaux MH, Kurland AA, Agallianos DD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. Current Therapeutic Research, Clinical and Experimental 1966;8(supplement):117-52. Links Millar 1963 Millar J. A trial of fluphenazine in schizophrenia. British Journal of Psychiatry 1963;109:428-32. [MedLine: 74100099]. Links Milne 1960 Milne H, Fowler DB. A clinical trial of Largactil (chlorpromazine), Stemeticl (prochlorperazine) and Veractil (methotrimeprazine). British Journal of Psychiatry 1960;106:1105-10. Links Milton 1978 Milton F, Patwa VK, Hafner RJ. Confrontation versus belief modification in persistently deluded patients. British Journal of Medical Psychology 1978;51:127-30. Links Mitchell 1956 Mitchell P. Chlorpromazine in the treatment of the chronic disturbed schizophrenic patient. British Journal of Psychiatry 1956;102:151-4. Links Mitchell 1960 Mitchell LE, Zax M. Psychological response to chlorpromazine in a group of psychiatric patients. Journal of Clinical Psychology 1960;16:440-2. Links Monteleone 1999 Monteleone P, Tortorella A, Borriello R, Cassandro P, Maj M. Prolactin hyperresponsiveness to D fenfluramine in drug free schizophrenic patients: a placebo controlled study. Biological Psychiatry 1999;45(12):1606-11. [MedLine: 99304410]. Links Morgenstern 1960 Morgenstern FV, Funk IC, Holt WL. Comparative short-term evaluation of triflupromazine hydrochloride, chlorpromazine hyrochloride, and placebo in acutely disturbed patients. New York State Journal of medicine 1960;60:254-8. Links Morton 1968 Morton MR. A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry 1968;124:1585-8. Links Moss 1958 Moss CS, Jensen RE, Morrow W, Freund HG. Specific behavioural changes produced by chlorpromazine in chronic schizophrenia. American Journal of Psychiatry 1958;115:449-51. Links Neal 1969 Neal CD, Collis MP, Imlah NW. A comparative trial of oxypertine and chlorpromazine in chronic schizophrenia. Current Therapeutic Research - Clinical and Experimental 1969;11:367-78. Links Newbold 1956 Newbold, Steed. The Use of Chlorpromazine in Psychotherapy. Journal of Nervous and Mental Diseases 1956. Links Okuma 1979 Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe S. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology Berlin 1981;73:95-6. Links Orzack 1969 Orzack MH, Taylor CL, Kornetsky C. A comparison of the behavioral effects of periodic administration of chlorpromazine and a &amp;quot;sustained-release&amp;quot; form of chlorpromazine. Clinical Pharamacology and Therapeutics 1969;10(2):258-64. [MedLine: 69143232]. Links Osmakova 1972 Os'makova EI. Use of psychological methods for studying the particular psychotropic action of various psychopharmacologic drugs [Primenenie psikhologicheskikh metodik dlia issledovaniia sobstvenno psikhotropnogo deistviia nekotorykh psikhofarmakologic heskikh sredtsv]. Zhurnal Nevropatologii i Psikhiatrii 1972;72:1705-8. Links Rojo-Sierra M, Alonso J, D&amp;#237;ez E, Giner J, Lloret E. [Aportaci&amp;#243;n sobre el espectro psicofarmacoter&amp;#225;pico del R P. 19 366 y R P. 19 552]. 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Ciudad de Mexico, Mexico. 1971. Pai 2001 Pai Y-M, Yu S-C, Lin C-C. Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study. Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA. Marathon Multimedia, 2001. Paredes 1966 Paredes A, Baumgold J, Pugh LA, Ragland R. Clinical judgment in the assessment of psychopharmacological effects. Journal of Nervous and Mental Disease 1966;142(2):153-60. Links Park 1981 Park S, Hardesty AS, Garcia E. Effects of triiodothyronine and chlorpromazine combination treatment in schizophrenia. Current Therapeutic Research - Clinical and Experimental 1981;29:929-35. Links Pasamanick 1967 Pasamanick B, Scarpitti FR, Dinitz S. Schizophrenics in the community: an experimental study in the prevention of hospitalization. New York: Appleton-Century-Crofts, 1967. Patterson 1981 Patterson T, Venables PH. Bilateral skin conductance and the pupillary light dark reflex - manipulation by chlorpromazine, haloperidol, scopolamine, and placebo. Psychopharmacology 1981;73:63-9. Links Peet 1980 Peet M, Middlemiss DN, Yates RA. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients [letter]. Lancet 1980;2:978. Links Pennington 1957 Pennington V. A two-year comparative study of ataraxics in neuropsychiatric patients. Journal of the American Geriatric Association 1957;5:42-9. Links Pietzcker 1978 Pietzcker A. Long-term medication in schizophrenia [Langzeitmedikation bei schizophrenen Kranken]. Nervenarzt 1978;49:518-33. Links Pigache 1973 Pigache RM. The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine. Schizophrenia Research 1993;10:39-50. Links Pigache RM, Norris HN. Measurement of drug action in schizophrenia. Clinical Science 1973;44:28P. Links Pigache 1993 Pigache RM. Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two-year longitudinal study. Schizophrenia Research 1993;10:51-9. Links Platz 1967 Platz AR, Klett CJ, Caffey EMJ. Selective drug action related to chronic schizophrenic subtype. (A comparative study of carphenazine, chlorpromazine, and trifluoperazine). Diseases of the Nervous System 1967;28:601-5. Links Pleasure 1956 Pleasure H. Chlorpromazine (Thorazine) for mental illness in the presence of pulmonary tuberculosis. Psychiatry Quarterly 1956;30:23-30. Links Pollack 1956 Pollack, B. The effect of chlorpromazine on the return rate of 250 patients released from the Rochester State Hospital. American Journal of Psychiatry 1956;112:937. Links Pollard 1959 Pollard JC. Combined Effects of Chlorpromazine and Meprobamate in Chronically Disturbed Psychotic Patients. Diseases of the Nervous System 1959;20:427-9. Links Quigley 1996 Quigley N, Morgan D, Idzikowski C, King DJ. The effect of chlorpromazine and benzhexol on memory and psychomotor function in healthy volunteers. Journal of Psychopharmacology 1996;10:146-52. Links Quinn 1960 Quinn PJG, Johnston J, Latner G, Kiloh LG. A comparative controlled trial of methotrimeprazine ('veractil') in chronic schizophrenia. British Journal of Psychiatry 1960;106:161-70. Links Raaska 2000 Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. European Journal of Clinical Pharmacology 2000;56(8):585-9. [MedLine: 21026257]. Links Ragland 1968 Ragland R, Clark ML, Ray TS, Paredes A, Costiloe JP, Segal B, Wolf S. The evaluation of chlorpromazine therapy in chronic schizophrenic women. A replicated experiment. Journal of Chronic Diseases 1968;21:445-60. Links Raja 2000 Raja M, Azzoni A. Second generation antipsychotics in the emergency care setting. A prospective naturalistic study. General Hospital Psychiatry 2000;22(2):107-14. [MedLine: 20283566]. Links Rappaport 1967 Rappaport M. Competing voice messages. Effects of message load and drugs on the ability of acute schizophrenics to attend. Archives of General Psychiatry 1967;17:97-103. Links Rappaport 1968 Rappaport M. Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background. Journal of Nervous and Mental Disease 1968;146:404-11. Links Rathod 1958 Rathod N, Rees L. A controlled study of the prognostic significance of autonomic responses in the chlorpromazine treatment of disturbed psychotic patients. British Journal of Psychiatry 1958;104:705-12. Links Raymond 1957 Raymond MJ, Lucas CJ, Beesley ML, O'Connell BA, Fraser Roberts JA. A trial of five tranquillizing drugs in psychoneurosis. British Medical Journal 1957;2:63-6. Links Remr 1970 Remr J. The effects of chlorpromazine on fine psychomotor performance with a simultaneous secondary task in schizophrenics. Activitas Nervosa Superior 1971;13:179. Links Remr J. The effects of chlorpromazine on some components of psychomotor performance in schizophrenics. Activitas Nervosa Superior 1970;12:253-4. Links Rifkin 1978 Rifkin A, Quitkin F, Kane J, Struve F, Klein DF. Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. Archives of General Psychiatry 1978;35(4):483-9. [MedLine: 79081577]. Links Rinaldi 1956 Rinaldi F, Rudy L, Himwich HE. Clinical evaluation of azacyclonol, chlorpromazine, and reserpine on a group of chronic psychotic patients. American Journal of Psychiatry 1956;112:678-83. Links Rivera-Calimlim 1973 Rivera Calimlim L, Castaneda L, Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clinical Pharmacology and Therapeutics 1973;14:978-86. Links Rosen 1972 Rosen B, Engelhardt DM, Freedman N, Margolis R, Rudorfer L, Paley HM. Prediction of psychiatric hospitalization. II. The Hospitalization Proneness Scale: a cross-validation. Journal of Nervous and Mental Disease 1972;80:271-4. Links Rosenheck 2000 Rosenheck R, Cramer J, Jurgis G, Perlick D, Xu W, Thomas J, Henderson W, Charney D. Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. Journal of Clinical Psychiatry 2000;61(9):671-6. Links Rosner 1955 Rosner H, Levine S, Hess H, Kaye H. A comparative study of the effect on anxiety of chlorpromazine, reserpine, phenobarbital, and a placebo. Journal of Nervous and Mental Diseases 1955;122:505-12. Links Rudy 1957 Rudy L, Himwich H, Tasher DC. Clinical evaluation of two phenothiazine compounds Promazine and Mepazine. American Journal of Psychiatry 1957;113:979-83. Links Rudy 1958 Rudy L, Rinaldi E, Himwich H, Tuteur W, Glotzer J. Trifluoperazine in the treatment of psychotic patients. American Journal of Psychiatry 1958;115:364-5. Links Sainz 1955 Sainz A. Chlorpromazine in psychiatric disorders. Prescriber 1955;2(2):14. [MedLine: 20283566]. Links Saletu 1972 Saletu B, Saletu M, Itil T. Effect of minor and major tranquilizers on somatosensory evoked potentials. Psychopharmacologia 1972;24:347-58. Links Salisbury 1957 Salisbury BJ, Hare EH. Ritalin and Chlorpromazine in chronic schizophrenia: a controlled clinical trial. British Journal of Psychiatry 1957;103:830-4. Links Schiele 1959 Schiele BC, Mendelsohn RM, Penman AS, Schofield W. Comparison of low and high dosage procedures in chlorpromazine therapy. Psychiatric Quarterly 1959;33:252-9. Links Schmidt 1957 Schmidt KE. Combined treatment with chlorpromazine and reserpine: an attempt at quantitative assessments in chronic schizophrenic patients. British Journal of Psychiatry 1957;103:200-8. Links Schooler 1976 Sakalis G, Chan TL, Sathananthan G, Schooler N, Goldberg S, Gershon S. Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. Communucations in Psychopharmacology 1977;1:157-66. Links Schooler NR, Sakalis G, Chan TL. Chlorpromazine metabolism and clinical response in acute schizophrenia - a preliminary report. Psychopharmacology Bulletin 1975;11:30-3. Links Schooler NR, Sakalis G, Chan TL, Gershon S, Goldberg SC, Collins P. Chlorpromazine metabolism and clinical response in acute schizophrenia - a preliminary report. Pharmacokinetics of psychoactive drugs. 1976:199-219. Seager 1955 Seager CP. Chlorpromazine in treatment of elderly psychotic women. British Medical Journal 1955;1:882-5. Links Serafetinides 1973 Serafetinides EA. Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry 1973;8:214-6. Links Shaskan 1975 Becker RE, Shaskan EG. Platelet monoamine oxidase activity in schizophrenic patients. American Journal of Psychiatry 1977;134:512-7. Links Shaskan EG, Becker RE. Blood platelet monoamine oxidase activity in anergic schizophrenics. National Institute of Drug Abuse Research Monograph Services 1975:29-35. Links Shaskan EG, Becker RE. Platelet monoamine oxidase in schizophrenics. Nature 1975;253:659-60. Links Shawver 1959 Shawver JR, Gorham DR, Leskin LW, Good WW, Kabnick DE. Comparison of chlorpromazine and reserpine in maintenance drug therapy. Diseases of the Nervous System 1959;20:452-7. Links Shopsin 1978 Shopsin B, Klein H, Aronson M. Clozapine: double-blind control trial in the treatment of acute schizophrenia. Psychopharmacology Bulletin 1978;14:12-4. Links Shopsin 1979 Honigfeld G, Patin J, Singer J. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Advances in Therapy 1984;1:77-97. Links Shopsin B, Klein H, Aaronson M, Collora M. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients. Archives of General Psychiatry 1979;36:657-64. Links Silver 2000 Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. International Clinical Psychopharmacology 2000;15(5):257-61. [MedLine: 20445223]. Links Simopoulos 1971 Simopoulos AM, Pinto A, Uhlenhuth EH, Mcgee J. Old wine in new bottles: decreased hostility in chronic psychotic inpatients treated with diphenylhydantoin (Dilantin). 5th World Congress of Psychiatry. Ciudad de Mexico. Ciudad de Mexico: 1971:abstract 1077. Simpson 1974 Simpson GM, Varga E, Reiss M, Cooper TB, Bergner PE, Lee JH. Bioequivalency of generic and brand-named chlorpromazine. Clinical Pharmacology and Therapeutics 1974;15:631-41. Links Simpson 1980 Simpson GM, Cooper TB, Bark N, Sud I, Lee JH. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Archives of General Psychiatry 1980;37:205-8. Links Singh 1974 Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Diseases of the Nervous System 1976;37:191-6. Links Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Journal of the Bronx State Hospital 1974;2:173-83. Links Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benzotropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Psychopharmacologia 1975;43:103-13. Links Singh MM, Kay SR. Therapeutic reversal with benztropine in schizophrenics: practical and theoretical significance. Journal of Nervous and Mental Disease 1975;160:258-66. Links Singh 1990 Singh H, Hunt JI, Vitiello B, Simpson GM. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Journal of Clinical Psychiatry 1990;51:319-21. Links Small 1987 Small J, Milstein V, Small IF, Miller MJ, Kellams JJ, Corsaro CJ. Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia. Clinical Electroencephalography 1987;18:124-35. Links Smith 1958 Smith JA, Christian D, Rutherford A, Mansfield E. A comparison of triflupromazine (Vesprin), chlorpromazine and placebo in 85 chronic patients. American Journal of Psychiatry 1958;115:253-4. Links Smith 1960 Smith ME. A comparative controlled study with chlordiazepoxide. American Journal of Psychiatry 1960;117:362-3. Links Smith 1967 Smith K, Surphlis WRP, Gynther MD, Shimkunas AM. ECT-chlorpromazine and chlorpromazine compared in the treatment of schizophrenia. Journal of Nervous and Mental Disease 1967;144:284-90. Links Sommerness 1957 Sommerness MD, Lucero RJ, Hamlon JS, Mahowald AM. Chlorpromazine: a controlled study with highly disturbed patients. Diseases of the Nervous System 1957;18:16-20. Links South-East 1961 South-East Region (Scotland) Therapeutic Trials Committee. Controlled trial of Prochlorperazine (Stemetil) in schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1961;107:514-22. [MedLine: 87204515]. Links Soyka 1968 * Soyka D. The effect of psychopharmacological drugs and other central nervous system effecting drugs on experimental nystagmus [Die Wirkung von Psychopharmaka und anderen zentral wirksamen substanzen auf den experimentellen Nystagmus]. Fortschritte Der Neurologie, Psychiatrie Und Ihrer Grenzgebiete 1968;36:526-39. Links Spiegel 1967 Spiegel DE, Keith-Spiegel P. The effects of carphenazine, trifluoperazine and chlorpromazine on ward behavior, physiological functioning and psychological test scores in chronic schizophrenic patients. Journal of Nervous and Mental Diseases 1967;144:111-6. Links Spohn 1974 Spohn HE, Lacoursiere RB, Williams RO. The effect of chlorpromazine on visual information processing in normal subjects. Journal of Nervous and Mental Disease 1974;159:198-204. Links Sugerman 1964 Pfeiffer CC, Goldstein L, Murphree HB, Sugerman AA. Time-series frequency analysis, and electrogenesis of the EEGs of normals and psychotics before and after drugs. American Journal of Psychiatry 1965;122:1147-55. Links Sugerman AA, Goldstein L, Murphree HB, Pfieffer CC, Jenney EH. EEG and behavioural changes in schizophrenia. Archives of General Psychiatry 1964;10:340-4. Links Syvalahti 1997 Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, Dahl ML, Salokangas RK. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. Journal of International Medical Research 1997;25(1):24-32. [MedLine: 97179384]. Links Talbot 1964 Talbot DR. Are tranquilizer combinations more effective than a single tranquilizer?. American Journal of Psychiatry 1964;121:597-600. Links Tassis 1959 Tassis JA. Full Coma Insulin therapy, Chlorpromazine and Electoconvulsive Treatment. A control study of 600 Schizophrenic patients. Medical journal of Malaya 1959;14:135-43. Links Teja 1975 Teja JS, Grey WH, Clum JM, Warren C. Tranquilizers or anti-depressants for chronic schizophrenics: a long-term study. Australian and New Zealand Journal of Psychiatry 1975;9:241-7. Links Tenenblatt 1956 Tenenblatt SS, Spagno A. A controlled study of chlorpromazine therapy in chronic psychotic patients. Journal of Clinical &amp;amp; Experimental Psychopathology 1956;17:81-92. Links Terminska 1989 Terminska K, Mrowiec W. [Badanie porownawcze wplywu perazyny, flufenazyny, trifluoroperazyny, chloropromazny i haloperydolu na objawy pierwotne i deficytowe pierwszego zachorowania na schizofrenie paranoidalna]. Psychiatria Polska 1989;23:24-30. Links Tetreault 1969 Tetreault L, Bordeleau JM, Albert JM, Rajotte P. Comparative study of fluphenazine ethanate, fluphenazine bichlorhydrate and placebos in chronic schizophrenics [Etude comparative de l'enanthate de fluphenazine, du bichlorhydrate de fluphenazine et du placebo chez le schizophrene chronique]. Canadian Psychiatric Association Journal 1969;14(2):191-8. [MedLine: 69202908]. Links Thorpe 1956 Thorpe J, Baker A. A research method to assess a new tranquillizing drug. British Journal of Psychiatry 1956;102:790-5. Links Tourlentes 1958 Tourlentes T L, Hunsicker A L, Hurd D E. Chlorpromazine and Communication Processes. A.M.A. Archives of Neurology and Psychiatry 1958;79:468-73. Links Troshinsky 1962 Troshinsky CH, Aaronson HG, Stone RK. Maintenance phenothiazines in aftercare of schizophrenic patients. Pennsylvania Psychiatric Bulletin 1962;2:11-5. Links Turner 1956 Turner M, Berard, E, Turner N, Franco N. Changes in the Electroencephalogram, the Electrodermogram, and the Electromyogram Provoked by Chlorpromazine in Man. Abstracts of World Medicine 1956;20:177. Links Turner 1966 Turner P. A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency. Journal of Pharmacy and Pharmacology 1966;18:836. Links Urquhart 1959 Urquhart R, Forrest AD. Clinical trial of promazine hydrochloride and acetylpromazine in chronic schizophrenic patients. British Journal of Psychiatry 1959;105:260-4. Links Van Praag 1975 van Praag HM, Dols LC, Schut T. Biochemical versus psychopathological action profile of neuroleptics. A comparative study of chlorpromazine and oxypertine in acute psychotic disorders. Comprehensive Psychiatry 1975;16:255-63. Links van Praag HM, Korf J. The dopamine hypothesis of schizophrenia. Some direct observations. In: van Praag HM editor(s). On the origin of schizophrenic psychoses. Amsterdam: De Erven Bohn BV, 1975:81-98. Vestre 1961 Vestre ND. An experimental study of the effects of chlorpromazine on association learning in schizophrenic patients. Dissertation Abstracts 1961:2374. Vinar 1973 Vinar O. Whom do neuroleptic drugs help?. Psychopharmacology, Sexual Disorders and Drug Abuse. Amsterdam, Netherlands: North-Holland, 1973:247-56. Volavka 1983 Volavka J, Hui KS, Anderson B, Nemes Z, O'Donnell J, Lajtha A. Short-lived effect of (des-tyr)-gamma-endorphin in schizophrenia. Psychiatry Research 1983;10:243-52. Links Warner 1996 Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatrica Scandinavica 1996;93:311-3. Links Weir 1968 Weir TW, Kernohan GA, MacKay DN. The use of pericyazine and chlorpromazine with disturbed mentally subnormal patients. British Journal of Psychiatry 1968;114:111-2. Links Welbel 1980 Welbel L. [Roznice w dziallaniu klinicznym niektorych neuroleptykow]. Psychiatria Polska 1980;14:113-8. Links Whitehead 1958 Whitehead WA, Thune LE. The effects of chlorpromazine on learning in chronic psychotics. Journal of Consulting Psychology 1958;22:379-83. Links Wilcott 1962 Wilcott RC, Helper MM, Garfield SL. Some Psychophysiological Effects of Chlorpromazine on Emotionally Disturbed Children. Journal of Nervous and Mental Diseases 1962;135:233-8. Links Wilson 1961 Wilson IC, McKay J, Sandifer MG. A double-blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia. British Journal of Psychiatry 1961;107:90-9. Links Winkelman 1957 Winkelman N W. An Appraisal of Chlorpromazine. General Principles for Administration of Chlorpromazine, Based on Experience with 1,090 Patients. American Journal of Psychiatry 1957. Links Winter 1956 Winter WD, Frederickson WK. The short-term effects of chlorpromazine on psychiatric patients. Journal of Consulting Psychology 1956;20:431-4. Links Wode-Helgodt 1977 Wode-Helgodt B, Eneroth P, Fyro B, Gullberg B, Sedvall G. Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatrica Scandinavica 1977;56:280-93. Links Wold 1959 Wold PN. A long term evaluation of chlorpromazine in six chronic schizophrenic patients. American Journal of Psychiatry 1959;116:461-2. Links Wolpert 1969 Wolpert A, Yaryura TJA, White L, Merlis S. Triiodothyronine and phenothiazines in schizophrenia. Diseases of the Nervous System 1969;30(7):487-9. [MedLine: 69288496]. Links Wyatt 1997 Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychological Medicine 1997;27:261-8. Links Yorkston 1977 Yorkston NJ, Zaki SA, Pitcher DR, Gruzelier JH, Hollander D, Sergeant HG. Propranolol as an adjunct to the treatment of schizophrenia. Lancet 1977;2:575-8. Links Yuan-guang 1994 Yuan-Guang C, Guang-rong X, Jing Ping Z. A study on the relationship between the chlorprmazine plasma levels and clinical response to chlorpromazine administrations in the schizophrenics. Chinese Journal of Neurology and Psychiatry 1994;27(3):153-5. Links Zeller 1956 Zeller WW, Graffagnino PN, Cullen CF, Rietman HJ. Use of chlorpromazine and reserpine in the treatment of emotional disorders. Journal of the American Medical Association 1956;160:179-84. Links References to studies awaiting assessment Magner 1974 Magner O, Moller S. The blood pressure lowering effect of chlorpromazine and methylperon (Buronil) [Blodtryksnedsaettende effekt af kllrpromazin og metylperon (Buronil)]. Ugeskrift for Laeger 1974;136:809-11. Links Rojo-Sierra 1971 Rojo-Sierra M, Alonso J, D&amp;#237;ez E, Giner J, Lloret E. [Aportaci&amp;#243;n sobre el espectro psicofarmacoter&amp;#225;pico del R P. 19 366 y R P. 19 552]. 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Ciudad de Mexico, Mexico. 1971:495-6. Vinar 1976 Vinar O, Taussigova D. Schizophrenic syndromes improving without neuroleptic drug treatment [Schizofrenni syndromy zlepsujici se bez neurolepticke lecby]. Ceskoslovenska Psychiatrie 1976;72(3):176-81. [MedLine: 77001715]. Links Yagi 1976 Yagi G. A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Rinsho Hyoka (Clinical Evaluation) 1976;4(3):351-403. Links Additional references Ahmed 1998 Ahmed I, Soares K, Seifas R, Adams CE. Randomised controlled trials in Archives of General Psychiatry (1959-1995): a prevalence study. Archives of General Psychiatry 1998;55(8):754-5. References to studies included in this review Abrams 1958 {published data only} Abrams J. Chlorpromazine in the treatment of chronic schizophrenia. Diseases of the Nervous System 1958;19:20-8. Links Baker 1959 {published data only} Baker JP. A controlled trial of ethylcrotonylurea. British Journal of Psychiatry 1959;105:852-62. Links Ban 1975 {published data only} Ban TA, Lehmann HE, Sterlin C, Climan M. Comprehensive clinical studies with thiothixene. Diseases of the Nervous System 1975;36:473-7. Links Bishop 1963 {published data only} Bishop M, Gallant DM. Behavioral toxicity associated with benzquinamide (Quantril) therapy in schizophrenic patients. American Journal of Psychiatry 1963;120:180-1. Links Borison 1991 {published data only} Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin 1991;27:103-6. Links Borison RL, Dren AT, Diamond BI. Sigma receptor antagonism and antipsychotic actions in schizophrenic patients. European Journal of Pharmacology 1990;183:2323. Links Chouinard 1990 {published data only} Chouinard G. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatria Scandinavica Supplementum 1990;358:111-9. Links Clark 1961 {published data only} Clark ML, Ray T, Paredes A, Costiloe J, Chappell J, Hagans J, Wolf S. Chlorpromazine in chronic schizophrenic women. I. Experimental design and effects at maximum point of treatment. Psychopharmacologia 1961;2:107-36. Links Clark ML, Ray TS, Ragland RE. Chlorpromazine in chronic schizophrenic women: rate of onset and rate of dissipation of drug effects. Psychosomatic Medicine 1963;25:212-17. Links Ray TS, Ragland RE, Clark ML. Chlorpromazine in chronic schizophrenic women: comparison of differential effects on various psychological modalities during and after treatment. Journal of Nervous and Mental Diseases 1964;138:348-53. Links Clark 1967 {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, Wolf S. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosomatic Medicine 1967;29:634-42. Links Clark 1968a {published data only} Clark ML, Huber WK, Kyriakopoulos AA, Ray TS, Colmore JP, Ramsey HR. Evaluation of trifluperidol in chronic schizophrenia. Psychopharmacologia 1968;12:193-203. Links Clark 1968b {published data only} Clark ML, Ray TS, Huber WK, Willis D, Ramsey HR. Evaluation of butaperazine in chronic schizophrenia. Clinical Pharmacology and Therapeutics 1968;97:57-64. Links Clark 1970a {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. Clinical Pharmacology and Therapeutics 1970;11:680-8. Links Serafetinides EA, Willis D, Clark ML. The EEG effects of chemically and clinically dissimilar antipsychotics: molindone vs. chlorpromazine. International Pharmacopsychiatry 1971;6:77-82. Links Clark 1970b {published data only} Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark M, Ramsey H, Rahhal D, Serafetinides E, Wood F, Costiloe J. Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships. Archives of General Psychiatry 1972;27:479-83. Links Clark ML, Ramsey HR, Ragland RE, Rahhal DK, Serafetinides EA, Costiloe JP. Chlorpromazine in chronic schizophrenia - behavioral dose-response relationships. Psychopharmacologia 1970;18:260-70. Links Serafetinides EA, Willis D, Clark ML. EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking. Biological Psychiatry 1972;4:251-6. Links Clark 1971 {published data only} Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP. Drug treatment in newly admitted schizophrenic patients. Archives of General Psychiatry 1971;25:404-9. Links Clark 1972 {published data only} Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972;33:783-91. Links Serafetinides EA, Willis D, Clark ML. The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects. International Pharmacopsychiatry 1971;6:38-44. Links Clark 1977 {published data only} Clark ML, Paredes A, Costiloe JP, Wood F. Evaluation of butaclamol in chronic schizophrenic patients. Journal of Clinical Pharmacology 1977;17:529-36. Links Cohen 1968 {published data only} Cohen M, Freedman N, Englehardt DM. Family interaction patterns, drug treatment, and change in social aggression. Archives of General Psychiatry 1968;19(1):50-6. Links Graupner OK, Kalman EV. Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments [Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)]. Psychopharmacologia 1972;27(4):343-7. [MedLine: 73085373]. Links Cole 1964 {published data only} * Cole JO, Goldberg SC, Klerman GL National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 1964;10:246-61. Links Goldberg S, Klerman G, Cole J. Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. British Journal of Psychiatry 1965;111:120-33. Links Goldberg SC, Mattsson NB. Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System 1968;29:153-8. Links Cooper 2000 {published and unpublished data} Cooper SJ, Butler A, Tweed J, Welch CP. Zotepine in the treatment of chronic schizophrenia. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria: September 13-17, 1997. Cooper SJ, Raniwalla J, Welch C. Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo. XXth Collegium Internationale Neuro-psychopharmacologicum. Melbourne, Australia. Melbourne, Australia: 1996. * Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C. A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica 2000;101(3):218-25. [MedLine: 20184895]. Links Cooper SJ, Tweed J, Raniwalla J, Welch C. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Unpublished manuscript 1996. Cooper SJ, Welch CP. A comparison of zotepine and chlorpromazine on BPRS subscores. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria: September 13-17, 1997. Dean 1958 {published data only} Dean EF, Buker S. Schizophrenia treated with and without chlorpromazine. Rocky Mountain Medical Journal 1958;55:47-50. Links Engelhardt 1960 {published data only} Engelhardt D, Freedman N, Rosen B, Mann D, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. Archives of General Psychiatry 1964;11:162-9. Links Engelhardt DM, Freedman N, Glick BS, Hankoff LD, Mann D, Margolis R. Prevention of psychiatric hospitalization with use of psychopharmacological agents. Journal of the American Medical Association 1960;173:147-9. Links Engelhardt DM, Margolis RA, Rudorfer L, Paley HM. Physician bias and the double-blind. Archives of General Psychiatry 1969;20(3):315-20. Links Engelhardt DM, Rosen B, Freedman N, Mann D, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure. Journal of the American Medical Association 1963;186:981-3. Links Engelhardt DM, Rosen B, Freedman N, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization - a reevaluation. Archives of General Psychiatry 1967;16:98-101. Links Freedman N, Cutler R, Engelhardt DM, Margolis R. On the modification of paranoid symptomatology. Journal of Nervous and Mental Disease 1967;144:29-36. Links Freedman N, Cutler R, Engelhardt DM, Margolis R. On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines. Journal of Nervous and Mental Disease 1970;150:68-76. Links Rosen B, Engelhardt DM, Freedman N. The hospitalization proneness scale as a predictor of response to phenothiazine treatment. Journal of Nervous and Mental Disease 1968;6:476-80. Links Fink 1963 {published data only} Belmont I, Pollack M, Willner A, Klein D, Fink M. The effects of imipramine and chlorpromazine on perceptual analytic ability, perceptual analytic responsivity and memory as revealed in rorschach responses. Journal of Nervous and Mental Disease 1963;137(1):42-50. Links * Fink M, Pollack M, Klein DF, Blumberg AG, Belmont I, Karp E, Kramer JC, Willner A. Comparative studies of chlorpromazine and imipramine. I. Drug discriminating patterns. Neuropsychopharmacology 1963;3:370-2. Links Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Archives of General Psychiatry 1967;16:118-26. Links Klein DF. Psychiatric diagnosis and a typology of clinical drug effects. Psychopharmacologia 1968;13:359-86. Links Klein DF, Honigfeld G, Feldman S. Prediction of drug effect by diagnostic decision tree. Diseases of the Nervous System 1968;29:159-87. Links Levenstein S, Klein DF, Pollack M. Follow up study of formerly hospitalized voluntary psychiatric patients: the first two years. American Journal of Psychiatry 1966;122:1102-8. Links Fleming 1959 {published data only} Fleming B, Spencer A, Whitelaw E. A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis. British Journal of Psychiatry 1959;105:349-58. Links Grygier 1958 {published data only} Grygier P, Waters MA. Chlorpromazine used with an intensive occupational therapy program. A.M.A. Archives of Neurology and Psychiatry 1958;79:697-705. Links Hall 1955 {published data only} Hall RA, Dunlap DJ. A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics. Journal of Nervous and Mental Disease 1955;122:301-14. Links Hollister LE, Hall RA. Phenothiazine derivatives and morphologic changes in the liver. American Journal of Psychiatry 1966;123:211-2. Links Hamill 1975 {published data only} Hamill WT, Fontana AF. The immediate effects of chlorpromazine in newly admitted schizophrenic patients. American Journal of Psychiatry 1975;132:1023-6. Links Hamilton 1960 {published data only} Hamilton M, Smith A, Lapidus HR, Cadogan EP. A controlled trial of Thiopropazate Dihydrochloride (Dartalan), Chlorpromazine and occupational therapy in chronic schizophrenics. British Journal of Psychiatry 1960;106:40-55. Links Hine 1958 {published data only} Hine FR. Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic. Journal of Nervous and Mental Diseases 1958;127:220-7. Links Hogarty 1973 {published data only} Goldberg S, Schooler N, Hogarty G, Roper M. Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry 1977;34:171-84. Links Hogarty G, Goldberg S. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Archives of General Psychiatry 1973;28:54-64. Links Hogarty G, Goldberg S, Schooler N. Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients. Archives of General Psychiatry 1974;31:609-18. Links Hogarty G, Goldberg S, Schooler N, Ulrich R. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Archives of General Psychiatry 1974;31:603-8. Links Hogarty G, Ulrich R. Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry 1977;34:297-301. Links Hogarty GE, Munetz MR. Pharmacogenic depression among outpatient schizophrenic patients - a failure to substantiate. Journal of Clinical Psychopharmacology 1984;4:17-24. Links Klein 1973 {published data only} Klein D, Rosen B. Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients. Archives of General Psychiatry 1973;29:480-5. Links Kurland 1961 {published data only} Kurland AA, Hanlon TE, Tatom MH, Ota KY, Simopoulos AL. The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness. Journal of Nervous and Mental Disease 1961;133:1-18. Links Kurland AA, Hanlon TE, Tatom MH, Simopoulos AL. Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations. Journal of Nervous and Mental Disease 1961;132:61-74. Links Kurland AA, Nilsson GL, Hanlon TE. Pre-admission drug treatment of state psychiatric hospital patients. American Journal of Psychiatry 1959;115:1028-9. Links Kurland AA, Sutherland GF. The phenothiazine tranquilizers - their neurological complications and significance. Psychosomatics 1960;1:192-4. Links Letemendia 1967 {published data only} Letemendia F, Harris AD. Chlorpromazine and the untreated chronic schizophrenic: a long-term trial. British Journal of Psychiatry 1967;113:950-8. Links Nishikawa 1982 {published data only} Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology 1982;77:301-4. Links Payne 1960 {published data only} Payne P. A Comparison of Trifluopromazine, Chlorpromazine and a Placebo in Twenty-one Chronic Schizophrenic Patients. Manitoba Medical Review 1960:196-8. Links Peet 1981 {published data only} Peet M, Bethell M, Coates A, Khamnee A, Hall P, Cooper S, King D, Yates R. Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo. British Journal of Psychiatry 1981;139:105-11. Links Prien 1968 {published data only} Crane GE. Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie 1968;2:209-18. Links De Long SL. Incidence and significance of chlorpromazine-induced eye changes. Diseases of the Nervous System 1968;29:19-22. Links Gardos G, Cole JO, LaBrie RA. A 12-year follow-up study of chronic schizophrenics. Hospital and Community Psychiatry 1982;33:983-4. Links Mandel A, Gross M. Agranulocyctosis and phenothiazines. Diseases of the Nervous System 1968:32-6. Links Prien R, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group. Archives of General Psychiatry 1968;18:482-95. Links Prien R, DeLong S, Cole J, Levine J. Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry 1970;23:464-8. Links Prien RF, Cole JO, Belkin NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry 1968;115:679-86. Links Prien RF, Levine J, Cole JO. Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System 1970;31:739-45. Links Rappaport 1978 {published data only} Rappaport M, Hopkins HK, Hall K, Belleza T, Silverman J. Are there schizophrenics for whom drugs may be unnecessary or contraindicated?. International Pharmacopsychiatry 1978;13:100-11. Links Reardon 1966 {published data only} Reardon JD, Abrams S. Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System 1966;27:265-70. Links Reschke 1974 {published data only} Reschke RW. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Diseases of the Nervous System 1974;35:112-5. Links Saretsky 1966 {published data only} Saretsky T. Effects of chlorpromazine on primary-process thought manifestations. Journal of Abnormal Psychology 1966;71:247-52. Links Schiele 1961 {published data only} Schiele BC, Vestre ND, Stein KE. A comparison of thioridazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients. Journal of Clinical and Experiemental Psychopathology 1961;22:151-62. Links Serafetinides 1972 {published data only} Serafetinides EA, Clark ML. Psychological effects of single dose antipsychotic medication. Biological Psychiatry 1973;7:263-7. Links Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Diseases 1972;154:31-42. Links Serafetinides EA, Willis D. A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry 1973;8:245-7. Links Serafetinides EA, Willis D, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Diseases 1972;155:366-9. Links Shepherd 1956 {published data only} Shepherd M, Watt DC. A controlled clinical study of chlorpromazine and reserpine. Journal of Neurology, Neurosurgery and Psychiatry 1956;19:232-5. Links Simon 1958 {published data only} Simon W, Wirt AL, Wirt RD, Halloran AV. Long-term follow-up study of schizophrenic patients. Archives of General Psychiatry 1965;12:510-5. Links Simon W, Wirt R, Wirt A, Halloran A, Hinckley R, Lund J, Hopkins GW. A controlled study of the short-term differential treatment of schizophrenia. American Journal of Psychiatry 1958;114:1077-86. Links Smith 1961 {published data only} Smith ME. A clinical study of chlorpromazine and chlordiazepoxide. Connecticut State Medical Journal 1961;25:153-7. Links Somerville 1960 {published data only} Somerville DM, Cohen PH, Graves GD. Phenothiazine side-effects. Comparison of two major tranquillizers. British Journal of Psychiatry 1960;106:1417-24. Links Spohn 1977 {published data only} Spohn H, Lacoursiere R, Thompson K, Coyne L. Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Archives of General Psychiatry 1977;34(6):633-44. Links Tetreault 1969a {published data only} Tetreault L. Comparative study of two drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques 1969;22:221-8. Links Tetreault L, Bordeleau JM, Gauthier R, Vulpe M, Lapointe L. Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients. Diseases of the Nervous System 1969;30(2):74-84. Links Vaughan 1955 {published data only} Vaughan GF, Leiberman DM, Cook LC. Chlorpromazine in psychiatry. Lancet 1955;1:1083-7. Links Walsh 1959 {published data only} Walsh GP, Walton D, Black DA. The relative efficacy of &amp;quot;Vespral&amp;quot; and chlorpromazine in the treatment of a group of chronic schizophrenic patients. British Journal of Psychiatry 1959;105:199-209. Links Zuoze 1986 {published data only} Zuoze L, Youjun W, Shuzhong Z, Anguo H, Yuande C. Therapeutic effect of He-Ne laser irradiation of Point Erman in schizophrenic auditory hallucination - a clinical assessment. Journal of Traditional Chinese Medicine 1986;6:253-6. Links References to studies excluded from this review Abse 1960 Abse WD, Dahlstrom WG, Tolley AG. Evaluation of tranquilizing drugs in the management of acute mental disturbance. American Journal of Psychiatry 1960;117:973-80. Links Acker 1965 Acker CW. An exploration of the autonomic effects of phenothiazines. Psychopharmacologia 1965;7:150-8. Links Affleck 1966 Affleck DC, Eaton MT, Mansfield E. The action of a medication and the physician's expectations. Nebraska State Medical Journal 1966;51:331-4. Links Agarwal 1985 Agarwal AK, Winny GC. Role of ECT phenothiazine combination in schizophrenia. Indian Journal of Psychiatry 1985;27:233-6. Links Akimoto 1966 Akimoto H, Shimazaki T, Shibata N, Sato Y, Takahashi R. Current status of pharmacotherapy in schizophrenia. Folia Psychiatrica et Neurologica Japonica 1966;20(1):1-8. [MedLine: 67213329]. Links Alpert 1966 Alpert M, Hekimian LJ, Frosch WA. Evaluation of treatment with recorded interviews. American Journal of Psychiatry 1966;122:1258-64. Links Alpert 1978 Alpert M, Friedhoff A, Marcos L, Diamond F. Paradoxical reaction to L-dopa in schizophrenic patients. American Journal of Psychiatry 1978;135:1329-32. Links Alson 1964 Alson E, Hastings K. The use of adjective check lists with psychotic patients: the problem of pseudo-responses. Journal of Clinical Psychology 1964;20(4):462-3. Links Aman 1985 Aman MG, Singh NN. Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment. Journal of Mental Deficiency Research 1985;29(2):187-95. [MedLine: 85293054]. Links Amin 1977 Amin MM, Ban TA, Lehmann HE. A standard-controlled clinical study with benzquinamide in the treatment of chronic schizophrenic patients. Psychopharmacology Bulletin 1977;13:20-1. Links Ananth 1972 Ananth JV, Vacaflor L, Kekhwa G, Sterlin C, Ban TA. Nicotinic acid in the treatment of newly admitted schizophrenic patients: a placebo-controlled study. Internationale Zeitschrift Fur Klinische Pharmakologie Therapie und Toxikologie 1972;5(4):406-10. [MedLine: 72239308]. Links Andrews 1976 Andrews P, Hall JN, Snaith RP. A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. British Journal of Psychiatry 1976;128:451-5. Links Ashcroft 1961 Ashcroft GW, MacDougall EJ, Barker PA. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1961;107:287-93. [MedLine: 72239308]. Links Ayers 1984 Ayers T, Liberman RP, Wallace CJ. Subjective response to antipsychotic drugs: failure to replicate predictions of outcome. Journal of Clinical Psychopharmacology 1984;4:89-93. Links Azima 1954 Azima H, Ogle W. Effects of Largactil in mental syndomes. Canadian Medical Association Journal 1954;71:116-21. Links Bagadia 1981 Bagadia VN, Shah LP, Pradhan PV, Doshi J, Abhyankar R. Evaluation of cognitive effects of ECT: preliminary observations. Indian Journal of Psychiatry 1981;23:324-9. Links Ban 1977 Ban TA, Lehmann HE, Deutsch M. Negative findings with megavitamins in schizophrenic patients - preliminary report. Communications in Psychopharmacology 1977;1:119-22. Links Hoffer, J. Megavitamin treatment of schizophrenia. Canadian Psychiatric Association Journal 1975;20:492-5. Links Beech 1990 Beech A, Powell TJ, McWilliam J, Claridge GS. The effect of a small dose of chlorpromazine on a measure of 'cognitive inhibition'. Personality and Individual Differences 1990;11:1141-5. Links Benaim 1960 Benaim S. The effect of chlorpromazine on the incidence of epileptic phenomena during insulin coma therapy: A statistical investigation. Journal of Mental Science 1960;106:317-21. Links Bennett 1956 Bennett A, Ford F, Turk RE. Clinical investigation of chlorpromazine and reserpine in private psychiatric practice. American Journal of Psychiatry 1956;112:782-7. Links Blumberg 1964 Blumberg AG, Klein DF, Pollack M. Effects of chlorpromazine and imipramine on systolic blood pressure in psychiatric patients: Relationships to age, diagnosis and initial blood pressure. Journal of Psychiatric Research 1964;2(1):51-60. Links Blumberg 1969 Blumberg AG, Klein DF. Chlorpromazine-procyclidine and imipramine: effects on thyroid function in psychiatric patients. Clinical Pharmacology and Therapeutics 1969;10:350-4. Links Boullin 1975 Boullin DJ, Woods HF, Grimes RP, Grahame-Smith DG, Wiles D, Gelder MG, Kolakowska T. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. British Journal of Clinical Pharmacology 1975;2:29-35. Links Bowes 1956 Bowes, HA. The ataractic drugs: the present position of chlorpromazine, frenquel, pacatal, and reserpine in the psychiatric hospital. American Journal of Psychiatry 1956;113:530-9. Links Bressler 1971 Bressler B, Friedel RO. A comparison between chlorpromazine and thiothixene in a Veterans Administration Hospital population. Psychosomatics 1971;12:275-7. Links Brizer 1985 Brizer DA, Hartman N, Sweeney J, Millman RB. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. American Journal of Psychiatry 1985;142(9):1106-7. Links Burnett 1975 Burnett GB, Little SR, Graham N, Forrest AD. The assessment of thiothixene in chronic schizophrenia. A double-blind controlled trial. Diseases of the Nervous System 1975;36:625-9. Links Cabrera Gomez 1994 Cabrera Gomez JA, Cordero Gutierrez JR, Fernandez Lopez O, Reyes Gutierrez B, Romero Garcia K, Simon Consuegra J, Feas Cruz. Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon. Biotherapy 1994;7(1):27-37. Links Caffey 1963 * Caffey E, Forrest I, Frank T, Klett CJ. Phenothiazine excretion in chronic schizophrenics. American Journal of Psychiatry 1963;120:578-82. Links Caffey EM, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, Rothstein C. Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases 1964;17(4):347-58. Links Caffey 1975 Caffey EMJ, Prien RF. Practical considerations on treatment with antipsychotic preparations [Prakticheskie soobrazheniia o lechenii antipsikhoticheskimi preparatami]. Zhurnal Nevropatologii i Psikhiatrii 1975;75:1399-401. Links Campbell 1972 Campbell M, Fish B, Shapiro T, Floyd A. Acute responses of schizophrenic children to a sedative and a 'stimulating' neuroleptic: a pharmacologic yardstick. Current Therapeutic Research 1972;14:759-66. Links Campbell M, Fish B, Shapiro T, Floyd A. Thiothixene in young disturbed children. A pilot study. Archives of General Psychiatry 1970;23:70-2. Links Cardone 1969 Cardone S, Olson R. Chlorpromazine and body image. Effects on chronic schizophrenics. Archives of General Psychiatry 1969;20:576-82. Links Carrillo 1971 Carrillo C. Pharmacologlal treatment of the emotionally unstable character disorder. Vth World Congress of Psychiatry. Ciudad de Mexico. 1971. Casey 1960 Casey JF, Bennet IF, Lindley CJ, Hollister LE, Gordon MH, Springer NN. Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Archives of General Psychiatry 1960;2:210-20. Links Casey 1961 Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM. Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry 1961;117:997-1003. Links Chacon 1972 Chacon C, Harper P. Clinical and work performance variables in phenothiazine therapy of schizophrenia. Acta Psychiatrica Scandinavica 1973;49:65-76. Links Chacon Carlos, Harper P, Harvey GF. Work study in the assessment of the effects of phenothiazines in schizophrenia. Comprehensive Psychiatry 1972;13(6):549-54. [MedLine: 73051431]. Links Childers 1961 Childers RT, Therrien R. A comparison of the effectiveness of triluoperazine and chlorpromazine in schizophrenia. American Journal of Psychiatry 1961;118:552-4. Links Chouinard 1977 Chouinard G, Annable L, Kolivakis TN. Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. Journal of Clinical Pharmacology 1977;17(2-3):162-7. [MedLine: 77094284]. Links Chouinard-G 1983 Chouinard-G, Annable-L. Fluspirilene in the treatment of newly admitted schizophrenic patients. Psychopharmacology Bulletin 1983;19(1):136-8. Links Claghorn 1983 Claghorn J, Abuzzahab F, Wang R, Larson C, Gelenberg A, Klerman G, Tuason V, Steinbook R. The current status of Clozapine. Psychopharmacology Bulletin 1983;19:138-40. Links Clark 1970c Clark ML, Serafetinides EA, Wise JB, Colmore JP. Ocular pigment deposits: drug-induced false-positives. Journal of the American Medical Association 1970;214:2339. Links Clark 1970d Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics 1970;11:883-9. Links Clark 1975 Clark ML, Kaul PN. A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. In: Gottschalk LA, Merlis S editor(s). Pharmacokinetics of psychoactive drugs. New York: Spectrum Publications, 1976:191-7. Clark ML, Kaul PN. A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. Psychopharmacology Bulletin 1975;11:28-30. Links Clark ML, Kaul PN, Whitfield LR. Chlorpromazine kinetics and clinical response. Psychopharmacology Bulletin 1978;14:43-5. Links Cole 1967 Cole JO, Schooler NR. Differences in clinical effects of three phenothiazines in &amp;quot;acute&amp;quot; schizophrenia. Diseases of the Nervous System 1967;28:369-83. Links Coons 1962 Coons WH, Boyd BA, White JG. Chlorpromazine, trifluoperazine and placebo with long term mental hospital patients. Canadian Psychiatric Association Journal 1962;7:159-63. [MedLine: 62022417]. Links Cowden 1956 Cowden RC, Zax M, Hague JR, Finney RC. Chlorpromazine: alone and as an adjunct to group psychotherapy in the treatment of psychiatric patients. American Journal of Psychiatry 1956;4:898-902. Links Crane 1970 Crane GE. High doses of trifluperazine and tardive dyskinesia. Archives of Neurology 1970;22(2):176-80. [MedLine: 70065772]. Links Crane 1971 Crane GE. Persistence of neurological symptoms due to neuroleptic drugs. American Journal of Psychiatry 1971;127:1407-10. Links Crow 1986 Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. II. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986;148:120-7. Links Johnstone EC, Crow TJ, Johnson AL, MacMillan JF. The Northwick Park study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. British Journal of Psychiatry 1986;148:115-20. Links MacMillan JF, Crow TJ, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. III. Short-term outcome in trial entrants and trial eligible patients. British Journal of Psychiatry 1986;148:128-33. Links Curry 1972 Curry SH, Adamson L. Double-blind trial of fluphenazine decanoate. Lancet 1972;2:543-4. Links Cutler 1957 Cutler RP, Monroe JJ, Anderson TE. Effects of &amp;quot;tranquilizers&amp;quot; upon pathological activity in psychotic patients: II. Reserpine. Archives of Neurology and Psychiatry 1957;78:61-8. Links Dally 1966 Dally P, Sargant W. Treatment and outcome of anorexia nervosa. British Medical Journal 1966;2:793-5. Links Danion 1992 Danion JM, Peretti S, Grange D, Bilik M, Imbs JL, Singer L. Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers. Psychopharmacology 1992;108(3):345-51. [MedLine: 92396807]. Links Daston 1958 Daston PG. Stylus maze performance of chronic schizophrenics taking chlorpromazine. Journal of Consulting Psychology 1958;22(5):384. Links Daston 1959 Daston PG. Effects of two phenothiazine drugs on concentrative attention span of chronic schizophrenics. Journal of Clinical Psychology 1959;15:106-9. Links Davies 1973 Davies AL, O'Leary J. The use of chlorpromazine in schizophrenia. Nursing Times 1973;69:1694-5. Links Dean 1967 Dean G. Mefenamic acid and chlorpromazine in porphyria variegata. South African Medical Journal 1967;41:925-7. Links Den 2000 Den Boer JA, Vahlne J O, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Human Psychopharmacology 2000;15(3):179-89. Links Denber 1955 Denber HCB, Merlis S. Studies on Mescaline. VI. Therapeutic Aspects of the Mescaline-Chlorpromazine Combination. Journal of Nervous and Mental Diseases 1955;122:463. Links Denber 1956 Denber H, Bird EG. Chlorpromazine in the treatment of mental illness. III. The problem of depression. American Journal of Psychiatry 1956;112:1021. Links Denber 1957 Denber HCB. Chlorpromazine-diethazine in the treatment of depression. Diseases of the Nervous System 1957;18:76-9. Links Desager 1988 Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF. Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology Berlin 1988;96:63-6. Links Douglas 1969 Douglas KW, Hindley JP. A comparison of mesoridazine and chlorpromazine in chronic psychiatric patients. Journal of Clinical Pharmacology and The Journal of New Drugs 1969;9:176-82. Links Downing 1963 Downing RW, Ebert JN, Shubrooks SJ. Effect of phenothiazines on the thinking of acute schizophrenics. Perceptual and Motor Skills 1963;17(2):511-20. Links Dube 1981 Dube S, Sethi B. Efficacy of lithium in schizophrenia. Indian Journal of Psychiatry 1981;23(2):193-9. Links Eitan 1991 Eitan N, Levin Y, Ben-Artzi E, Levy A, Neumann M. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica 1992;85:74-6. Links Ekdawi 1966 Ekdawi MY, Fowke R. A controlled trial of anti-parkinson drugs in drug-induced parkinsonism. British Journal of Psychiatry 1966;112(487):633-6. Links Elkes 1954 Elkes J, Elkes C. Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients. British Medical Journal 1954;2:560-5. Links Feldman 1956 Feldman PE, Lacy BS, Walker AE, Garrez NJ. A controlled, blind study of effects of thorazine on psychotic behavior. Bulletin of the Menninger Clinic 1956;20:25-47. Links Fink 1958 Fink M, Shaw R, Gross GE, Coleman FS. Comparative study of chlorpromazine and insulin coma in therapy of psychosis. Journal of the American Medical Association 1958;166(15):1846-50. Links Fink 1965 Fink M, Klein DF, Kramer JC. Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders. Psychopharmacologia 1965;7:27-36. Links Fleischhacker 1995 Fleischhacker W. Broadening treatment perspectives of schizophrenia: a clinical update on seroquel. 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 - Oct 4; Venice, Italy. 1995. Fleming 1958 Fleming B, Currie J. Investigation of a new compound, B.W.203, and of Chlorpromazine in the treatment of psychosis. British Journal of Psychiatry 1958;104:749-57. Links Foote 1958 Foote E. Combined Chlorpromazine and Reserpine in the treatment of chronic psychotics. British Journal of Psychiatry 1958;104:201-5. Links Forrest 1967 Forrest GL, Bortner TW, Bakker CB. The role of personality variables in response to chlorpromazine, dextroamphetamine and placebo. Journal of Psychiatric Research 1967;5:281-8. Links Freed 1956 Freed H, Peifer CA. Treatment of hyperkinetic emotionally disturbed children with prolonged administration of chlorpromazine. American Journal of Psychiatry 1956;113:22. Links Freedman 1965 Freedman N, Engelhardt D, Mann D, Margolis R, London S. Communication of body complaints and paranoid symptom change under conditions of phenothiazine treatment. Journal of Personality and Social Psychology 1965;1(4):310-8. Links Freeman 1956 Freeman H, Arnold AL, Cline HS. Effects of chlorpromazine and reserpine in chronic schizophrenic patients. Diseases of the Nervous System 1956;17:213-9. Links Freeman H, Cline HS. Effects of chlorpromazine on chronic lobotomized schizophrenic patients. A.M.A. Archives of Neurology and Psychiatry 1956;76:500-7. Links Freeman 1973 Freeman Harry. A double blind comparison of mesoridazine and chlorpromazine in chronic schizophrenics. Diseases of the Nervous System 1973;34(6):289-93. [MedLine: 74114021]. Links Friedhoff 1960 Friedhoff A, Alpert M. The effect of chlorpromazine on the variability of motor task performance in schizophrenics. Journal of Nervous and Mental Disease 1960;131:110-6. Links Fromm 1956 Fromm GH, Forsberg IA. Controlled study on the value of chlorpromazine in allaying anxiety. Diseases of the Nervous System 1956;17:16-9. Links Gaitz 1955 Gaitz C M, Roy H, Thompson W, Kimbell I, Mullen A J, Pokorny A D. Evaluation of Chlorpromazine in Comparison with other Methods of treatments of hospitalized psychiatric patients, using the lorr multidimensional scale for rating psychiatric patients. Psychiatric Research Reports 1955;1:1984. Links Galbrecht 1968 Galbrecht CR, Klett CJ. Predicting response to phenothiazines: the right drug for the right patient. Journal of Nervous and Mental Disease 1968;147:173-83. Links Galdi 1988 Galdi J, Bonato RR. Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics. Canadian Journal of Psychiatry 1988;33:816-8. Links Gallant 1963 Gallant D, Bishop M, Steele C, Noblin CD. The relationship between serotonin antagonism and tranquilizing activity. American Journal of Psychiatry 1963;119:882. Links Gallant 1967 Gallant DM, Bishop MP, O'Meallie L. BL-KR140: a controlled evaluation in chronic schizophrenic patients previously stabilized on chlorpromazine. Current Therapeutic Research 1967;9:447-50. Links Gardner 1955 Gardner MJ, Hawkins HM, Judah LN, Murphree OD. Objective measurement of psychiatric changes produced by chlorpromazine and reserpine in chronic schizophrenia. Psychiatric Research Reports 1955;1:77-83. Links Gardos 1968 Gardos G, Rapkin RM, DiMascio A. Trifluoperazine and chlorpromazine in combination and individually. Current Therapeutic Research Clinical and Experimental 1968;10(12):609-12. [MedLine: 69054114]. Links Gardos 1976 Gardos G, Cole J O. Maintenance antipsychotic therapy: is the cure worse than the disease?. American Journal of Psychiatry 1976;133:32-6. Links Garfield 1962 Garfield SL, Helper MM, Wilcott RC, Muffly R. Effects of chlorpromazine on behaviour in emotionally disturbed children. Journal of Nervous and Mental Diseases 1962;135:147-54. Links Garmezy 1969 Garmezy N. Effects of censure and chlorpromazine on visual discrimination behavior of schizophrenic and alcoholic patients. Proceedings of the Annual Convention of the American Psychological Association 1969;4(2):491-2. Links Gauthier 1967 Gauthier R, Hillel J, Bordeleau J M, Tetreault L. Comparative study of trifluperidol and trifluoperazine in the treatment of acute schizophrenia. Union Medicale du Canada 1967;96:936-43. Links Gendron 1973 Gendron JL, Zimmermann RL, Schiele BC. A double blind comparison of AL 1021 and chlorpromazine in hospitalized schizophrenics. Current Therapeutic Research 1973;15(6):333-6. Links Gibbs 1956 Gibbs JJ, Wilkens B, Lauterbach CG. A controlled clinical psychiatric study of chlorpromazine. Journal of Clinical and Experimental Psychopathology 1957;18:269-83. Links Gibbs JJ, Wilkens B, Lauterbach CG. A controlled clinical psychiatric study of the drug chlorpromazine. American Journal of Psychiatry 1956;113:254-5. Links Gilgash 1957 Gilgash CA. Effects of Thorazine on Wechsler scores of adult catatonic schizophrenics. Psychological Reports 1957;3:561-4. Links Goldberg 1968 Goldberg SC, Mattsson NB. Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System 1968;29(5):S153-8. [MedLine: 68399894]. Links Goldberg 1970 Goldberg GJ, Brooke G, Townsend HR, Brahma RK, Hill GB. A comparison of oxypertine and chlorpromazine in chronic schizophrenia. Acta Psychiatrica Scandinavica 1970;46(2):126-35. [MedLine: 71030938]. Links Goldberg 1972 Goldberg S, Frosch W, Drossman A, Schooler N, Johnson G. Prediction of response to phenothiazines in schizophrenia. A crossvalidation study. Archives of General Psychiatry 1972;26:367-73. Links Goldman 1955 Goldman D. Treatment of psychotic states with chlorpromazine. Journal of the American Medical Association 1955;157:1274-8. Links Good 1958 Good WW, Sterling M, Holtzman WH. Termination of chlorpromazine with schizophrenic patients. American Journal of Psychiatry 1958;115:443-8. Links Mefferd RB, Labrosse EH, Gawienowski AM, Williams RJ. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. Journal of Nervous and Mental Diseases 1958;127:167-79. Links Goodwin-Austin 1971 Godwin-Austen RB, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. British Medical Journal 1971;4(778):25-6. Links Goyne 1958 Goyne J B, Groebner E, Pueblita M. Clinical Research - Vesperin-Chlorpromazine Therapy. Scientific Papers of the 114th Annual Meeting of the American Psychiatric Association. 1958:104-5. Graupner 1972 Graupner OK, Kalman EV. Effects of various drugs on flicker fusion frequency. II. Phenothiazine derivatives (with reference to the dependence of the results on the chronological course of experiments [Die Flimmer-Verschmelzung-Frequenz unter dem Einfluss verschiedener Pharmaka. II. Phenothiazinderivate (mit einem Hinweis auf die Abhangigkeit der Ergebnisse vom zeitlichen Verlauf der Versuche)]. Psychopharmacologia 1972;27(4):343-7. [MedLine: 73085373]. Links Green 1996 Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology 1996;128(1):67-73. Links Green 1998 Green JF, King DJ. Antisaccade and no-saccade distractibilty with chlorpromazine and lorazepam. Schizophrenia Research 1998;29(1,2):117. Links Greenberg 1966 Greenberg LM, Roth S. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. American Journal of Psychiatry 1966;123:221-6. Links Griffiths 1979 Griffiths RR, Bigelow G, Liebson I. Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. Journal of Pharmacology and Experimental Therapeutics 1979;210:301-10. Links Guy 1978 Guy W, Petrie W, Cleary P. The incidence of treatment emergent symptoms under chlorpromazine and placebo conditions. Psychopharmacology Bulletin 1978;14:22-4. Links Hammond 1978 Hammond NV, Gruzelier JH. Laterality, attention and rate effects in the auditory temporal discrimination of chronic schizophrenics - the effect of treatment with chlorpromazine. Quarterly Journal of Experimental Psychology 1978;30:91-103. Links Hamner 1996 Hamner MB, Arvanitis LA, Miller BG, Link CGG, Hong WW. Plasma prolactin in schizophrenia subjects treated with seroquel (TM) (ICI 204,636). Psychopharmacology Bulletin 1996;32(1):107-10. [MedLine: 96267998]. Links Hankoff 1960 Hankoff L, Engelhardt D, Freedman N, Mann D, Margolis R. Denial of illness in schizophrenic outpatients: effects of psychopharmacological treatment. Archives of General Psychiatry 1960;3:657-64. Links Hanlon 1958 Hanlon T E, Kurland A A, Esquibel A J, Ota K Y. A Comparative Study of Chlorpromazine and Triflupromazine in the Management of the Chronic Hospitalized Psychotic Patient. Journal of Nervous and Mental Diseases 1958;127:17-20. Links Hanlon 1960 Hanlon TE, Wiener G, Kurland AA. The psychiatric physician and the phenothiazine tranquilizers. Journal of Nervous and Mental Diseases 1960;130:67-71. Links Harper 1976 Harper P, Chacon C. Work performance versus clinical assessment in the evaluation of phenothiazine therapy. British Journal of Clinical Pharmacology 1976;3:50-5. Links Hartley 1978 Hartley L, Henry T, Couper-Smartt J. Chlorpromazine and serial reaction performance. British Journal of Psychology 1978;69:271-6. Links Hartley 1987 Hartley LR, Coxon L, Spencer J. Pharmacological effects on lateralized behavior. Current Psychology Research and Reviews 1987;6:301-12. Links Hartley 1989 Hartley LR, Strother N, Arnold PK, Mulligan B. Lateralization of emotional expression under a neuroleptic drug. Physiology and Behavior 1989;45:917-21. Links Hartley 1991 Hartley LR, Ireland LK, Arnold PK, Spencer J. Chlorpromazine and the lateralisation of the perception of emotion. Physiology and Behavior 1991;50:881-5. Links Hartmann 1973 Hartmann E, Cravens J. The effects of long term administration of psychotrophic drugs on human sleep. IV. The effects of chlorpromazine. Psychopharmacologia 1973;33:203-18. Links Haskell 1974 Haskell DS, McNair DM, Fisher S, Kahn RJ. A controlled outpatient trial of perphenazine-amitriptyline and chlorpromazine. Journal of Clinical Pharmacology 1974;14:536-42. Links Heilizer 1959 Heilizer F. The effects of chlorpromazine upon psychomotor and psychiatric behavior of chronic schizophrenic patients. Journal of Nervous and Mental Disease 1959;128:358-64. Links Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. Journal of Clinical and Experimental Psychopathology 1959;20:53-7. Links Hekimian 1967 Hekimian LJ, Friedhoff AJ. A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients. Diseases of the Nervous System 1967;28:675-8. Links Herrera 1988 Herrera JN, Sramek JJ, Costa JF, Roy S, High potency neuroleptics and violence in schizophrenics. Journal of Nervous and Mental Disease 1988;176(9):558-61. Links Herrmann 1991a Herrmann WM, Scharer E, Delini-Stula A. Predictive value of pharmaco electroencephalography in early human pharmacological evaluations of psychoactive drugs - first example - Savoxepine. Pharmacopsychiatry 1991;24:196-205. Links Herrmann 1991b Herrmann WM, Scharer E, Wendt G, Delini-Stula A. Pharmaco EEG profile of maroxepine - third example to discuss the predictive value of pharmaco electroencephalography in early human pharmacological evaluations of psychoactive drugs. Pharmacopsychiatry 1991;24:214-24. Links Herz 1991 Herz M, Glazer W, Mostert M, Sheard M, Szymanski H, Hafez H, Mirza M, Vana J. Intermittent versus maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry 1991;48:333-9. Links Hoffer 1975 Hoffer J. Megavitamin treatment of schizophrenia. Canadian Psychiatric Association Journal 1975;20:492-5. Links Hogarty 1976 Hogarty G E, Ulrich R F, Mussare F, Aristigueta N. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Diseases of the Nervous System 1976;37:494-500. Links Hollis 1968 Hollis JH. Chlorpromazine: direct measurement of differential behavioral effect. Science 1968;159:1487-9. Links Hollister 1955 Hollister LE, Jones KP, Brownfield B, Johnson F. Chlorpromazine alone and with reserpine. California Medicine 1955;83:218-21. Links Hollister LE, Traub L, Beckman WG. Psychiatric use of reserpine and chlorpromazine: results of double-blind studies. In: Kline NS editor(s). Psychopharmacology. Washington DC: AAAS, 1956:65-74. Holt 1984 Holt RJ. Neuroleptic drug-induced changes in platelet levels. Journal of Clinical Psychopharmacology 1984;4:130-2. Links Hong 1996a Hong W, Arvanitis L. Reduction of the positive symptoms of schizophrenia by '(ICI 204,636): results from phase II and III clinical trials. 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands. 1996. Hong 1996b Hong WW, Arvanitis LA. The atypical profile of '(ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands. 1996. Hopkin 1954 Hopkin DA. Action of chlorpromazine and promethazine. British Medical Journal 1954;1:1036. Links Horenstein 1957 Horenstein. Resperpine and chlorpromazine in hyperactive mental defectives. American Journal of Mental Deficiency 1957:525-29. Links Hrushka 1966 Hrushka M, Bruck M, Hsu J J. Therapeutic effects of different modes of chlorpromazine administration. Diseases of the Nervous System 1966;27:522-7. Links Huang 1967 Huang CL, Hirano K. The effect of antipyretic analgesics on the metabolism of chlorpromazine in man. Biochemical Pharmacology 1967;16:2023-6. Links Hughes 1967 Hughes JS, Little JC. An appraisal of the continuing practice of prescribing tranquillizing drugs for long-stay psychiatric patients. British Journal of Psychiatry 1967;113:867-73. Links Hurst 1960 Hurst L. Chlorpromazine and Pecazine in chronic schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1960;106:726-31. Links Hurst 1996 Hurst BC, Link C. A comparison of the tolerance profile of seroquel with typical neuroleptics and placebo. Xth World Congress of Psychiatry. Madrid, Spain. Madrid, Spain: August 23-28, 1996. Hussar 1969 Hussar AE, Bragg DG. The effect of chlorpromazine on the swallowing function in chronic schizophrenic patients. American Journal of Psychiatry 1969;126:570-3. Links Itil 1968 Itil T, Shapiro D, Fink M. Differentiation of psychotropic drugs by quantitative EEG analysis. Agressologie 1968;9:267-80. Links Itil 1971 Itil TM, Ulett GA, Fukuda T. Quantitative pharmaco-electroencephalography in early evaluation of psychotropic drugs. Folia Psychiatrica et Neurologica Japonica 1971;25:195-202. Links Johnstone 1978 Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978;1(8069):848-51. [MedLine: 78155245]. Links Jones 1969 Jones IH. Drugs and motor activity in chronic schizophrenia. British Journal of Psychiatry 1969;115:851-6. Links Jones 1971 Jones IH, Pikler N. Effects of chlorpromazine and trifluoperazine on the activity of chronic schizophrenics. British Journal of Psychiatry 1971;119:545-6. Links Joseph 1979 Joseph MH, Baker HF, Johnstone EC, Crow TJ. 3-Methoxy-4-hydroxyphenylglycol excretion in acutely schizophrenic patients during a controlled clinical trial of the isomers of flupenthixol. Psychopharmacology 1979;64(1):35-40. [MedLine: 80013695]. Links Joshi 1980 Joshi VG, Nagesh R, Eswaran S, Nagesh R, Pai M, Mathews G, Mallick PN. Vitamins B1, B6, and B12 in the adjunctive treatment of schizophrenia - further studies to examine the effect of reduction of chlorpromazine dosage. Journal of Orthomolecular Psychiatry 1980;11:45-9. Links Kabes 1982 Kabes J, Sikora J, Pisvejc J, Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. International Pharmacopsychiatry 1982;17(3):185-92. [MedLine: 83056096]. Links Kammerer 1968 Kammerer M, Wartel R, Gurfein L, Weil J, Wysoki V, Gelb F. Clinical experimentation with desipramine with statistical control [Experimentation clinique de la desipramine avec controle statistique]. Annales Medico-psychologiques 1968;1:109-13. Links Kaplan 1974 Kaplan J, Dawson S, Vaughan T, Green R, Wyatt RJ. Effect of prolonged chlorpromazine administration on the sleep of chronic schizophrenics. Archives of General Psychiatry 1974;31:62-6. Links Keskiner 1970 Keskiner A, Itil TM, Todt N. A comparative study of butaperazine, chlorpromazine and placebo in chronic schizophrenics. Psychosomatics 1970;11:120-6. Links Kim 1960 Kim K. Responses to treatment-refractory chronic schizophrenics to chlorpromazine with concurrent adrenocortical steroid. American Journal of Psychiatry 1960;116:1023-4. Links Kimbell 1971 Kimbell I Jr, Winkelman GW, Hughes WM. Comparison of thioridazine and chlorpromazine in doctor's choice research design. Clinical Pharmacology and Therapeutics 1971;12:825-32. Links King 1959 King PD, Weinberger W. Comparison of proclorperazine and chlorpromazine in hospitalized chronic schizophrenics. American Journal of Psychiatry 1959;115:1026-7. [MedLine: 69202908]. Links King 1994 King DJ. Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatrica Scandinavica Supplementum 1994;89(380):53-8. Links Kinross-Wright 1954 Kinross-Wright V. Chlorpromazine - a major advance in psychiatric treatment. Postgraduate Medicine 1954:297-300. Links Klein 1974 Klein RH, Lynn EJ, Axelrod H, Dluhy J. Self-administration of medication by psychiatric inpatients. Journal of Nervous and Mental Disease 1974;158:450-5. Links Kopell 1968 Kopell BS, Wittner WK. The effects of chlorpromazine and methamphetamine on visual signal-from-noise detection. Journal of Nervous and Mental Disease 1968;147:418-24. Links Kordas 1968 Kordas S, Kazamias N, Georgas J, Papadokostakis J. Clopenthixol: a controlled trial in chronic hospitalised schizophrenic patients. British Journal of Psychiatry 1968;114:833-6. Links Kornetsky 1957 Kornetsky C, Humphries O. Relationship between effects of a number of centrally acting drugs and personality. Archives of Neurology and Psychiatry 1957;77:325-7. Links Kornetsky C, Humphries O, Evarts EV. Comparison of psychological effects of certain centrally acting drugs in man. Archives of Neurology and Psychiatry 1957;77:318-24. Links Primac DW, Mirsky AF, Rosvold HE. Effects of centrally acting drugs on two tests of brain damage. Archives of Neurology and Psychiatry 1957;77:328-32. Links Kornetsky 1958 Kornetsky C, Humphries O. Psychological effects of centrally acting drugs in man. Journal of Mental Science 1958;104:1093-9. Links Mirsky AF, Primac DW, Bates R. The effects of chlorpromazine and secobarbital on the C.P.T. Journal of Nervous and Mental Diseases 1959;128:12-7. Links Kornetsky 1959 Kornetsky C, Pettit M, Wynne R, Evarts EV. A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenic patients. Journal of Mental Science 1959;105:190-8. Links Korol 1965 Korol B, Lang WJ, Brown ML, Gershon S. Effects of chronic chlorpromazine administration on systemic arterial pressure in schizophrenic patients: relationship of body position to blood pressure. Clinical Pharmacology and Therapeutics 1965;6:587-91. Links Kovitz 1955 Kovitz B, Carter JT, Addison WP. A comparison of chlorpromazine and reserpine in chronic psychosis. Archives of Neurology and Psychiatry 1955;74:467-71. Links Kramer 1975 Kramer M, Roth T, Goldstein S, Ryan MS, Blackwell B. A double-blind evaluation of metiapine in hospitalized acute schizophrenics. Current Therapeutic Research 1975;18:839-48. Links Kugler 1980 Kugler BT, Gruzelier JH. The influence of chlorpromazine and amylobarbitone on the recovery limb of the electrodermal response. Psychiatry Research 1980;2:75-84. Links Kupfer 1971 Kupfer DJ, Wyatt RJ, Synder F, Davis JM. Chlorpromazine and sleep in psychiatric patients. Archives of General Psychiatry 1971;24:185-9. Links Kurland 1981 Kurland AA, Nagaraju A. Viloxazine and the depressed schizophrenic - methodological issues. Journal of Clinical Pharmacology 1981;21(1):37-41. [MedLine: 81168674]. Links Lampe 1969 Lampe WT. A double blind study of clomacran. Current Therapeutic Research 1969;11:300-6. Links Latz 1965 Latz A, Kornetsky C. The effects of chlorpromazine and secobarbital under two conditions of reinforcement on the performance of chronic schizophrenic subjects. Psychopharmacologia 1965;7:77-88. Links Laurian 1981 Laurian S, Le PK, Baumann P, Perey M, Gaillard JM. Relationship between plasma-levels of chlorpromazine and effects on EEG and evoked potentials in healthy volunteers. Pharmacopsychiatria 1981;14:199-204. Links Leff 1971 Leff JP. Influence of selection of patients on results of clinical trials. British Medical Journal 1973;4:156-8. Links Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. British Medical Journal 1971;3:599-604. Links Leszek 1991 Leszek J, Inglot AD, Cantell K, Wasik A. Natural human leukocyte interferon in the treatment of schizophrenia. European Journal of Psychiatry 1991;5(1):55-63. Links Levin 1959 Levin ML. A comparison of the effects of phenobarbital, promethazine, chlorpromazine, and placebo upon mental hospital patients. Journal of Consulting Psychology 1959;23:167-70. Links Levine 1997 Levine J, Caspi N, Laufer N. Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients. Schizophrenia Research 1997;26(1):55-63. [MedLine: 98017426]. Links Levita 1961 Levita E. Effects of chlorpromazine and promazine on perseveration. Journal of General Psychology 1961;65:181-7. Links Lewis 1973 Lewis PJ, James NM. Haloperidol and chlorpromazine - a double-blind cross-over trial and clinical study in children and adolescents. Australian and New Zealand Journal of Psychiatry 1973;7:59-65. Links Liberman 1973 Liberman RP, Davis J, Moon W, Moore J. Research design for analyzing drug-environment-behavior interactions. Journal of Nervous and Mental Diseases 1973;156:432-9. Links Little 1958 Little JC. A double-blind controlled comparison of the effects of Chlorpromazine, Barbiturate and a placebo in 142 chronic psychotic in-patients. British Journal of Psychiatry 1958;4:334-49. Links Loranger 1968 Loranger AW. Treatment of acute mental disorders with an adrenal steroid. British Journal of Psychiatry 1968;114:843-4. Links Lorr 1961 Lorr M, McNair DM, Weinstein GJ, Michaux WW, Raskin A. Meprobamate and chlorpromazine in psychotherapy. Some effects on anxiety and hostility of outpatients. Archives of General Psychiatry 1961;4:381-9. Links Lyberi 1956 Lyberi G, S L Last. The Use of Chlorpromazine As An Activating Agent. Electroencephalography and Clinical Neurophysiology 1956:711-12. Links Maculans 1964 Maculans GA. Comparison of diazepam, chlorprothixine and chlorpromazine in chronic schizophrenic patients. Diseases of the Nervous System 1964;25:164-8. Links Mahal 1976 Mahal AS, Ramu NG, Chaturvedi DD. Double blind controlled study of brahmyadiyoga and tagara in the management of various types of unmada (schizophrenia). Indian Journal of Psychiatry 1976;18(4):283-92. Links Majewski 1968 Majewski J, Stempurska K. Results of treatment of schizophrenic psychoses with neuroleptics combined with subcomatic insulin [Wyniki leczenia psychoz schizofrenicznych neuroleptykami skojarzonymi z insulina podspiaczkowa]. Psychiatria Polska 1968;2(1):37-42. [MedLine: 68366839]. Links Marjerrison 1969 Marjerrison G, Keogh RP. Integrated EEG variability - drug effects in acute schizophrenics. Canadian Psychiatric Association Journal 1969;14:403-5. Links Marrazzi 1972 Marrazzi AS, Woodruff S, Kennedy D. Perceptual challenge to measure illness and therapy. American Journal of Psychiatry 1972;128:886-90. Links Mason-Browne 1957 Mason-Browne NL. Perphenazine - a drug modifying consciousness. American Journal of Psychiatry 1957;114:173-4. Links Mason-Browne NL, Borthwick JW. Effect of perphenazine (Trilafon) on modification of crude consciousness. Diseases of the Nervous System 1957;18:300-6. Links Mathur 1981 Mathur S, Hall JN. Phenothiazine withdrawal in schizophrenics in a hostel (letter). British Journal of Psychiatry 1981;138:271-2. Links Mattila 1994 Mattila MJ, Vanakoski J, Mattila Evenden ME, Karonen SL. Suriclone enhances the actions of chlorpromazine on human psychomotor performance but not on memory or plasma prolactin in healthy subjects. European Journal of Clinical Pharmacology 1994;46:215-20. Links McClelland 1990 McClelland GR, Cooper SM, Pilgrim AJ. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. British Journal of Clinical Pharmacology 1990;30:795-803. Links Melnyk 1966 Melnyk WT, Worthington AG, Laverty SG. Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic in-patients. Canadian Psychiatric Association Journal 1966;11(5):410-3. Links Merry 1957 Merry J, Pargiter MB, Munro H. Chlorpromazine and chronic neurotic tension. American Journal of Psychiatry 1957;113:988-90. Links Michaux 1966 Kurland AA, Bethon GD, Michaux MH, Agallianos DD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings. Journal of New Drugs 1966;6:80-95. Links Michaux MH, Kurland AA, Agallianos DD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. Current Therapeutic Research, Clinical and Experimental 1966;8(supplement):117-52. Links Millar 1963 Millar J. A trial of fluphenazine in schizophrenia. British Journal of Psychiatry 1963;109:428-32. [MedLine: 74100099]. Links Milne 1960 Milne H, Fowler DB. A clinical trial of Largactil (chlorpromazine), Stemeticl (prochlorperazine) and Veractil (methotrimeprazine). British Journal of Psychiatry 1960;106:1105-10. Links Milton 1978 Milton F, Patwa VK, Hafner RJ. Confrontation versus belief modification in persistently deluded patients. British Journal of Medical Psychology 1978;51:127-30. Links Mitchell 1956 Mitchell P. Chlorpromazine in the treatment of the chronic disturbed schizophrenic patient. British Journal of Psychiatry 1956;102:151-4. Links Mitchell 1960 Mitchell LE, Zax M. Psychological response to chlorpromazine in a group of psychiatric patients. Journal of Clinical Psychology 1960;16:440-2. Links Monteleone 1999 Monteleone P, Tortorella A, Borriello R, Cassandro P, Maj M. Prolactin hyperresponsiveness to D fenfluramine in drug free schizophrenic patients: a placebo controlled study. Biological Psychiatry 1999;45(12):1606-11. [MedLine: 99304410]. Links Morgenstern 1960 Morgenstern FV, Funk IC, Holt WL. Comparative short-term evaluation of triflupromazine hydrochloride, chlorpromazine hyrochloride, and placebo in acutely disturbed patients. New York State Journal of medicine 1960;60:254-8. Links Morton 1968 Morton MR. A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry 1968;124:1585-8. Links Moss 1958 Moss CS, Jensen RE, Morrow W, Freund HG. Specific behavioural changes produced by chlorpromazine in chronic schizophrenia. American Journal of Psychiatry 1958;115:449-51. Links Neal 1969 Neal CD, Collis MP, Imlah NW. A comparative trial of oxypertine and chlorpromazine in chronic schizophrenia. Current Therapeutic Research - Clinical and Experimental 1969;11:367-78. Links Newbold 1956 Newbold, Steed. The Use of Chlorpromazine in Psychotherapy. Journal of Nervous and Mental Diseases 1956. Links Okuma 1979 Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe S. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology Berlin 1981;73:95-6. Links Orzack 1969 Orzack MH, Taylor CL, Kornetsky C. A comparison of the behavioral effects of periodic administration of chlorpromazine and a &amp;quot;sustained-release&amp;quot; form of chlorpromazine. Clinical Pharamacology and Therapeutics 1969;10(2):258-64. [MedLine: 69143232]. Links Osmakova 1972 Os'makova EI. Use of psychological methods for studying the particular psychotropic action of various psychopharmacologic drugs [Primenenie psikhologicheskikh metodik dlia issledovaniia sobstvenno psikhotropnogo deistviia nekotorykh psikhofarmakologic heskikh sredtsv]. Zhurnal Nevropatologii i Psikhiatrii 1972;72:1705-8. Links Rojo-Sierra M, Alonso J, D&amp;#237;ez E, Giner J, Lloret E. [Aportaci&amp;#243;n sobre el espectro psicofarmacoter&amp;#225;pico del R P. 19 366 y R P. 19 552]. 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Ciudad de Mexico, Mexico. 1971. Pai 2001 Pai Y-M, Yu S-C, Lin C-C. Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study. Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA. Marathon Multimedia, 2001. Paredes 1966 Paredes A, Baumgold J, Pugh LA, Ragland R. Clinical judgment in the assessment of psychopharmacological effects. Journal of Nervous and Mental Disease 1966;142(2):153-60. Links Park 1981 Park S, Hardesty AS, Garcia E. Effects of triiodothyronine and chlorpromazine combination treatment in schizophrenia. Current Therapeutic Research - Clinical and Experimental 1981;29:929-35. Links Pasamanick 1967 Pasamanick B, Scarpitti FR, Dinitz S. Schizophrenics in the community: an experimental study in the prevention of hospitalization. New York: Appleton-Century-Crofts, 1967. Patterson 1981 Patterson T, Venables PH. Bilateral skin conductance and the pupillary light dark reflex - manipulation by chlorpromazine, haloperidol, scopolamine, and placebo. Psychopharmacology 1981;73:63-9. Links Peet 1980 Peet M, Middlemiss DN, Yates RA. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients [letter]. Lancet 1980;2:978. Links Pennington 1957 Pennington V. A two-year comparative study of ataraxics in neuropsychiatric patients. Journal of the American Geriatric Association 1957;5:42-9. Links Pietzcker 1978 Pietzcker A. Long-term medication in schizophrenia [Langzeitmedikation bei schizophrenen Kranken]. Nervenarzt 1978;49:518-33. Links Pigache 1973 Pigache RM. The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine. Schizophrenia Research 1993;10:39-50. Links Pigache RM, Norris HN. Measurement of drug action in schizophrenia. Clinical Science 1973;44:28P. Links Pigache 1993 Pigache RM. Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two-year longitudinal study. Schizophrenia Research 1993;10:51-9. Links Platz 1967 Platz AR, Klett CJ, Caffey EMJ. Selective drug action related to chronic schizophrenic subtype. (A comparative study of carphenazine, chlorpromazine, and trifluoperazine). Diseases of the Nervous System 1967;28:601-5. Links Pleasure 1956 Pleasure H. Chlorpromazine (Thorazine) for mental illness in the presence of pulmonary tuberculosis. Psychiatry Quarterly 1956;30:23-30. Links Pollack 1956 Pollack, B. The effect of chlorpromazine on the return rate of 250 patients released from the Rochester State Hospital. American Journal of Psychiatry 1956;112:937. Links Pollard 1959 Pollard JC. Combined Effects of Chlorpromazine and Meprobamate in Chronically Disturbed Psychotic Patients. Diseases of the Nervous System 1959;20:427-9. Links Quigley 1996 Quigley N, Morgan D, Idzikowski C, King DJ. The effect of chlorpromazine and benzhexol on memory and psychomotor function in healthy volunteers. Journal of Psychopharmacology 1996;10:146-52. Links Quinn 1960 Quinn PJG, Johnston J, Latner G, Kiloh LG. A comparative controlled trial of methotrimeprazine ('veractil') in chronic schizophrenia. British Journal of Psychiatry 1960;106:161-70. Links Raaska 2000 Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. European Journal of Clinical Pharmacology 2000;56(8):585-9. [MedLine: 21026257]. Links Ragland 1968 Ragland R, Clark ML, Ray TS, Paredes A, Costiloe JP, Segal B, Wolf S. The evaluation of chlorpromazine therapy in chronic schizophrenic women. A replicated experiment. Journal of Chronic Diseases 1968;21:445-60. Links Raja 2000 Raja M, Azzoni A. Second generation antipsychotics in the emergency care setting. A prospective naturalistic study. General Hospital Psychiatry 2000;22(2):107-14. [MedLine: 20283566]. Links Rappaport 1967 Rappaport M. Competing voice messages. Effects of message load and drugs on the ability of acute schizophrenics to attend. Archives of General Psychiatry 1967;17:97-103. Links Rappaport 1968 Rappaport M. Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background. Journal of Nervous and Mental Disease 1968;146:404-11. Links Rathod 1958 Rathod N, Rees L. A controlled study of the prognostic significance of autonomic responses in the chlorpromazine treatment of disturbed psychotic patients. British Journal of Psychiatry 1958;104:705-12. Links Raymond 1957 Raymond MJ, Lucas CJ, Beesley ML, O'Connell BA, Fraser Roberts JA. A trial of five tranquillizing drugs in psychoneurosis. British Medical Journal 1957;2:63-6. Links Remr 1970 Remr J. The effects of chlorpromazine on fine psychomotor performance with a simultaneous secondary task in schizophrenics. Activitas Nervosa Superior 1971;13:179. Links Remr J. The effects of chlorpromazine on some components of psychomotor performance in schizophrenics. Activitas Nervosa Superior 1970;12:253-4. Links Rifkin 1978 Rifkin A, Quitkin F, Kane J, Struve F, Klein DF. Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. Archives of General Psychiatry 1978;35(4):483-9. [MedLine: 79081577]. Links Rinaldi 1956 Rinaldi F, Rudy L, Himwich HE. Clinical evaluation of azacyclonol, chlorpromazine, and reserpine on a group of chronic psychotic patients. American Journal of Psychiatry 1956;112:678-83. Links Rivera-Calimlim 1973 Rivera Calimlim L, Castaneda L, Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clinical Pharmacology and Therapeutics 1973;14:978-86. Links Rosen 1972 Rosen B, Engelhardt DM, Freedman N, Margolis R, Rudorfer L, Paley HM. Prediction of psychiatric hospitalization. II. The Hospitalization Proneness Scale: a cross-validation. Journal of Nervous and Mental Disease 1972;80:271-4. Links Rosenheck 2000 Rosenheck R, Cramer J, Jurgis G, Perlick D, Xu W, Thomas J, Henderson W, Charney D. Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. Journal of Clinical Psychiatry 2000;61(9):671-6. Links Rosner 1955 Rosner H, Levine S, Hess H, Kaye H. A comparative study of the effect on anxiety of chlorpromazine, reserpine, phenobarbital, and a placebo. Journal of Nervous and Mental Diseases 1955;122:505-12. Links Rudy 1957 Rudy L, Himwich H, Tasher DC. Clinical evaluation of two phenothiazine compounds Promazine and Mepazine. American Journal of Psychiatry 1957;113:979-83. Links Rudy 1958 Rudy L, Rinaldi E, Himwich H, Tuteur W, Glotzer J. Trifluoperazine in the treatment of psychotic patients. American Journal of Psychiatry 1958;115:364-5. Links Sainz 1955 Sainz A. Chlorpromazine in psychiatric disorders. Prescriber 1955;2(2):14. [MedLine: 20283566]. Links Saletu 1972 Saletu B, Saletu M, Itil T. Effect of minor and major tranquilizers on somatosensory evoked potentials. Psychopharmacologia 1972;24:347-58. Links Salisbury 1957 Salisbury BJ, Hare EH. Ritalin and Chlorpromazine in chronic schizophrenia: a controlled clinical trial. British Journal of Psychiatry 1957;103:830-4. Links Schiele 1959 Schiele BC, Mendelsohn RM, Penman AS, Schofield W. Comparison of low and high dosage procedures in chlorpromazine therapy. Psychiatric Quarterly 1959;33:252-9. Links Schmidt 1957 Schmidt KE. Combined treatment with chlorpromazine and reserpine: an attempt at quantitative assessments in chronic schizophrenic patients. British Journal of Psychiatry 1957;103:200-8. Links Schooler 1976 Sakalis G, Chan TL, Sathananthan G, Schooler N, Goldberg S, Gershon S. Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. Communucations in Psychopharmacology 1977;1:157-66. Links Schooler NR, Sakalis G, Chan TL. Chlorpromazine metabolism and clinical response in acute schizophrenia - a preliminary report. Psychopharmacology Bulletin 1975;11:30-3. Links Schooler NR, Sakalis G, Chan TL, Gershon S, Goldberg SC, Collins P. Chlorpromazine metabolism and clinical response in acute schizophrenia - a preliminary report. Pharmacokinetics of psychoactive drugs. 1976:199-219. Seager 1955 Seager CP. Chlorpromazine in treatment of elderly psychotic women. British Medical Journal 1955;1:882-5. Links Serafetinides 1973 Serafetinides EA. Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry 1973;8:214-6. Links Shaskan 1975 Becker RE, Shaskan EG. Platelet monoamine oxidase activity in schizophrenic patients. American Journal of Psychiatry 1977;134:512-7. Links Shaskan EG, Becker RE. Blood platelet monoamine oxidase activity in anergic schizophrenics. National Institute of Drug Abuse Research Monograph Services 1975:29-35. Links Shaskan EG, Becker RE. Platelet monoamine oxidase in schizophrenics. Nature 1975;253:659-60. Links Shawver 1959 Shawver JR, Gorham DR, Leskin LW, Good WW, Kabnick DE. Comparison of chlorpromazine and reserpine in maintenance drug therapy. Diseases of the Nervous System 1959;20:452-7. Links Shopsin 1978 Shopsin B, Klein H, Aronson M. Clozapine: double-blind control trial in the treatment of acute schizophrenia. Psychopharmacology Bulletin 1978;14:12-4. Links Shopsin 1979 Honigfeld G, Patin J, Singer J. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Advances in Therapy 1984;1:77-97. Links Shopsin B, Klein H, Aaronson M, Collora M. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients. Archives of General Psychiatry 1979;36:657-64. Links Silver 2000 Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. International Clinical Psychopharmacology 2000;15(5):257-61. [MedLine: 20445223]. Links Simopoulos 1971 Simopoulos AM, Pinto A, Uhlenhuth EH, Mcgee J. Old wine in new bottles: decreased hostility in chronic psychotic inpatients treated with diphenylhydantoin (Dilantin). 5th World Congress of Psychiatry. Ciudad de Mexico. Ciudad de Mexico: 1971:abstract 1077. Simpson 1974 Simpson GM, Varga E, Reiss M, Cooper TB, Bergner PE, Lee JH. Bioequivalency of generic and brand-named chlorpromazine. Clinical Pharmacology and Therapeutics 1974;15:631-41. Links Simpson 1980 Simpson GM, Cooper TB, Bark N, Sud I, Lee JH. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Archives of General Psychiatry 1980;37:205-8. Links Singh 1974 Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Diseases of the Nervous System 1976;37:191-6. Links Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Journal of the Bronx State Hospital 1974;2:173-83. Links Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benzotropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Psychopharmacologia 1975;43:103-13. Links Singh MM, Kay SR. Therapeutic reversal with benztropine in schizophrenics: practical and theoretical significance. Journal of Nervous and Mental Disease 1975;160:258-66. Links Singh 1990 Singh H, Hunt JI, Vitiello B, Simpson GM. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Journal of Clinical Psychiatry 1990;51:319-21. Links Small 1987 Small J, Milstein V, Small IF, Miller MJ, Kellams JJ, Corsaro CJ. Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia. Clinical Electroencephalography 1987;18:124-35. Links Smith 1958 Smith JA, Christian D, Rutherford A, Mansfield E. A comparison of triflupromazine (Vesprin), chlorpromazine and placebo in 85 chronic patients. American Journal of Psychiatry 1958;115:253-4. Links Smith 1960 Smith ME. A comparative controlled study with chlordiazepoxide. American Journal of Psychiatry 1960;117:362-3. Links Smith 1967 Smith K, Surphlis WRP, Gynther MD, Shimkunas AM. ECT-chlorpromazine and chlorpromazine compared in the treatment of schizophrenia. Journal of Nervous and Mental Disease 1967;144:284-90. Links Sommerness 1957 Sommerness MD, Lucero RJ, Hamlon JS, Mahowald AM. Chlorpromazine: a controlled study with highly disturbed patients. Diseases of the Nervous System 1957;18:16-20. Links South-East 1961 South-East Region (Scotland) Therapeutic Trials Committee. Controlled trial of Prochlorperazine (Stemetil) in schizophrenia. Journal of Mental Science (British Journal of Psychiatry from 1963) 1961;107:514-22. [MedLine: 87204515]. Links Soyka 1968 * Soyka D. The effect of psychopharmacological drugs and other central nervous system effecting drugs on experimental nystagmus [Die Wirkung von Psychopharmaka und anderen zentral wirksamen substanzen auf den experimentellen Nystagmus]. Fortschritte Der Neurologie, Psychiatrie Und Ihrer Grenzgebiete 1968;36:526-39. Links Spiegel 1967 Spiegel DE, Keith-Spiegel P. The effects of carphenazine, trifluoperazine and chlorpromazine on ward behavior, physiological functioning and psychological test scores in chronic schizophrenic patients. Journal of Nervous and Mental Diseases 1967;144:111-6. Links Spohn 1974 Spohn HE, Lacoursiere RB, Williams RO. The effect of chlorpromazine on visual information processing in normal subjects. Journal of Nervous and Mental Disease 1974;159:198-204. Links Sugerman 1964 Pfeiffer CC, Goldstein L, Murphree HB, Sugerman AA. Time-series frequency analysis, and electrogenesis of the EEGs of normals and psychotics before and after drugs. American Journal of Psychiatry 1965;122:1147-55. Links Sugerman AA, Goldstein L, Murphree HB, Pfieffer CC, Jenney EH. EEG and behavioural changes in schizophrenia. Archives of General Psychiatry 1964;10:340-4. Links Syvalahti 1997 Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, Dahl ML, Salokangas RK. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. Journal of International Medical Research 1997;25(1):24-32. [MedLine: 97179384]. Links Talbot 1964 Talbot DR. Are tranquilizer combinations more effective than a single tranquilizer?. American Journal of Psychiatry 1964;121:597-600. Links Tassis 1959 Tassis JA. Full Coma Insulin therapy, Chlorpromazine and Electoconvulsive Treatment. A control study of 600 Schizophrenic patients. Medical journal of Malaya 1959;14:135-43. Links Teja 1975 Teja JS, Grey WH, Clum JM, Warren C. Tranquilizers or anti-depressants for chronic schizophrenics: a long-term study. Australian and New Zealand Journal of Psychiatry 1975;9:241-7. Links Tenenblatt 1956 Tenenblatt SS, Spagno A. A controlled study of chlorpromazine therapy in chronic psychotic patients. Journal of Clinical &amp;amp; Experimental Psychopathology 1956;17:81-92. Links Terminska 1989 Terminska K, Mrowiec W. [Badanie porownawcze wplywu perazyny, flufenazyny, trifluoroperazyny, chloropromazny i haloperydolu na objawy pierwotne i deficytowe pierwszego zachorowania na schizofrenie paranoidalna]. Psychiatria Polska 1989;23:24-30. Links Tetreault 1969 Tetreault L, Bordeleau JM, Albert JM, Rajotte P. Comparative study of fluphenazine ethanate, fluphenazine bichlorhydrate and placebos in chronic schizophrenics [Etude comparative de l'enanthate de fluphenazine, du bichlorhydrate de fluphenazine et du placebo chez le schizophrene chronique]. Canadian Psychiatric Association Journal 1969;14(2):191-8. [MedLine: 69202908]. Links Thorpe 1956 Thorpe J, Baker A. A research method to assess a new tranquillizing drug. British Journal of Psychiatry 1956;102:790-5. Links Tourlentes 1958 Tourlentes T L, Hunsicker A L, Hurd D E. Chlorpromazine and Communication Processes. A.M.A. Archives of Neurology and Psychiatry 1958;79:468-73. Links Troshinsky 1962 Troshinsky CH, Aaronson HG, Stone RK. Maintenance phenothiazines in aftercare of schizophrenic patients. Pennsylvania Psychiatric Bulletin 1962;2:11-5. Links Turner 1956 Turner M, Berard, E, Turner N, Franco N. Changes in the Electroencephalogram, the Electrodermogram, and the Electromyogram Provoked by Chlorpromazine in Man. Abstracts of World Medicine 1956;20:177. Links Turner 1966 Turner P. A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency. Journal of Pharmacy and Pharmacology 1966;18:836. Links Urquhart 1959 Urquhart R, Forrest AD. Clinical trial of promazine hydrochloride and acetylpromazine in chronic schizophrenic patients. British Journal of Psychiatry 1959;105:260-4. Links Van Praag 1975 van Praag HM, Dols LC, Schut T. Biochemical versus psychopathological action profile of neuroleptics. A comparative study of chlorpromazine and oxypertine in acute psychotic disorders. Comprehensive Psychiatry 1975;16:255-63. Links van Praag HM, Korf J. The dopamine hypothesis of schizophrenia. Some direct observations. In: van Praag HM editor(s). On the origin of schizophrenic psychoses. Amsterdam: De Erven Bohn BV, 1975:81-98. Vestre 1961 Vestre ND. An experimental study of the effects of chlorpromazine on association learning in schizophrenic patients. Dissertation Abstracts 1961:2374. Vinar 1973 Vinar O. Whom do neuroleptic drugs help?. Psychopharmacology, Sexual Disorders and Drug Abuse. Amsterdam, Netherlands: North-Holland, 1973:247-56. Volavka 1983 Volavka J, Hui KS, Anderson B, Nemes Z, O'Donnell J, Lajtha A. Short-lived effect of (des-tyr)-gamma-endorphin in schizophrenia. Psychiatry Research 1983;10:243-52. Links Warner 1996 Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatrica Scandinavica 1996;93:311-3. Links Weir 1968 Weir TW, Kernohan GA, MacKay DN. The use of pericyazine and chlorpromazine with disturbed mentally subnormal patients. British Journal of Psychiatry 1968;114:111-2. Links Welbel 1980 Welbel L. [Roznice w dziallaniu klinicznym niektorych neuroleptykow]. Psychiatria Polska 1980;14:113-8. Links Whitehead 1958 Whitehead WA, Thune LE. The effects of chlorpromazine on learning in chronic psychotics. Journal of Consulting Psychology 1958;22:379-83. Links Wilcott 1962 Wilcott RC, Helper MM, Garfield SL. Some Psychophysiological Effects of Chlorpromazine on Emotionally Disturbed Children. Journal of Nervous and Mental Diseases 1962;135:233-8. Links Wilson 1961 Wilson IC, McKay J, Sandifer MG. A double-blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia. British Journal of Psychiatry 1961;107:90-9. Links Winkelman 1957 Winkelman N W. An Appraisal of Chlorpromazine. General Principles for Administration of Chlorpromazine, Based on Experience with 1,090 Patients. American Journal of Psychiatry 1957. Links Winter 1956 Winter WD, Frederickson WK. The short-term effects of chlorpromazine on psychiatric patients. Journal of Consulting Psychology 1956;20:431-4. Links Wode-Helgodt 1977 Wode-Helgodt B, Eneroth P, Fyro B, Gullberg B, Sedvall G. Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatrica Scandinavica 1977;56:280-93. Links Wold 1959 Wold PN. A long term evaluation of chlorpromazine in six chronic schizophrenic patients. American Journal of Psychiatry 1959;116:461-2. Links Wolpert 1969 Wolpert A, Yaryura TJA, White L, Merlis S. Triiodothyronine and phenothiazines in schizophrenia. Diseases of the Nervous System 1969;30(7):487-9. [MedLine: 69288496]. Links Wyatt 1997 Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychological Medicine 1997;27:261-8. Links Yorkston 1977 Yorkston NJ, Zaki SA, Pitcher DR, Gruzelier JH, Hollander D, Sergeant HG. Propranolol as an adjunct to the treatment of schizophrenia. Lancet 1977;2:575-8. Links Yuan-guang 1994 Yuan-Guang C, Guang-rong X, Jing Ping Z. A study on the relationship between the chlorprmazine plasma levels and clinical response to chlorpromazine administrations in the schizophrenics. Chinese Journal of Neurology and Psychiatry 1994;27(3):153-5. Links Zeller 1956 Zeller WW, Graffagnino PN, Cullen CF, Rietman HJ. Use of chlorpromazine and reserpine in the treatment of emotional disorders. Journal of the American Medical Association 1956;160:179-84. Links References to studies awaiting assessment Magner 1974 Magner O, Moller S. The blood pressure lowering effect of chlorpromazine and methylperon (Buronil) [Blodtryksnedsaettende effekt af kllrpromazin og metylperon (Buronil)]. Ugeskrift for Laeger 1974;136:809-11. Links Rojo-Sierra 1971 Rojo-Sierra M, Alonso J, D&amp;#237;ez E, Giner J, Lloret E. [Aportaci&amp;#243;n sobre el espectro psicofarmacoter&amp;#225;pico del R P. 19 366 y R P. 19 552]. 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Ciudad de Mexico, Mexico. 1971:495-6. Vinar 1976 Vinar O, Taussigova D. Schizophrenic syndromes improving without neuroleptic drug treatment [Schizofrenni syndromy zlepsujici se bez neurolepticke lecby]. Ceskoslovenska Psychiatrie 1976;72(3):176-81. [MedLine: 77001715]. Links Yagi 1976 Yagi G. A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Rinsho Hyoka (Clinical Evaluation) 1976;4(3):351-403. Links Additional references Ahmed 1998 Ahmed I, Soares K, Seifas R, Adams CE. Randomised controlled trials in Archives of General Psychiatry (1959-1995): a prevalence study. Archives of General Psychiatry 1998;55(8):754-5.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed I, Soares K, Seifas R, Adams CE</AU>
<TI>Randomised controlled trials in Archives of General Psychiatry (1959-1995): a prevalence study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>8</NO>
<PG>754-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="OLZ020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caldwell-1992" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Caldwell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Caldwell CB, Gottesman II</AU>
<TI>Schizophrenia - a high-risk factor for suicide: clues to risk reduction</TI>
<SO>Suicide and life-threatening behavior</SO>
<YR>1992</YR>
<VL>22</VL>
<PG>479-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CATIE-2005" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="CATIE 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>1209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curson-1985" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Curson 1985" TYPE="JOURNAL_ARTICLE">
<AU>Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC</AU>
<TI>Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>146</VL>
<PG>474-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1975" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Davis 1975" TYPE="JOURNAL_ARTICLE">
<AU>Davis JM</AU>
<TI>Overview: maintenance therapy in psychiatry - I. Schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1975</YR>
<VL>132</VL>
<PG>1237-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donne A, Klaar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Essali-1993" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Essali 1993" TYPE="JOURNAL_ARTICLE">
<AU>Essali MA, Maddocks PD</AU>
<TI>Seventeen years in the life of a depot neuroleptic clinic - an audit study of schizophrenia and other psychosis</TI>
<SO>British Journal of Medical Economics</SO>
<YR>1993</YR>
<VL>6</VL>
<PG>3-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbetr-1995" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Gilbetr 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert PL, Harris J, Mc Adams LA, Jest DV</AU>
<TI>Neuroleptic withdrawal in schizophrenic patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<PG>174-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy U</AU>
<SO>ECD EU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<EN>Revised</EN>
<PB>National Institute of Mental Health</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2012-07-31 12:54:13 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jusic-1994" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Jusic 1994" TYPE="JOURNAL_ARTICLE">
<AU>Jusic N, Lader M</AU>
<TI>Post-mortem antipsychotic drug concentrations and unexplained deaths</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>165</VL>
<PG>787-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lorr-1953" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Lorr 1953" TYPE="BOOK">
<AU>Lorr M</AU>
<SO>The Multidimensional Scale for Rating Psychiatric Patients</SO>
<YR>1953</YR>
<PG>19-507</PG>
<PB>U.S.V.I, T.B</PB>
<CY>Washington D.C.</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>15</NO>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIMH-1964" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="NIMH 1964" TYPE="JOURNAL_ARTICLE">
<AU>National Institute of Mental Health</AU>
<TI>Phenothiazine treatment in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1964</YR>
<VL>10</VL>
<PG>246-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA: Journal of American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shepherd-1989" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Shepherd 1989" TYPE="JOURNAL_ARTICLE">
<AU>Shepherd M, Watt D, Falloon I, et al</AU>
<TI>The Natural History of Schizophrenia: a five-year follow-up study of outcome prediction in a representative sample of schizophrenics.</TI>
<SO>Psychological Medicine. Monograph supplement</SO>
<YR>1989</YR>
<VL>15 (Suppl.)</VL>
<PG>1-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornley-1998" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Thornley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Thornley B, Adams CE</AU>
<TI>Content and quality of 2000 controlled trials in schizophrenia over 50 years</TI>
<SO>British Medical Journal</SO>
<YR>1998</YR>
<VL>317</VL>
<PG>1181-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornley-2006" MODIFIED="2012-07-31 12:55:07 +0100" MODIFIED_BY="[Empty name]" NAME="Thornley 2006" TYPE="COCHRANE_REVIEW">
<AU>Thornley B, Rathbone J, Adams CE, Awad G</AU>
<TI>Chlorpromazine versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-07-31 12:55:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-31 12:55:07 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000284.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="10982317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wing-1961" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="Wing 1961" TYPE="JOURNAL_ARTICLE">
<AU>Wing JK</AU>
<TI>A simple and reliable sub-classification of chronic schizophrenia.</TI>
<SO>The Journal of Mental Science</SO>
<YR>1961</YR>
<VL>107</VL>
<PG>862-75</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andrews-1976">
<CHAR_METHODS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Blinding: double, identical capsules given by the hospital pharmacist who "alone held the key to the drug assignment".<BR/>Duration: 42 weeks (preceded by 8 weeks stabilisation on chlorpromazine).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=32.<BR/>Age: mean 55 yrs.<BR/>Sex: all male.<BR/>History: in hospital &gt; 6 yrs, mean 23 yrs, on oral phenothiazine.<BR/>Excluded: on depot injections of phenothiazine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorpromazine cessation: placebo. N=17.<BR/>2. Chlorpromazine continuation: dose 50,150-200 or 200-450 mg/day. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse.</P>
<P>Unable to use - <BR/>Behaviour change: WBRSW (no SD).<BR/>Leaving the study early: due to deterioration of behaviour - 3 people (not reported by group).<BR/>Death: coronary thrombosis (not reported by group).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>For one patient in the Control Group, the urine test for CPZ was negative and this patient "who did not relapse" was omitted from analysis in the results.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caffey-1964">
<CHAR_METHODS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Blinding: double, identical capsules.<BR/>Duration: 16 weeks (preceded by 3 months stabilisation on either chlorpromazine or thioridazine).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=438 (269 to relevant interventions).<BR/>Age: &lt; 56, mean 40 yrs.<BR/>Sex: all males.<BR/>History: in hospital &gt;2yrs, mean 10 yrs.<BR/>Excluded: CNS disease, any seizures, prefrontal lobotomy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorpromazine cessation: placebo. N=171. <BR/>2. Chlorpromazine or thioridazine intermittent treatment: dose 400 mg, 350 mg respectively 3 days a week. N=89.<BR/>3. Chlorpromazine or thioridazine continuation: dose 400 mg, 350 mg/day respectively. N=88.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse.</P>
<P>Unable to use - <BR/>Global state: IMPS (no SD), Ward Evaluation Scale (no data).<BR/>Behaviour change: PRP (no SD).<BR/>Biochemistry: urine test (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>* Data not detailed for each drug. We considered CPZ and Thioridazine patients as one group.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freeman-1962">
<CHAR_METHODS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned, pairs matched on morbidity.<BR/>Blinding: double, identical capsules, "neither experimenters nor staff knew which patients were receiving the placebo".<BR/>Duration: 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: psychosis (86 schizophrenia, 6 chronic brain syndrome, 2 personality disorders).<BR/>N=94.<BR/>Age: mean 44 yrs.<BR/>Sex: all males.<BR/>History: "chronic" in hospital &gt;12 yrs, only on chlorpromazine in last 2 months. <BR/>Excluded: physically assaultive, considered for discharge.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorpromazine cessation: placebo. N=46.<BR/>2. Chlorpromazine continuation: dose 220 mg/day. N=48.</P>
<P>Sedatives were permitted for occasional use when required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse.</P>
<P>Unable to use -<BR/>Behaviour change: LBRS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenberg-1966">
<CHAR_METHODS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation unclear, implied and supported by demographic data.<BR/>Blinding: double.<BR/>Duration: 60 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=42.<BR/>Age: mean 42 yrs.<BR/>Sex: all males.<BR/>History: "chronic" in hospital mean 13 yrs, received chlorpromazine &gt;8 months mean 2.5 yrs.<BR/>Excluded: patients judged to have substantially decompensated. <BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorpromazine cessation: placebo. N=21.<BR/>2. Chlorpromazine continuation: dose 510 mg/day. N=21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse.</P>
<P>Unable to use -<BR/>Global state: Rating Scale for Chronic Schizophrenia (no data).<BR/>Behaviour change: Gardner Behaviour Chart (no data).<BR/>Adverse effects: no usable data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hogarty-1973-a">
<CHAR_METHODS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned, stratified by sex, factorial design (2*2).<BR/>Blinding : double, identical capsules.<BR/>Duration: 3 years (preceded by 2 months stabilisation on chlorpromazine).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM II).<BR/>N=374. <BR/>Age: range 18-53, mean 34 yrs.<BR/>Sex: male and female. <BR/>History: recently discharged, hospital&lt;2 yrs, IQ&gt;70. <BR/>Excluded: serious suicidal or homicidal behaviour, organic brain syndrome, unmanageable drinking or drug abuse.<BR/>Setting: community.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorpromazine cessation: placebo. N=182.<BR/>2. Chlorpromazine continuation: dose ~270 mg/day. N=192. </P>
<P>Factored to:<BR/>A. Major Role Therapy. N=190.<BR/>B. Rehabilitation counselling. N=184.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse.<BR/>Leaving study early.</P>
<P>Unable to use -<BR/>Death: not reported by group.<BR/>Trouble with police. not reported by group.<BR/>Mental state: BPRS, symptom checklist, IMPS, SSI (no SD).<BR/>Social functioning: Major Role Adjustment Inventory, Katz Adjustment Scale, Casework Evaluation Schedule. (no SD).<BR/>Carer morbidity: Family Distress Scale. (no SD).<BR/>Global state: KAS (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mathur-1981">
<CHAR_METHODS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned, cross-over design (after 6months).<BR/>Blinding: double, given by hospital pharmacist in individual bottles. <BR/>Duration: 16 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=24.<BR/>Age: mean 55 yrs.<BR/>Sex: unknown.<BR/>History: in hospital mean 27 yrs, stable on chlorpromazine &gt;6 months.<BR/>Setting: hostel.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorpromazine cessation: placebo. N=12.<BR/>2. Chlorpromazine continuation: (dose not reported). N=12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse.<BR/>Leave the study early.</P>
<P>Unable to use -<BR/>Death: 1 suicide (not reported by group).<BR/>Behaviour: 1 person threatening (not reported by group).<BR/>Global state: deterioration (not reported by group).<BR/>Urine tests for the presence of phenothiazine. no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morton-1968">
<CHAR_METHODS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Blinding: double, identical capsule given by the hospital pharmacist. "no one concerned with the care of patients knew which patients were started on placebo".<BR/>Duration: 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=40 (12 to relevant interventions).<BR/>Age: 25-55 yrs.<BR/>Sex: all male.<BR/>History: in hospital &gt;2 yrs, on chlorpromazine &gt;18 months, maintenance doses of tranquillizer had been administered for at least 18 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorpromazine cessation: placebo. N=6.<BR/>2. Trifluoperazine cessation: placebo. N=14.<BR/>3. Chlorpromazine continuation: (dose not reported). N=6<BR/>4. Trifluoperazine continuation: (dose not reported). N=14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse.<BR/>Mental state: Wing scale.</P>
<P>Unable to use -<BR/>Behaviour change: WPRS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pigache-1973">
<CHAR_METHODS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned, pairs matched on clinical status and IQ, cross-over design.<BR/>Blinding: double, independent pharmacist, sealed in individual envelopes.<BR/>Duration: 55 weeks (preceded by 3 months stabilisation on chlorpromazine).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=20.<BR/>Age: 30-50 yrs.<BR/>Sex: all males.<BR/>History: chronic&gt; 2 yrs, unmarried.<BR/>Excluded: given ECT or Insulin therapy during the last 12 months, physically unwell.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorpromazine cessation: placebo. N=10.<BR/>2. Chlorpromazine continuation: dose 50-100 mg/day. N=10.</P>
<P>Minor analgesics, antibiotics (as necessary).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse.<BR/>Mental state: BPRS, PAT.<BR/>Leaving the study early (cross over design: 2 patients; placebo at the time of leaving. 1 patient; CPZ 50% at the time of leaving).</P>
<P>Unable to use -<BR/>Biochemistry: Blood + urine tests (no data).<BR/>Global state: Average Global Rating Scale (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shawver-1959">
<CHAR_METHODS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned, pairs matched on the morbidity score and ward location (randomised block design).<BR/>Blinding: double, identical capsule.<BR/>Duration: 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=120 (80 to relevant interventions).<BR/>Age: &lt; 50 yrs.<BR/>Sex: unknown.<BR/>History: in hospital mean 8 yrs, on chlorpromazine &gt;6 months.<BR/>Excluded: leucotomy or organic conditions, ECT for the past year.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorpromazine cessation: placebo. N=40.<BR/>2. Chlorpromazine continuation: dose 200 mg/day. N= 40.<BR/>3. Reserpine continuation: dose 2 mg/day. N=40.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse.<BR/>Global state: MSRPP (morbidity score).</P>
<P>Unable to use -<BR/>Behaviour change: AAMI (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>A team of two including the ward psychiatric made a joint interview to increase the reliability of the rating.<BR/>AAMI consisted of five separated measures: Level of activity, level of anxiety, mental disorganization, interpersonal relationships and abnormality of activity.<BR/>No data about whether relapses occured during the short term or medium term. All considered medium term.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zeller-1956">
<CHAR_METHODS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned, pairs matched on diagnosis.<BR/>Blinding: stated as double blind, but "only one investigator knew which patients were in each group and when placebo treatment was instituted'.<BR/>Duration: 1 month.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: mainly people with schizophrenia*.<BR/>N=176 (95 to relevant interventions).<BR/>Age: unknown.<BR/>Sex: unknown.<BR/>History: stable on either CPZ or reserpine.<BR/>Excluded: receiving medication &lt; 1month.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorpromazine cessation: placebo. N=51.<BR/>2. Chlorpromazine continuation: dose &gt;200 mg/day. N=44.<BR/>3. Reserpine continuation: dose 2 mg/day. N=37.<BR/>4. Reserpine cessation: placebo. N=44.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse.</P>
<P>Unable to use-<BR/>Global state: Malmud and Sands Worchester Rating Scale (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>*Almost 60% of the patients have schizophrenic reaction, the others have depressive, organic, neurotic and manic-depressive reactions.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CPZ- chlorpromazine.<BR/>CNS- Central Nervous System.<BR/>ECT- Electroconvulsive Therapy.</P>
<P>Mental state -<BR/>BPRS- Brief Psychiatric Rating Scale.<BR/>IMPS- Inpatient Multidimensional psychiatric Scale.<BR/>MSRPP- Multi-dimensional Scale for Rating Psychiatric Patients. <BR/>PRP- Psychotic Reaction Profile.</P>
<P>Behaviour -<BR/>WBRSW- Ward Behaviour Rating Scale of Wing.<BR/>SW- Social Withdrawal.<BR/>SE- Socially Embarrassing Behaviour .<BR/>LBRS- Lyons Behaviour Rating Scale.<BR/>PRP- Psychotic Reaction Profile, ward behaviour scale completed by two nurses.<BR/>Ward Evaluation Scale- completed by the patients.<BR/>WBRSW - Ward Behaviour Rating Scale of Wing.</P>
<P>AAMI- consisted of five separated measures: Level of activity, level of anxiety, mental disorganization, interpersonal relationships and abnormality of activity.</P>
<P>PAT- Pigache Attention Task(auditory attention task).<BR/>SSI- Springfield Symptom Inventory.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blackburn-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine, prochlorperazine, perphenazine, promazine, trifluoperazine versus placebo, not chlorpromazine withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bouchard-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participant: people with schizophrenia. <BR/>Intervention: risperidone versus classical neuroleptics.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chouinard-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Intervention: remoxipride versus chlorpromazine versus placebo, not chlorpromazine withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crow-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with first episode of schizophrenia.<BR/>Interventions: chlorpromazine, fluphenazine, haloperidol, pimozide or trifluoperazine versus placebo, withdrawal study.<BR/>Outcomes: results not broken down by individual drug.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diamond-1960">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation unclear.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine versus triflupromazine versus placebo, withdrawal study.<BR/>Outcomes: results not broken down by individual drug.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garfield-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine, thioridazine, trifluoperazine, perphenazine, prochlorperazine versus placebo, withdrawal study. <BR/>Outcomes: results not broken down by individual drug.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldberg-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine versus acetophenazine versus fluphenazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Good-1958">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned, cross over design.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine versus placebo, withdrawal study.<BR/>Outcomes: global state, behaviour change (no usable data).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gross-1960">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine, perphenazine, prochlorperazine, promazine, reserpine versus placebo, not chlorpromazine withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hine-1958">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine versus placebo, not chlorpromazine withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hogarty-1973-b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine versus placebo, withdrawal study.<BR/>Outcomes: global state (no usable data).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Howanitz-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Intervention: chlorpromazine versus clozapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knight-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Interventions: thiothixene versus trifluoperazine versus chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lapolla-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participant: people with schizophrenia.<BR/>Intervention: chlorpromazine versus etrafon.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levine-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participant: people with schizophrenia.<BR/>Intervention: chlorpromazine, perphenazine versus placebo, not chlorpromazine withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mefferd-1958">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned. <BR/>Participants: people with schizophrenia. <BR/>Interventions: chlorpromazine versus placebo. <BR/>Outcomes: behaviour change (MSRPP), mental state, side effects- no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Melnyk-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Interventions: thioridazine and chlorpromazine versus placebo, withdrawal study.<BR/>Outcomes: results not broken down by individual drug.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montero-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation unclear.<BR/>Participant: people with schizophrenia.<BR/>Intervention: chlorpromazine and trifluoperazine versus thioridazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moss-1958">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pai-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned. <BR/>Participant: people with schizophrenia.<BR/>Intervention: reserpine versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pigache-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned, cross over design.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine low dose versus medium dose versus high dose.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pokorny-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation unclear.<BR/>Participant: people with schizophrenia.<BR/>Intervention: chlorpromazine, trifluoperazine versus thioridazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pollack-1956">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prien-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine high dose versus chlorpromazine low dose, versus placebo versus drug chosen by physician, not chlorpromazine withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schiele-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation unclear.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine versus thioridazine versus trifluoperazine versus placebo, not chlorpromazine withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Slotnick-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation unclear.<BR/>Participant: agitated psychiatric patients. <BR/>Intervention: haloperidol versus chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Troshinsky-1962">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participant: people with schizophrenia.<BR/>Interventions: chlorpromazine, trifluoperazine, triflupromazine, thioridazine versus placebo, withdrawal study.<BR/>Outcomes: results not broken down by individual drug.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilson-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Participant: people with schizophrenia.<BR/>Intervention: chlorpromazine versus pimozide.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wode_x002d_Helgodt-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andrews-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caffey-1964">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Freeman-1962">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greenberg-1966">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hogarty-1973-a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mathur-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morton-1968">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pigache-1973">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shawver-1959">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zeller-1956">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-12-04 13:49:01 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-12-04 13:49:01 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>CESSATION OF CHLORPROMAZINE vs CONTINUATION OF CHLORPROMAZINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9941947751957434" CI_START="1.5095673883534504" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.455505279034691" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.6014292392352839" LOG_CI_START="0.17885250506153472" LOG_EFFECT_SIZE="0.3901408721484093" METHOD="MH" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.9569249291852345E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="44" WEIGHT="100.0" Z="3.6190447626183087">
<NAME>Global state: 1. Not improved or worsened - short term</NAME>
<GROUP_LABEL_1>CPZ cessation</GROUP_LABEL_1>
<GROUP_LABEL_2>CPZ continuation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cessation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuation</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9941947751957434" CI_START="1.5095673883534504" EFFECT_SIZE="2.455505279034691" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="13" LOG_CI_END="0.6014292392352839" LOG_CI_START="0.17885250506153472" LOG_EFFECT_SIZE="0.3901408721484093" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16725" O_E="0.0" SE="0.2482236654422304" STUDY_ID="STD-Zeller-1956" TOTAL_1="51" TOTAL_2="44" VAR="0.061614988085576326" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="44.69441458388246" CI_END="3.0558333070884505" CI_START="2.21331885273278" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6006794245711307" ESTIMABLE="YES" EVENTS_1="395" EVENTS_2="140" I2="75.38842358175381" I2_Q="93.21592481176837" ID="CMP-001.02" LOG_CI_END="0.48512966018305986" LOG_CI_START="0.34504398329346625" LOG_EFFECT_SIZE="0.4150868217382631" METHOD="MH" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.490810750963249E-6" P_Q="3.96579784567308E-7" P_Z="3.453466574147863E-31" Q="29.480805334666872" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="944" TOTAL_2="792" WEIGHT="300.0" Z="11.615109254965228">
<NAME>Global state: 2. Relapse</NAME>
<GROUP_LABEL_1>CPZ cessation</GROUP_LABEL_1>
<GROUP_LABEL_2>CPZ continuation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cessation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuation</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6696209413730685" CI_END="13.539294521815325" CI_START="3.374133734759657" DF="2" EFFECT_SIZE="6.75894891169505" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="8" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="1.1315960355998773" LOG_CI_START="0.5281622919807675" LOG_EFFECT_SIZE="0.8298791637903223" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7154737465984395" P_Z="7.009561006932731E-8" STUDIES="3" TAU2="0.0" TOTAL_1="233" TOTAL_2="143" WEIGHT="100.00000000000003" Z="5.390925813309918">
<NAME>short term</NAME>
<DICH_DATA CI_END="35.57335111305226" CI_START="2.1515239623855935" EFFECT_SIZE="8.748538011695906" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="2" LOG_CI_END="1.551124778915177" LOG_CI_START="0.3327461873574004" LOG_EFFECT_SIZE="0.9419354831362887" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16726" O_E="0.0" SE="0.7156816157523341" STUDY_ID="STD-Caffey-1964" TOTAL_1="171" TOTAL_2="88" VAR="0.5122001751258717" WEIGHT="29.313183714897942"/>
<DICH_DATA CI_END="65.4088746237074" CI_START="1.5288445272188664" EFFECT_SIZE="10.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8156366770494337" LOG_CI_START="0.18436332295056668" LOG_EFFECT_SIZE="1.0" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16727" O_E="0.0" SE="0.958218043131008" STUDY_ID="STD-Mathur-1981" TOTAL_1="11" TOTAL_2="11" VAR="0.9181818181818183" WEIGHT="11.099582722454045"/>
<DICH_DATA CI_END="12.190942402360887" CI_START="2.198012825134487" EFFECT_SIZE="5.176470588235294" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="5" LOG_CI_END="1.0860372793940396" LOG_CI_START="0.34203022214974993" LOG_EFFECT_SIZE="0.7140337507718947" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16728" O_E="0.0" SE="0.43703342831962605" STUDY_ID="STD-Zeller-1956" TOTAL_1="51" TOTAL_2="44" VAR="0.19099821746880571" WEIGHT="59.58723356264803"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.27458793571865" CI_END="5.80695642688954" CI_START="2.805403628397929" DF="5" EFFECT_SIZE="4.0361933340642375" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="33" I2="39.574030285947416" ID="CMP-001.02.02" LOG_CI_END="0.7639485672710667" LOG_CI_START="0.44799535435337207" LOG_EFFECT_SIZE="0.6059719608122194" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14173793939198276" P_Z="5.557988721579824E-14" STUDIES="6" TAU2="0.0" TOTAL_1="462" TOTAL_2="388" WEIGHT="100.0" Z="7.518095529811606">
<NAME>medium term</NAME>
<DICH_DATA CI_END="36.34054182438087" CI_START="0.6718453740036048" EFFECT_SIZE="4.9411764705882355" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5603913981944855" LOG_CI_START="-0.1727306688272701" LOG_EFFECT_SIZE="0.6938303646836077" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16729" O_E="0.0" SE="1.0180444812611729" STUDY_ID="STD-Andrews-1976" TOTAL_1="17" TOTAL_2="14" VAR="1.0364145658263306" WEIGHT="3.2069644403593163"/>
<DICH_DATA CI_END="26.17621083047169" CI_START="3.7491067915400795" EFFECT_SIZE="9.90643274853801" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="4" LOG_CI_END="1.4179067799336853" LOG_CI_START="0.5739278112713834" LOG_EFFECT_SIZE="0.9959172956025343" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16730" O_E="0.0" SE="0.4957574239555091" STUDY_ID="STD-Caffey-1964" TOTAL_1="171" TOTAL_2="88" VAR="0.24577542340700237" WEIGHT="15.444123096384045"/>
<DICH_DATA CI_END="233.94639260851125" CI_START="0.7851756015519924" EFFECT_SIZE="13.553191489361701" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3691163528738013" LOG_CI_START="-0.10503320407453537" LOG_EFFECT_SIZE="1.132041574399633" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16731" O_E="0.0" SE="1.4533276969892808" STUDY_ID="STD-Freeman-1962" TOTAL_1="46" TOTAL_2="48" VAR="2.112161394836167" WEIGHT="1.4315401928932365"/>
<DICH_DATA CI_END="3.97284566295762" CI_START="1.7229050706674034" EFFECT_SIZE="2.616263736263736" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="25" LOG_CI_END="0.5991016939182403" LOG_CI_START="0.23626134917114192" LOG_EFFECT_SIZE="0.41768152154469107" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16732" O_E="0.0" SE="0.21313421459311896" STUDY_ID="STD-Hogarty-1973-a" TOTAL_1="182" TOTAL_2="192" VAR="0.045426193430225685" WEIGHT="71.14538130114526"/>
<DICH_DATA CI_END="21.29721415269401" CI_START="0.4225904822796525" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3283227979345185" LOG_CI_START="-0.37408028849519337" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16733" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Morton-1968" TOTAL_1="6" TOTAL_2="6" VAR="0.9999999999999999" WEIGHT="2.923996989739377"/>
<DICH_DATA CI_END="15.829585532656859" CI_START="0.7738673874137717" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1994695438429925" LOG_CI_START="-0.11133345514244114" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16734" O_E="0.0" SE="0.7699721701835351" STUDY_ID="STD-Shawver-1959" TOTAL_1="40" TOTAL_2="40" VAR="0.5928571428571427" WEIGHT="5.847993979478754"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5896770589788314" CI_END="2.007742479784523" CI_START="1.4443354604062297" DF="2" EFFECT_SIZE="1.7028956688290462" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="99" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.3027080078849702" LOG_CI_START="0.15966807390068602" LOG_EFFECT_SIZE="0.2311880408928281" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7446518467744595" P_Z="2.364552057110237E-10" STUDIES="3" TAU2="0.0" TOTAL_1="249" TOTAL_2="261" WEIGHT="100.0" Z="6.335576662893323">
<NAME>long term</NAME>
<DICH_DATA CI_END="5.443914544819055" CI_START="0.9389440537399496" EFFECT_SIZE="2.260869565217391" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.735911299300434" LOG_CI_START="-0.02736028406602135" LOG_EFFECT_SIZE="0.3542755076172062" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16735" O_E="0.0" SE="0.44834950632472836" STUDY_ID="STD-Freeman-1962" TOTAL_1="46" TOTAL_2="48" VAR="0.20101727982162762" WEIGHT="6.090852981404795"/>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16736" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-Greenberg-1966" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="1.0372104714711063"/>
<DICH_DATA CI_END="1.9728454037090764" CI_START="1.4206813652335946" EFFECT_SIZE="1.6741519350215002" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="92" LOG_CI_END="0.29509305436185673" LOG_CI_START="0.15249668395285643" LOG_EFFECT_SIZE="0.22379486915735664" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16737" O_E="0.0" SE="0.0837618138416643" STUDY_ID="STD-Hogarty-1973-a" TOTAL_1="182" TOTAL_2="192" VAR="0.0070160414580456255" WEIGHT="92.8719365471241"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.061766374269108" CI_START="-0.0433368870896208" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.009214743589743599" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-1.2092478913146367" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.035516744992793" METHOD="MH" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7310923767414186" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="192" WEIGHT="100.0" Z="0.3436727905336091">
<NAME>Leaving study early - any reasons - medium term</NAME>
<GROUP_LABEL_1>CPZ cessation</GROUP_LABEL_1>
<GROUP_LABEL_2>CPZ continuation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cessation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuation</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.061766374269108" CI_START="-0.0433368870896208" EFFECT_SIZE="0.009214743589743599" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16738" O_E="0.0" SE="0.02681254915594621" STUDY_ID="STD-Hogarty-1973-a" TOTAL_1="182" TOTAL_2="192" VAR="7.189127922400318E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.658743726765969" CI_START="0.6028658820911937" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.21977929340914595" LOG_CI_START="-0.21977929340914598" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.0">
<NAME>Mental state: Not improved or worsened</NAME>
<GROUP_LABEL_1>CPZ cessation</GROUP_LABEL_1>
<GROUP_LABEL_2>CPZ continuation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cessation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuation</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6587437267659695" CI_START="0.6028658820911936" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.2197792934091461" LOG_CI_START="-0.21977929340914606" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16739" O_E="0.0" SE="0.2581988897471612" STUDY_ID="STD-Morton-1968" TOTAL_1="6" TOTAL_2="6" VAR="0.06666666666666671" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.55023913920507" CI_END="2.5131903878607504" CI_START="1.7856940842575284" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="2.11844027723602" ESTIMABLE="YES" EVENTS_1="237" EVENTS_2="109" I2="65.81243165743115" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.40022539001134616" LOG_CI_START="0.2518070598725391" LOG_EFFECT_SIZE="0.3260162249419426" METHOD="MH" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.007460201116886167" P_Q="0.5847841442306545" P_Z="7.272512796442485E-18" Q="0.2985640171904299" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="528" TOTAL_2="448" WEIGHT="200.0" Z="8.610527536111148">
<NAME>Sensitivity analysis: HIGH DOSE vs LOW DOSE - outcome relapse</NAME>
<GROUP_LABEL_1>CPZ cessation</GROUP_LABEL_1>
<GROUP_LABEL_2>CPZ continuation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cessation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuation</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.954425656523698" CI_START="0.06686983659340748" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.0">
<NAME>high dose (&gt;500mg/day)</NAME>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16740" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-Greenberg-1966" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.49614238460834" CI_END="2.526397469681051" CI_START="1.79401735499944" DF="5" EFFECT_SIZE="2.128943612741887" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="108" I2="71.4222718923539" ID="CMP-001.05.02" LOG_CI_END="0.40250167769584216" LOG_CI_START="0.2538266400146694" LOG_EFFECT_SIZE="0.3281641588552558" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0036489177120931915" P_Z="5.0475220362784615E-18" STUDIES="6" TAU2="0.0" TOTAL_1="507" TOTAL_2="427" WEIGHT="100.0" Z="8.652292172307712">
<NAME>low dose (&lt;500mg/day)</NAME>
<DICH_DATA CI_END="39.11497783286503" CI_START="0.7165460192936717" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5923430884599135" LOG_CI_START="-0.1447559123378117" LOG_EFFECT_SIZE="0.723793588061051" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16741" O_E="0.0" SE="1.020380551847317" STUDY_ID="STD-Andrews-1976" TOTAL_1="17" TOTAL_2="15" VAR="1.0411764705882354" WEIGHT="0.997799721819958"/>
<DICH_DATA CI_END="35.57335111305226" CI_START="2.1515239623855935" EFFECT_SIZE="8.748538011695906" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="2" LOG_CI_END="1.551124778915177" LOG_CI_START="0.3327461873574004" LOG_EFFECT_SIZE="0.9419354831362887" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16742" O_E="0.0" SE="0.7156816157523341" STUDY_ID="STD-Caffey-1964" TOTAL_1="171" TOTAL_2="88" VAR="0.5122001751258717" WEIGHT="2.4801090519186055"/>
<DICH_DATA CI_END="5.443914544819055" CI_START="0.9389440537399496" EFFECT_SIZE="2.260869565217391" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.735911299300434" LOG_CI_START="-0.02736028406602135" LOG_EFFECT_SIZE="0.3542755076172062" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16743" O_E="0.0" SE="0.44834950632472836" STUDY_ID="STD-Freeman-1962" TOTAL_1="46" TOTAL_2="48" VAR="0.20101727982162762" WEIGHT="5.5147478993203185"/>
<DICH_DATA CI_END="1.9728454037090764" CI_START="1.4206813652335946" EFFECT_SIZE="1.6741519350215002" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="92" LOG_CI_END="0.29509305436185673" LOG_CI_START="0.15249668395285643" LOG_EFFECT_SIZE="0.22379486915735664" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16744" O_E="0.0" SE="0.0837618138416643" STUDY_ID="STD-Hogarty-1973-a" TOTAL_1="182" TOTAL_2="192" VAR="0.0070160414580456255" WEIGHT="84.08761770193584"/>
<DICH_DATA CI_END="15.829585532656859" CI_START="0.7738673874137717" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1994695438429925" LOG_CI_START="-0.11133345514244114" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16745" O_E="0.0" SE="0.7699721701835351" STUDY_ID="STD-Shawver-1959" TOTAL_1="40" TOTAL_2="40" VAR="0.5928571428571427" WEIGHT="1.8782112410728622"/>
<DICH_DATA CI_END="12.190942402360887" CI_START="2.198012825134487" EFFECT_SIZE="5.176470588235294" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="5" LOG_CI_END="1.0860372793940396" LOG_CI_START="0.34203022214974993" LOG_EFFECT_SIZE="0.7140337507718947" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16746" O_E="0.0" SE="0.43703342831962605" STUDY_ID="STD-Zeller-1956" TOTAL_1="51" TOTAL_2="44" VAR="0.19099821746880571" WEIGHT="5.0415143839324195"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.001178175687933" CI_END="2.6028155542349594" CI_START="1.8526247471948407" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1959145038364634" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="111" I2="63.63831092991066" I2_Q="93.50697662335983" ID="CMP-001.06" LOG_CI_END="0.41544339338156183" LOG_CI_START="0.2677874610207564" LOG_EFFECT_SIZE="0.3416154272011591" METHOD="MH" MODIFIED="2013-12-04 13:49:01 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0049136916835690325" P_Q="8.693733876896648E-5" P_Z="1.1999328852100217E-19" Q="15.401145845211042" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="546" TOTAL_2="465" WEIGHT="200.0" Z="9.069109830838963">
<NAME>Sensitivity analysis: DIAGNOSTIC CRITERIA vs NO-DIAGNOSTIC CRITERIA - outcome relapse</NAME>
<GROUP_LABEL_1>CPZ cessation</GROUP_LABEL_1>
<GROUP_LABEL_2>CPZ continuation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cessation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuation</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9728454037090764" CI_START="1.4206813652335946" DF="0" EFFECT_SIZE="1.6741519350215002" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="92" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.29509305436185673" LOG_CI_START="0.15249668395285643" LOG_EFFECT_SIZE="0.22379486915735664" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="7.648854435474318E-10" STUDIES="1" TAU2="0.0" TOTAL_1="182" TOTAL_2="192" WEIGHT="100.0" Z="6.1520483616122625">
<NAME>diagnostic criteria</NAME>
<DICH_DATA CI_END="1.9728454037090764" CI_START="1.4206813652335946" EFFECT_SIZE="1.6741519350215002" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="92" LOG_CI_END="0.29509305436185673" LOG_CI_START="0.15249668395285643" LOG_EFFECT_SIZE="0.22379486915735664" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16747" O_E="0.0" SE="0.0837618138416643" STUDY_ID="STD-Hogarty-1973-a" TOTAL_1="182" TOTAL_2="192" VAR="0.0070160414580456255" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.516283474494796" CI_END="7.253198199354758" CI_START="2.834677821927488" DF="7" EFFECT_SIZE="4.534366557056821" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="19" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.8605295450627415" LOG_CI_START="0.45250370587084354" LOG_EFFECT_SIZE="0.6565166254667926" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5972206070510402" P_Z="2.841406841294642E-10" STUDIES="9" TAU2="0.0" TOTAL_1="364" TOTAL_2="273" WEIGHT="100.0" Z="6.307193405766229">
<NAME>no diagnostic criteria</NAME>
<DICH_DATA CI_END="36.34054182438087" CI_START="0.6718453740036048" EFFECT_SIZE="4.9411764705882355" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5603913981944855" LOG_CI_START="-0.1727306688272701" LOG_EFFECT_SIZE="0.6938303646836077" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16748" O_E="0.0" SE="1.0180444812611729" STUDY_ID="STD-Andrews-1976" TOTAL_1="17" TOTAL_2="14" VAR="1.0364145658263306" WEIGHT="5.489782829054665"/>
<DICH_DATA CI_END="35.57335111305226" CI_START="2.1515239623855935" EFFECT_SIZE="8.748538011695906" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="2" LOG_CI_END="1.551124778915177" LOG_CI_START="0.3327461873574004" LOG_EFFECT_SIZE="0.9419354831362887" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16749" O_E="0.0" SE="0.7156816157523341" STUDY_ID="STD-Caffey-1964" TOTAL_1="171" TOTAL_2="88" VAR="0.5122001751258717" WEIGHT="13.218868397373964"/>
<DICH_DATA CI_END="5.443914544819055" CI_START="0.9389440537399496" EFFECT_SIZE="2.260869565217391" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.735911299300434" LOG_CI_START="-0.02736028406602135" LOG_EFFECT_SIZE="0.3542755076172062" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16750" O_E="0.0" SE="0.44834950632472836" STUDY_ID="STD-Freeman-1962" TOTAL_1="46" TOTAL_2="48" VAR="0.20101727982162762" WEIGHT="29.393355372585553"/>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16751" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-Greenberg-1966" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="5.005390226491018"/>
<DICH_DATA CI_END="65.4088746237074" CI_START="1.5288445272188664" EFFECT_SIZE="10.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8156366770494337" LOG_CI_START="0.18436332295056668" LOG_EFFECT_SIZE="1.0" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16752" O_E="0.0" SE="0.958218043131008" STUDY_ID="STD-Mathur-1981" TOTAL_1="11" TOTAL_2="11" VAR="0.9181818181818183" WEIGHT="5.005390226491018"/>
<DICH_DATA CI_END="21.29721415269401" CI_START="0.4225904822796525" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3283227979345185" LOG_CI_START="-0.37408028849519337" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16753" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Morton-1968" TOTAL_1="6" TOTAL_2="6" VAR="0.9999999999999999" WEIGHT="5.005390226491018"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16754" O_E="0.0" SE="0.0" STUDY_ID="STD-Pigache-1973" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.829585532656859" CI_START="0.7738673874137717" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1994695438429925" LOG_CI_START="-0.11133345514244114" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16755" O_E="0.0" SE="0.7699721701835351" STUDY_ID="STD-Shawver-1959" TOTAL_1="40" TOTAL_2="40" VAR="0.5928571428571427" WEIGHT="10.010780452982036"/>
<DICH_DATA CI_END="12.190942402360887" CI_START="2.198012825134487" EFFECT_SIZE="5.176470588235294" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="5" LOG_CI_END="1.0860372793940396" LOG_CI_START="0.34203022214974993" LOG_EFFECT_SIZE="0.7140337507718947" MODIFIED="2008-04-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16756" O_E="0.0" SE="0.43703342831962605" STUDY_ID="STD-Zeller-1956" TOTAL_1="51" TOTAL_2="44" VAR="0.19099821746880571" WEIGHT="26.87104226853073"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>